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Hydrogen sulfide (H2S), a malodorous gas with the characteristic odor of rotten eggs, 
has been recognized as an important endogenous gaseous signaling molecule of the 
cardiovascular, gastrointestinal, genitourinary, and nervous systems. Besides acting as 
a potent vasodilator and an atypical neuromodulator, H2S is increasingly being 
established as a novel mediator of inflammation. However, the part played by H2S in 
modulating neurogenic inflammatory response in sepsis is not known. Therefore, this 
study aimed to investigate the role of H2S in mediating neurogenic inflammation in a 
mouse model of polymicrobial sepsis induced by cecal ligation and puncture (CLP).  
 
Of major significance in the development of neurogenic inflammation is the transient 
receptor potential vanilloid type 1 (TRPV1) receptor, a non-selective cation channel 
found predominantly in primary sensory neurons. In particular, the results of the 
present study indicate that H2S promotes TRPV1-mediated neurogenic inflammation 
in sepsis. It was found that capsazepine, a selective receptor antagonist of TRPV1, 
significantly attenuated systemic inflammation and multiple organ damage caused by 
CLP-induced sepsis under the pro-inflammatory impact of H2S. Capsazepine also 
delayed the onset of lethality and protected against sepsis-associated mortality. 
Administration of sodium hydrosulfide, an H2S donor, exacerbated but capsazepine 
reversed deleterious effects of sepsis. In the presence of DL-propargylglycine, an 
inhibitor of endogenous H2S synthesis, capsazepine caused no further changes to the 
DL-propargylglycine-mediated attenuation of systemic inflammation, multiple organ 
damage, and mortality in sepsis. Moreover, capsazepine had no effect on endogenous 
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generation of H2S, suggesting that H2S is located upstream of TRPV1 activation, and 
may play a critical role in regulating the release of sensory neuropeptides in sepsis.  
 
Importantly, the neuropeptide substance P has been identified as an important 
endogenous neural mediator that is implicated in H2S-driven neurogenic inflammation 
in sepsis in a TRPV1 channel-dependent manner. Furthermore, the H2S-induced 
neurogenic inflammatory response following septic insults was found to be regulated 
by the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and nuclear 
factor-κB (NF-κB) pathways. In addition, our results indicate that H2S augmented 
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) metabolite production in 
septic lungs by a TRPV1 channel-dependent mechanism. Notably, COX-2 inhibition 
with parecoxib attenuated H2S-augmented lung PGE2 metabolite production, 
neutrophil infiltration, edema, pro-inflammatory cytokines, chemokines, and adhesion 
molecules levels, restored lung histoarchitecture, and protected against CLP-induced 
lethality.  
 
In summary, the present study suggests that endogenous H2S induces TRPV1-
mediated neurogenic inflammation in polymicrobial sepsis through the enhancement 
of substance P production and activation of the ERK-NF-κB signal transduction 
pathways. In addition, H2S works in conjunction with other prominent mediators of 
inflammation such as COX-2 and PGE2 in a TRPV1-dependent manner, thereby 
contributes to sepsis-evoked acute lung injury. Finally, our data also indicate that 
blockade of TRPV1 channels provides potent anti-inflammatory effects and 
protection against multi-organ injury and mortality in sepsis, thus highlighting the 
xi 
 
potential utility of TRPV1 antagonist as a promising therapeutic target for the 
management of sepsis and its associated complications in critically ill patients. 
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Chapter I Introduction 
 
1.1 General overview  
Sepsis is an uncontrolled systemic inflammatory response syndrome (SIRS) occurring 
due to overwhelming immune reaction in response to infection [1]. It develops when 
the initial, appropriate host response to invading microorganisms or their products 
becomes amplified, and then delocalized and dysregulated. Excessive liberation of 
inflammatory mediators in organs remote from the initial insult synergistically 
interacts to mediate tissue damage, followed by multiple organ dysfunction syndrome 
(MODS), and consequently death of the host [2]. Despite advances in critical care 
management, sepsis and its sequelae remain an important global healthcare problem 
for both scientists and clinicians and are a leading cause of morbidity and mortality in 
medical and surgical intensive care units (ICUs). Therefore, intense research on 
elucidating the cascades of mechanisms associated with pathogenesis of sepsis and 
potential preventive and therapeutic strategies are of great interest. 
 
Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) are 
biologically active gases that have received considerable attention as important 
gaseous signaling molecules regulating many physiological processes. Collectively, 
they compose a novel family of “gasotransmitters”, with H2S being the most recent 
member of the family [3]. For many decades, H2S has been traditionally viewed as a 
toxic gas emanating from sewers, swamps, hot springs, geysers, volcanic emissions 
and as an environmental hazard of industrial processes such as paper and pulp 
industries, petroleum refineries, tanneries, mining, and livestock farming [4]. In recent 
years, however, it was being examined for its physiological and pathophysiological 
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significance in health and disease. To date, it has been recognized as the third 
endogenous signaling gasotransmitter of the cardiovascular, gastrointestinal, 
genitourinary, and nervous systems [3, 5].  
 
H2S exerts its effects on various biological targets through a host of interrelated 
mechanisms. By stimulating adenosine triphosphate (ATP)-sensitive potassium 
channels (K+ATP) in vascular smooth muscle cells, gastrointestinal smooth muscle 
cells, cardiomyocytes, neurons, and pancreatic β-cells, H2S regulates vascular tone, 
intestinal contractility, myocardial contractility, neurotransmission, and insulin 
secretion, respectively [5, 6]. In the nervous system, H2S promotes hippocampal long-
term potentiation by enhancing the sensitivity of N-methyl-D-aspartate (NMDA) 
receptors to glutamate and plays a role in neurodegenerative diseases [6]. Besides 
acting as a potent vasodilator and an atypical neuromodulator, H2S is increasingly 
being established as a novel mediator of inflammation. It has been demonstrated to 
play a pro-inflammatory role in animal models of local and systemic inflammation, 
including carrageenan-induced hindpaw edema [7], burn-induced acute lung injury 
(ALI) [8], caerulein-induced acute pancreatitis [9], lipopolysaccharide (LPS)-evoked 
endotoxemia [10], and cecal ligation and puncture (CLP)-induced polymicrobial 
sepsis [11]. 
 
Importantly, several recent investigations have proposed the potential involvement of 
H2S in neurogenic inflammation, most probably by stimulating transient receptor 
potential vanilloid type 1 (TRPV1), a non-selective cation channel best known for its 
expression on a subset of primary sensory nerve fibers that release inflammatory 
neuropeptides. Specifically, H2S induced contraction in rat urinary bladder via a 
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neurogenic mechanism that involved TRPV1 activation with consequent release of 
tachykinins [12, 13]. H2S also provoked the release of neuropeptides from TRPV1-
expressing sensory nerve terminals found on isolated guinea pig airways [14]. Given 
that endogenous H2S is known to be overproduced in sepsis and neurogenic 
inflammation has been proposed to relate to H2S, it is hypothesized that H2S may 
modulate neuroinflammation in sepsis. However, there has been little progress in 
understanding the potential interaction and involvement of both H2S and TRPV1 in 
the setting of sepsis. Therefore, in the present study, we have investigated the 
potential role of H2S in instigating TRPV1-mediated neurogenic inflammation in a 
mouse model of polymicrobial sepsis. Additionally, we have identified the 
endogenous neural element involved and have explored the molecular mechanisms by 
which H2S would regulate the neural inflammatory responses in sepsis in a TRPV1 
relevance context.   
 
1.2 H2S 
1.2.1 Chemical properties of H2S 
H2S is a colorless, flammable, and water-soluble gas with the characteristic odor of 
rotten eggs. It has a molecular mass of 34.08. It is a weak diprotic acid that dissociates 
in two steps:  
                                                     H2S  →  H+  +  HS- 
                                                     HS-  →  H+  +  S2- 
Under physiologically relevant conditions, i.e. in aqueous solutions and at pH 7.4, 
approximately one third of H2S exists as the undissociated form and two thirds 
dissociate into H+ and HS- (hydrosulfide ion); which may subsequently decompose to 
H+ and S2- (sulfide ion). Since the latter reaction occurs only at high pH, the 
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concentration of S2- in vivo is negligible. Sodium hydrosulfide (NaHS) is commonly 
used experimentally as an H2S donor since it dissociates into Na+ and HS-; the latter 
then partially binds H+ to form H2S. H2S is lipophilic and freely permeates plasma 
membranes without using specific transporters [5].  
 
1.2.2 H2S toxicity  
H2S has been known as a highly toxic gas for almost 300 years. H2S poisoning is a 
rarity, mainly observed in industrial settings. As a broad-spectrum cellular toxicant, 
H2S affects all organ systems, particularly the central nervous system (CNS) and the 
respiratory system [15]. In humans, inhalation of up to 10 parts per million (ppm) H2S 
has little or no metabolic effect on body systems in either resting or exercising states. 
However, increased exposure (up to 30 ppm) causes headache, nausea, vomiting, and 
breathlessness whilst even pronounced inhalation (up to 250 ppm) triggers respiratory 
tract irritation and pulmonary edema [4]. At concentrations in excess of 1000 ppm, 
coma and death can ensue. Recovery from acute intoxication is often rapid and 
complete, depending upon exposure; however, some irreversible adverse effects may 
persist such as brain damage featured by permanent neurological sequelae as a result 
of hypoxia secondary to H2S-induced respiratory paralysis [15].   
 
The major lethal consequences of H2S intoxication is the loss of central respiratory 
drive due to biochemical lesions of the respiratory centers of the brainstem [16]. In 
particular, H2S toxicity has been largely attributed to its ability to cause irreversible 
inhibition of mitochondrial oxidative phosphorylation by binding to the heme aa3 site 
of cytochrome c oxidase, leading to suppression of oxygen utilization and 
consequently respiratory paralysis [4]. Apart from this, recent evidence suggests that 
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other mechanisms may exist and are responsible for acute H2S poisoning. One study 
suggested that H2S-induced inhibition of monoamine oxidase contributes to the loss 
of central respiratory function after fatal intoxication with H2S [17] whilst another 
report found that generation of excessive reactive oxygen species via a cytochrome 
P450-dependent mechanism results in H2S-induced cytotoxicity [18].  
 
1.2.3 Biosynthesis of H2S  
H2S is synthesized by both enzymatic and non-enzymatic pathways. Cystathionine-γ-
lyase (CSE) and cystathionine-β-synthase (CBS) are the key enzymes mostly 
responsible for the enzymatic production of H2S in mammalian tissues that use L-
cysteine as the main substrate (Figure 1.1) [5]. L-cysteine can be obtained from 
dietary intake, liberated from endogenous proteins, or generated endogenously from 
the trans-sulfuration pathway that interconverts L-methionine and L-cysteine. CBS 
and CSE are both heme-containing enzymes whose activity depends on the cofactor 
pyridoxal-5’-phosphate [19]. They are widely expressed in a range of mammalian 
cells and tissues, and also in many invertebrates and bacteria. However, their 
distributions are not homogenous. CBS appears to be the main H2S-synthesizing 
enzyme in the CNS and is highly expressed in liver, kidney, and the hippocampus and 
cerebellum in mammalian brain. CSE is primarily responsible for H2S formation in 
the cardiovascular system and is predominantly found in the liver and in vascular and 
non-vascular smooth muscle, and at much lower levels, in small intestine and stomach 
of rodents [19]. The liver of several species, including humans, contains large 
amounts of both enzymes [20]. Both CBS and CSE are located exclusively in the 
cytosol [4]. CBS exists as multiple distinct isoforms differing in their 5’ untranslated 
region whilst CSE occurs as a single transcript with no splice variant in mouse brain, 
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lung, heart, liver, and kidney [21]. Several specific blockers for CBS and CSE are 
currently available. DL-propargylglycine (PAG) and β-cyano-L-alanine selectively 
inhibit CSE whilst amino oxyacetic acid and hydroxylamine are the specific CBS 
inhibitors [3]. 
 
Both enzymes are differentially regulated. The activity of CBS is regulated 
presumably at the transcriptional level by hormones such as glucocorticoid and 
insulin, which stimulates and inhibits CBS gene expression, respectively [22]. S-
adenosyl-L-methionine, an intermediate product of methionine metabolism and an 
endogenous methyl donor, markedly activates CBS by allosteric regulation [23]. The 
activity of CBS can also be regulated by post-transcriptional limited proteolysis of the 
full-length tetrametric form to the truncated dimeric form [24, 25] and by interaction 
with other gasotransmitters designated NO and CO which bind to the heme pocket of 
CBS (with CO having higher binding affinity than NO) and directly inhibit it [26]. 
Intriguingly, the NO donor sodium nitroprusside activates CBS in a manner that 
paradoxically does not involve the NO-releasing capability (i.e. independent of NO), 
but results from a chemical modification of the enzyme’s cysteine group [27]. In 
contrast to CBS, the CSE-dependent H2S generation is enhanced by NO donors in a 
cGMP-dependent manner. Bacterial endotoxin LPS and transcription factors myeloid 
zinc finger 1 and specificity protein 1 appear to upregulate CSE gene expression and 
to modulate its basal transcriptional activity, respectively [19]. CSE expression is also 
increased in animal models of certain diseases, including pancreatitis and type 1 
diabetes mellitus [20]. Furthermore, as the end product of CBS- and CSE-catalyzed 
cysteine metabolism, H2S exerts a negative feedback effect on the activity of these 
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enzymes, in which elevated H2S level inhibits CSE activity and the rate of 
gluconeogenesis from cysteine [5].  
 
 
Figure modified from Hu et al., Antioxid Redox Signal, 2011 [28]. 
 
Figure 1.1 Enzymatic pathway of H2S production in mammalian cells. H2S is 
synthesized endogenously by the action of cystathionine-β-synthase (CBS) and 
cystathionine-γ-lyase (CSE) in the trans-sulfuration pathway. Methionine 
adenosyltransferase (MAT) and glycine N-methyltransferase (GNMT) catalyze the 
conversion of methionine, obtained mainly by dietary intake, to S-
adenosylhomocysteine that is subsequently hydrolyzed to homocysteine. By adding 
serine to homocysteine, CBS catalyzes the conversion of homocysteine to 
cystathionine. Subsequently, cystathionine is converted to L-cysteine and α-
ketobutyrate by CSE. L-cysteine can also be obtained from dietary cysteine. Both 
CBS and CSE utilize L-cysteine as the main substrate to synthesize H2S. Furthermore, 
the synthesis of glutathione (GSH) is regulated at the substrate level by cysteine. Thus, 
the trans-sulfuration pathway also links to GSH homeostasis in the brain. In addition, 
cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfurtransferase (3-MST) 
are components of the cysteine catabolism pathway. CAT catalyzes the 
transamination of cysteine to yield 3-mercaptopyruvate, a substrate of 3-MST to 
produce pyruvate and sulfane sulfur, which may liberate H2S in the presence of 
reducing agents such as dithiothreitol (DTT) and GSH. 
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Most emphasis has been placed on the enzymatic route of H2S formation. The non-
enzymatic pathway, which proceeds via the non-enzymatic reduction of elemental 
sulfur to H2S using reducing equivalents obtained from the oxidation of glucose, may 
be important in certain cells such as erythrocytes (Figure 1.2) [29]. Liberation of H2S 
from intracellular sulfur stores, particularly in the brain by astrocytes, represents 
another neuronal source of H2S [30]. In addition, mammalian cells may also be 
exposed to appreciable amounts of H2S produced by enteric sulfate-reducing bacteria 
present in the colon. Notably, the intestinal epithelium expresses specialized enzyme 
systems that efficiently metabolize sulfide to thiosulfate and sulfate, presumably to 
protect colon against injurious concentrations of sulfide and to prevent its entry into 
the systemic circulation [19]. It is believed that defects in this detoxification 
mechanism could possibly contribute to the foul odor of both feces and flatus [4].  
 
Figure adapted from Wang, FASEB J, 2002 [5]. 
 
Figure 1.2 Non-enzymatic pathway of H2S production in erythrocytes. 
Erythrocytes can reduce elemental sulfur to H2S using reducing equivalents (NADPH 
obtained from glucose oxidation or glutathione). Oxidative stress may stimulate the 
phosphogluconate pathway to produce NADPH, which supports S0 reducing and can 
also be used in other anti-oxidative functions. 
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1.2.4 Metabolism of H2S 
H2S in vivo is metabolized rapidly by a multitude of different chemical and enzymatic 
processes (Figure 1.3). Of these, the mitochondrial oxidation mechanism represents 
the most important route of H2S catabolism. It involves several enzymatic steps 
catalyzed by quinine oxidoreductase, S-dioxygenase, and S-transferase and, overall, 
leads to the formation of thiosulfate. Subsequently, thiosulfate is converted to sulfite 
by rhodanase and finally the major and stable product, sulfate, by sulfite oxidase. In 
contrast, cytosolic methylation of H2S by thiol-S-methytransferase to yield 
methanethiol and dimethylsulfide represents another less important mechanism of 
H2S degradation, and therefore accounts for a smaller amount of H2S. Additionally, 
H2S can be scavenged by methemoglobin to form sulfhemoglobin or consumed by 
metallo- or disulfide-containing molecules such as oxidized glutathione [6]. Because 
hemoglobin may also bind NO and CO, it is a common “sink” for all three 
gasotransmitters [5]. H2S can also be oxidized by activated neutrophils to form sulfite 
[31]. Finally, H2S is an endogenous reducing agent which can be easily consumed by 
a variety of circulating oxidant species in the vasculature such as peroxynitrite, 
hypochlorite, superoxide, or hydrogen peroxide [32-34]. It is excreted mainly by the 
kidney as free or conjugated sulfate [20].  
 
1.2.5 Biological roles of H2S 
H2S functions as an important gaseous signaling molecule mediating various 
biological effects in mammals since it could be endogenously synthesized and 
regulated by mammalian tissues. In recent years, the potential role played by 
endogenous H2S in several physiological and pathological processes has become 
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better appreciated. These biological effects, ranging from the brain to the gut, are 
discussed together with literature evidence for the role of H2S in various diseases.   
 
 
Figure adapted from Martelli et al., Med Res Rev, 2010 [6]. 
 
Figure 1.3 Metabolism of H2S. In mitochondria, H2S undergoes several enzymatic 
steps and forms thiosulfate, which is then converted to sulfite by rhodanase, and 
finally sulfate by sulfite oxidase. In cytosol, methylation of H2S by thiol-S-
methyltransferase (TSMT) yields methanethiol and dimethylsulfide. In blood, H2S is 
scavenged by methemoglobin to form sulfhemoglobin. 
 
 
1.2.5.1 Roles of H2S in CNS 
1.2.5.1.1 Physiological roles of H2S in CNS 
 
Neuromodulator  
H2S functions as a neuromodulator that potentiates or inhibits the transmission of 
nerve pulses in neurons. It selectively enhances NMDA receptor-mediated currents 
and facilitates the induction of hippocampal long-term potentiation, a process of 
synaptic plasticity involved in the mechanisms of learning and memory, by increasing 
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the sensitivity of NMDA receptor to glutamate through activation of adenylyl cyclase 
(AC) and the subsequent cAMP/protein kinase A (PKA) cascades [35]. Besides, H2S 
promotes astrocytic glutamate uptake, thus playing an important role in clearing 
excessive glutamate in synaptic clefts and maintaining normal transmission between 
neurons [36]. H2S also reversibly inhibits both fast and slow synaptic responses in 
dorsal raphe serotonergic neurons [37]. These observations offer important and direct 
evidence for the modulatory role of H2S in CNS.  
 
Neuroprotectant  
Accumulating body of evidence suggests that H2S may be protective for neurons, and 
thus its deficiency in the brain may be detrimental. In particular, H2S protects neurons 
against neurotoxicity of glutamate independent of the stimulation of excitatory amino 
acid receptors by increasing intracellular glutathione (GSH) levels in rat cortical 
neurons and protects these cells against ischemia or glutamate-induced death [38, 39]. 
Similarly, H2S reduces the toxicity of oxidative glutamate in mouse hippocampal cell 
line by opening K+ATP and Cl-ATP channels [38]. Furthermore, H2S enhances the 
activity of γ-glutamylcysteine synthetase, a rate-limiting enzyme in GSH synthesis, 
thereby facilitates the redistribution of GSH into mitochondria and protects cells 
against oxidative stress. H2S also enhances glutamate uptake via glutamate 
transporter-1 in astrocytes and thus prevents excessive accumulation of glutamate in 
synaptic clefts [36]. Apart from these, H2S protects neurons by scavenging reactive 
oxygen and/or nitrogen species. H2S reduces peroxynitrite-induced tyrosine nitration 
and attenuates its cytotoxicity in cultured human neuroblastoma SH-SY5Y cells [32]. 
H2S also limits the neurotoxic effects of hypochlorous acid on these cells [33]. Finally, 
H2S has been suggested to confer neuroprotection through its anti-apoptotic properties. 
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It inhibits β amyloid-induced PC12 cell damage and protects hippocampal neurons 
against vascular dementia-induced injury via its anti-apoptotic effects [40, 41].  
 
1.2.5.1.2 H2S in CNS diseases 
 
Down syndrome  
Abnormalities of H2S biosynthesis and regulation have been implicated in certain 
CNS diseases. One such example is Down syndrome, a chromosomal disorder 
characterized by the presence of all or part of an extra chromosome 21. Since human 
CBS gene is located on chromosome 21 (21q22.3), H2S is expected to be 
overproduced in the brain of patients with Down syndrome [42]. Indeed, thiosulfate (a 
catabolite of H2S) was found to be two-fold higher in the urine of Down syndrome 
patients [43]. Besides, an increase in CBS activity and a consequent decrease in 
plasma level of CBS substrate homocysteine in Down syndrome patients have been 
observed [44]. It has been hypothesized that excess H2S may exert a toxic effect on 
neurons through the inhibition of cytochrome c oxidase and/or overstimulation of 
NMDA receptors, thereby leading to the progressive mental retardation seen in 
patients with Down syndrome [45].  
 
Ischemic stroke 
High plasma cysteine level, presumably associated with high H2S, has been found to 
correlate with poor clinical outcome in patients with ischemic stroke [46]. In a rat 
model of experimental stroke, administration of cysteine or NaHS increased, whereas 
CBS or CSE inhibitors decreased the volume of brain infarct induced by middle 
cerebral artery occlusion. Moreover, endogenous H2S and its synthesizing activity in 
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the affected cerebral cortex were significantly increased under the same conditions 
[47]. These findings strongly indicate that abnormal formation of H2S may contribute 
to the tissue infarction involved in the pathogenesis of ischemic stroke.  
 
Febrile seizure 
Febrile seizure is the most common seizure type in children, often causing 
hippocampal damage. Plasma level of H2S and expression of CBS mRNA in 
hippocampus were significantly elevated in a rat model of recurrent febrile seizure. 
NaHS attenuated recurrent febrile seizure-induced neuronal damage in hippocampus 
whilst CBS inhibitor hydroxylamine aggravated the neuronal injury [48]. The 
underlying mechanisms may be linked to the ability of H2S to regulate γ-aminobutyric 
acid (GABA)B receptor function since it has been documented to reverse 
downregulation of both GABAB receptor subunits 1 and 2 proteins and mRNA in the 
hippocampus of rats subjected to recurrent febrile seizure [49].  
 
Alzheimer’s disease 
The concentration of H2S in the brain of Alzheimer’s patients was found to be 
significantly suppressed than that observed in matched control subjects, which was 
probably associated with the deficiency of a CBS activator, S-adenosyl- L-methionine 
[50]. Accumulation of plasma homocysteine secondary to the dysfunction of trans-
sulfuration pathway may also contribute to the lowered production of H2S in 
Alzheimer’s disease [51]. It has also been suggested that H2S deficiency may lead to 
increased levels of peroxynitrite and hypochlorous acid, resulting in neuronal injury in 
Alzheimer’s disease. In fact, myeloperoxidase (MPO) activity and brain level of 3-
chlorotyrosine, a marker of hypochlorous acid-induced neuronal injury, have been 
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found to be heightened in patients with Alzheimer’s disease [52]. On the other hand, 
convincing evidence suggests that NaHS administration elicited neuroprotective 
effects against pathological progression of Alzheimer’s disease. In particular, H2S 
scavenged the cytotoxic lipid oxidation product 4-hydroxynonenal, which was 
markedly increased in brains of Alzheimer’s patients [53]. H2S also ameliorated β 
amyloid-induced damage in PC12 cells by reducing the loss of mitochondrial 
membrane potential and attenuating the increase of intracellular reactive oxygen 
species [40]. Moreover, H2S-releasing compounds are capable of attenuating 
neuroinflammation, a contributing factor implicated in the pathogenesis of 
Alzheimer’s disease [54]. Finally, H2S attenuated LPS-induced cognitive impairment 
in rats via its anti-inflammatory actions [55]. Considering these neuroprotective roles 
of H2S, it is obvious that H2S exerts beneficial effects on the disease progression of 
Alzheimer’s disease.  
 
Parkinson’s disease 
Similar to Alzheimer’s disease, plasma homocysteine levels were found to be elevated 
in patients with Parkinson’s disease [56]. Additionally, H2S levels in the substantia 
nigra and striatum were substantially reduced in both 6-hydroxydopamine- and 
rotenone-induced rat models of Parkinson’s disease, indicating that impaired 
endogenous H2S production may contribute to the development of Parkinson’s disease. 
Importantly, administration of NaHS greatly alleviated the progression of movement 
dysfunction and loss of tyrosine hydroxylase positive-neurons in the substantia nigra 
induced by either rotenone or 6-hydroxydopamine. Furthermore, NaHS treatment 
inhibited microglial activation in the substantia nigra and accumulation of pro-
inflammatory factors such as tumor necrosis factor-α (TNF-α) and NO in the striatum 
15 
 
[57]. These observations highlight the importance of endogenous H2S in the 
pathogenesis of Parkinson’s disease. 
 
Huntington’s disease 
Apart from Alzheimer’s disease and Parkinson’s disease, H2S also contributes to the 
pathogenesis of Huntington’s disease, another age-related neurodegenerative disorder 
that often gives rise to dementia. Specifically, CBS has been found to interact with 
huntingtin, mutants of which cause Huntington’s disease [58]. The plasma levels of 
homocysteine were also found to be elevated in patients with Huntington’s disease 
[59]. Considering that increased plasma homocysteine level is a common feature 
among patients with Alzheimer’s disease, Parkinson’s disease, and Huntington’s 
disease, it is clear that there exists a correlationship between homocysteine aberration 
and the pathophysiology of neurodegenerative disorders, thus highlighting the 
significance of H2S in these CNS diseases.  
 
1.2.5.2 Roles of H2S in cardiovascular system 
1.2.5.2.1 Physiological roles of H2S in cardiovascular system  
 
Effects on blood pressure and vascular tone 
Over the years, H2S has been reported to relax different blood vessels, including 
isolated rat aorta, gastric artery and portal vein, and to dilate the perfused rat 
mesenteric and hepatic but not coronary vascular beds [20]. H2S also relaxes the 
corpus cavernosum of rabbits and man [60, 61]. The vasodilating activity of H2S has 
been described in vivo, in which an intravenous bolus injection of H2S was shown to 
transiently and dose-dependently decrease mean arterial pressure of rats [62]. 
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Furthermore, genetic deletion of CSE in mice markedly reduces H2S concentrations in 
the serum, heart and aorta, coupled with development of hypertension and decreased 
endothelium-dependent vasorelaxant effects [63].  
 
Several mechanisms underlying the vasorelaxant activity of H2S have been suggested. 
Initial studies have unequivocally indicated that H2S relaxes blood vessels by opening 
K+ATP in the vascular smooth muscle cells [3]. More recent studies have suggested 
inhibition of voltage-gated calcium (Ca2+) channels, effects on ATP generation or 
metabolic inhibition, and induction of intracellular acidification in vascular smooth 
muscle through stimulation of CI-/HCO3- exchanger [64-66] as other potential 
mechanisms for the vasorelaxant effect of H2S. Although H2S is generally considered 
to be a vasodilator, it should be noted that H2S has a complex effect on vascular tone. 
In non-mammalian vertebrates, for example, H2S can cause blood vessel relaxation or 
constriction or both [67, 68]. One study also reported that the H2S-induced 
vasoconstrictive effects are mediated through downregulation of cAMP/PKA 
signaling pathways [69]. Irrespective of the vasorelaxant or vasoconstriction actions 
of H2S, these findings suggest that H2S is an important endogenous vasoregulator in 
the cardiovascular system and is the first identified gaseous opener of K+ATP channel 
in vascular smooth muscle cells.  
 
Effects on heart function 
Apart from its principal role as a vasodilator, H2S is endowed with several additional 
biological roles that are relevant for the polyhedric control of the cardiovascular 
system. Indeed, its role in regulating myocardial contractility has been described. At 
the tissue level, it has been reported that perfusion of H2S to isolated rat heart 
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decreased myocardial contractility in a dose-dependent manner while in vivo 
application of H2S resulted in a reduction of central venous pressure. In addition, the 
negative inotropic effect of H2S, both in vitro and in vivo, was partly blocked by 
glibenclamide (K+ATP channel blocker), suggesting that H2S acts as a cardiac function 
regulator through modulation of K+ATP channel [34].  
 
Effects on central modulation of hemodynamics 
It was demonstrated that perfusion of the isolated carotid sinuses of rats with NaHS 
dose-dependently facilitated the sinus baroreflex, coupled with an obvious increase in 
peak slope and reflex decrease in blood pressure and a marked decrease in threshold 
pressure. These effects were abolished by pretreatment with glibenclamide (a K+ATP 
channel blocker) or Bay K8644 (an agonist of calcium channel). Inhibition of 
endogenous H2S formation also resulted in blockade of carotid sinus reflex. These 
data indicate that H2S may regulate hemodynamics through its central effect on the 
baroreceptor reflex [70].  
 
Effects on platelet aggregation  
H2S dose-dependently inhibited platelet aggregation induced by adenosine 
diphosphate, collagen, epinephrine, arachidonic acid, thromboxane mimetic U46619, 
and thrombin. This effect occurred independently of cAMP/cGMP generation, NO 
release, and K+ channel activation; however, the precise mechanism of action remains 





1.2.5.2.2 H2S in cardiovascular diseases 
 
Hypertension  
In agreement with its vascular effects, deficiency of endogenous H2S contributes to 
the pathogenesis of hypertension. In spontaneous hypertensive rats (SHR), the 
expression and enzymatic activity of CSE in thoracic aorta and the plasma H2S 
concentration were significantly lowered. Chronic administration of NaHS reduced 
blood pressure in SHR but not in normotensive rats whilst inhibition of H2S synthesis 
by PAG only raised the blood pressure in normotensive rats but not in SHR, 
indicating that H2S is involved in the regulation of basal blood pressure and that H2S 
production is suppressed in hypertensive conditions [72]. The similar results were 
observed in rats with experimental hypertension induced by chronic NO synthase 
blocker NG-nitro- L-arginine methyl ester (L-NAME) [73]. Plasma H2S level was also 
found to be lower in human hypertension than in normotensive controls [74].  
 
In a rat model of hypoxic pulmonary hypertension (HPH), the expression and activity 
of CSE as well as the plasma level of H2S were markedly suppressed. Exogenous 
supply of H2S restored pulmonary expression and activity of CSE, increased plasma 
H2S level, lowered pulmonary arterial pressure, and attenuated pulmonary vascular 
structure remodeling [75, 76]. In another study of HPH, NaHS augmented the 
increase of plasma CO level and the expression of heme oxygenase protein and 
mRNA in pulmonary arteries whereas PAG, an inhibitor of CSE, reversed these 
parameters. Similarly, H2S alleviated the elevation of pulmonary arterial pressure but 
PAG decreased plasma H2S content and worsened HPH. The findings suggest that 
H2S may work in conjunction with CO to alleviate HPH, at least in part, by 
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stimulating the vasodilatory CO signaling [77]. Moreover, the endogenous H2S/CSE 
pathway was found to be downregulated in pulmonary hypertension and vascular 
structural remodeling induced by high pulmonary blood flow in rats [78]. 
Administration of NaHS ameliorated pulmonary vascular structural remodeling, 
reduced pulmonary blood pressure, and prevented right ventricular hypertrophy in this 
model [79]. Taken together, these data suggest that deficiency of H2S may contribute 
to the pathogenesis of arterial hypertension.  
 
Atherosclerosis 
H2S exerts some effects potentially associated with suppressing atherosclerosis. H2S 
inhibits proliferation and induces apoptosis of vascular smooth muscle cells, 
suppresses oxidative modification of low-density lipoproteins, inhibits platelet 
aggregation, attenuates pro-oxidant effect of homocysteine, and inhibits vascular 
inflammatory reactions [80]. H2S attenuated vascular remodeling and inhibited 
neointima formation after balloon-evoked injury of the rat carotid artery [81]. Besides, 
reduced plasma H2S level and decreased expression and activity of CSE in the aortic 
wall were also observed in experimental vascular calcification induced in the rats by 
vitamin D and nicotine. Importantly, administration of NaHS ameliorated the 
experimentally-induced vascular calcification; a manifestation that often develops in 
patients with hypertension and atherosclerosis which mediates thrombosis, plaque 
ruptures, and reduced arterial compliance [82]. A recent study investigating the role of 
H2S in the development of atherosclerotic lesions in apolipoprotein E knockout mice 
showed that the vascular H2S/CSE pathway was impaired in these mice. Specifically, 
administration of NaHS resulted in an increase of plasma H2S levels, concurrent with 
a reduction in atherosclerotic plaque size and intercellular adhesion molecule-1 
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(ICAM-1) expression in the plasma and aorta, whereas PAG greatly abolished these 
beneficial effects [83]. 
 
Shock 
The involvement of H2S in the regulation of hemodynamic parameters in several 
animal models of shock has been described. The production of H2S in various arterial 
tissues was markedly elevated in CLP-induced septic shock and LPS-induced 
endotoxic shock. The vascular levels of H2S negatively correlated with hemodynamic 
parameters, cardiac function, and the severity of hypoglycemia, supporting the role of 
H2S in the pathophysiology of septic and endotoxic shock [84]. In hemorrhagic shock 
in the rats, plasma H2S concentration and hepatic expression and activity of CSE were 
significantly lowered after blood withdrawal. Treatment with PAG and β-cyano-L-
alanine (CSE inhibitors) resulted in a rapid but partial restoration in blood pressure 
and heart rate [85].  
 
Myocardial injury 
Since myocardial cells are densely populated with K+ATP channels and activators of 
K+ATP channels have been documented to protect against myocardial ischemia-
reperfusion injury [86], H2S, which is known to act on K+ATP channels, was 
hypothesized to exert protective effects on myocardial ischemia injury. In a 
myocardial ischemic injury model induced by isoproterenol injection of rat hearts, 
myocardial and plasma H2S levels as well as CSE activity were significantly lowered. 
Exogenous administration of NaHS not only decreased the mortality rate of 
isoproterenol-treated rats but also attenuated the isoproterenol-induced impairment of 
myocardial contractility and ameliorated cardiomyocyte necrosis [87]. In addition, in 
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the isolated perfused rat heart preparation, NaHS limited the infarct size induced by 
left coronary artery ligation. The protective effect of H2S was abolished by K+ATP 
channel blockers [88]. The cardioprotective action of H2S was later confirmed in an in 
vivo rat model of myocardial ischemic injury in which increased CSE expression and 
plasma H2S concentration in the infarct area were documented and that NaHS 
protected cultured myocardial cells against hypoxia-induced death [89]. Furthermore, 
endogenous H2S was produced in sufficient amounts to limit myocardial ischemia and 
reperfusion injury and contributes to the cardioprotective effects of pre-conditioning 
with endotoxin. The protection afforded by H2S in the heart was mediated by the 
opening of mitochondrial K+ATP channels [90]. A further study highlighted that apart 
from its anti-inflammatory actions, H2S mediates cardioprotection through its anti-
apoptotic effects in a rat model of acute regional myocardial ischemia/reperfusion. 
Likewise, it has been suggested that the anti-apoptotic effects of H2S may be in part 
due to the activation of mitochondrial K+ATP channels [91]. Moreover, H2S has been 
reported to confer myocardial protection in vivo through ischemic pre- and post-
conditioning and in vitro through metabolic inhibition of myocardium in the absence 
of glucose and in the presence of glycolysis inhibitor [92-94].  
 
1.2.5.3 Roles of H2S in gastrointestinal system  
1.2.5.3.1 Physiological roles of H2S in gastrointestinal system  
 
Effects on intestinal motility  
Both CBS and CSE have been detected in the rat colon, where they are responsible for 
H2S generation. H2S was found to dose-dependently suppress spontaneous or 
acetylcholine-induced contractility of the ileum in various animal species, including 
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rats, rabbits, and guinea pigs [95, 96]. In another study, intraperitoneal administration 
of NaHS or L-cysteine dose-dependently relaxed the rat colon in vivo. Such a relaxant 
action was fully antagonized by glibenclamide (an inhibitor of K+ATP channels) but 
was restored by pinacidil (an agonist of K+ATP channels), revealing the importance of 
K+ATP channels in the regulation of gastrointestinal motility [97].  
 
Effects on visceral nociception  
The potential role of H2S as a modulator of visceral nociception has been described in 
rodent models of colorectal distension and colitis. NaHS and L-cysteine significantly 
ameliorated pain responses and reduced the increase in spinal cFos expression 
associated with colorectal distension. The analgesic effect of H2S was mimicked by 
pinacidil (an agonist of K+ATP channels) and blocked by glibenclamide (an inhibitor of 
K+ATP channels), suggesting the activation of K+ATP channels in the modulation of 
visceral pain [97]. A more pronounced anti-nociceptive effect of H2S was also 
observed in rats that were recovering from a bout of colitis induced by trinitrobenzene 
sulfonic acid, in which allodynia (perception of pain from a stimulus that is usually 
not perceived as painful) and enhanced hyperalgesia were evident. Notably, NaHS 
treatment produced a reversal of the allodynia and hyperalgesia in postcolitic rats [97]. 
These effects occurred independently of the relaxant activity of H2S since they were 
observed at doses of NaHS that did not increase colonic compliance. Additionally, 
ATB-429, an H2S-releasing non-steroidal anti-inflammatory drug (NSAID), produced 
a significantly greater effect in alleviating visceral pain perception induced by 
colorectal distension in both healthy and postcolitic rats by activating K+ATP channels 
as compared to its parent drug, thus, providing further evidence for an anti-
nociceptive effect of H2S [98].  
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Effects on gut secretion   
It has been revealed that a vast majority of guinea pig and human submucous and 
myenteric neurons express CBS and CSE, thus confirming that enteric neurons are 
able to synthesize H2S. NaHS and L-cysteine increased chloride secretion in human 
and guinea pig submucosa/mucosa preparations, but not in the colonic epithelial cell 
lines. The dose-related secretory response of NaHS was significantly abolished by 
tetrodotoxin, capsaicin desensitization, and the TRPV1 antagonist capsazepine 
whereas inhibition of endogenous H2S synthesis with CSE and CBS inhibitors and 
capsaicin desensitization markedly abrogated L-cysteine-evoked ion secretion. The 
H2S-induced excitatory response was also found to occur independently of K+ATP 
channels and Ca2+ mobilization. The findings suggest that H2S acts as a novel pro-
secretory modulator in the guinea pig and human colon and its action mainly involves 
TRPV1 on extrinsic primary afferent terminals, which in turn, activate enteric neurons 
that provide the final secretomotor pathway to the mucosa [99]. In a later study, it was 
shown that H2S evoked mucosal secretion and increased spike activity in afferent 
neurons by targeting TRPV1 that stimulates cholinergic secretomotor neurons via 
release of substance P (SP). The H2S-elicited activation of TRPV1 may also target 
intracellular Ca2+-dependent pathways and phosphoinositide 3-kinase (PI3K) 
signaling mechanisms [100]. Finally, another study has reported the involvement of 
H2S in modulating bile secretion. NaHS was found to inhibit bile secretion while 
inhibition of H2S generation with PAG provoked choleresis and biliary bicarbonate 






Effects on gastric mucosal integrity  
Several lines of evidence point to a protective role of H2S in maintaining mucosal 
integrity in the gastrointestinal tract. The gastric mucosa expresses both CBS and CSE 
and is capable of synthesizing H2S. In rodents exposed to acetylsalicyclic acid and 
NSAID, the expression of CSE mRNA and the extent of H2S production in gastric 
mucosa were significantly lowered. Exposure to H2S increased gastric mucosal blood 
flow, leading to reduction in systemic blood pressure. The H2S-evoked gastric 
vasodilatation was reversed by glibenclamide, clearly indicating the involvement of 
K+ATP channels [102]. In addition, it has been shown that suppression of endogenous 
H2S synthesis increased the susceptibility of gastric mucosa to NSAID-induced 
damage in the rats. In contrast, allyl disulfide, a garlic-derived H2S donor, prevented 
NSAID-induced decreases in gastric blood flow, increase in leukocyte adherence to 
vascular endothelium, and mucosal leukocyte infiltration [102].  
 
Effects on hepatic circulation  
Studies have shown that H2S is an important endogenous modulator of hepatic 
microcirculation. In particular, H2S attenuated vasoconstriction induced by 
norepinephrine in normal and cirrhotic (induced by bile duct ligation) rat liver. Such a 
vasoconstriction effect was blocked by glibenclamide. Similarly, administration of L-
cysteine in normal liver produced significant reduction in intrahepatic resistance as 
was observed with H2S. The vasorelaxation effect elicited by H2S appeared to be 
independent of endothelium since expression of CSE was detected only in hepatocyte 
and hepatic stellate cells but not in hepatic endothelial cells. Hence, it is logical to 
assume that hepatic stellate cells can generate H2S from L-cysteine and relax in 
response to H2S. Furthermore, induction of cirrhosis by either bile duct ligation or 
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administration of carbon tetrachloride caused a prominent reduction in CSE 
expression and H2S production in liver as well as a marked decrease in plasma H2S 
level. L-cysteine-induced relaxation of hepatic stellate cells or hepatic vessels was 
impaired in cirrhosis whereas the relaxant effect of NaHS remained intact, suggesting 
reduced synthesis of H2S but normal sensitivity to this gas in cirrhosis. These 
observations show that H2S insufficiency may result in an increase in hepatic vascular 
resistance in cirrhotic animals or humans and contributes to the pathogenesis of portal 
hypertension [103]. In addition, although H2S levels in cirrhotic patients were not 
measured, an elevated homocysteine level was evident in clinical cases of cirrhosis, 
indirectly supporting a possible role of H2S in the pathogenesis of cirrhosis [104].  
 
1.2.5.3.2 H2S in gastrointestinal diseases 
 
Gastric ulcer  
Gastric ulcer induced by serosal application of acetic acid produced significant 
upregulation of gastric CSE and CBS, leading to marked increase of H2S generation 
by gastric tissue. Treatment with H2S donors (Lawesson’s Reagent or 4-
hydroxybutyrate) or L-cysteine significantly accelerated ulcer healing. Combined 
treatment with an H2S donor (Lawesson’s Reagent) and an NO donor 
(glyceryltrinitrate) produced greater healing that was seen with either of these donors 
alone, but no synergistic effect was evident. Furthermore, the H2S-induced ulcer 
healing was not associated with opening of K+ATP channels since its agonist (pinacidil) 
and antagonist (glibenclamide) did not affect ulcer healing. For L-cysteine-induced 
enhancement of ulcer healing, administration of an inhibitor of CSE significantly 
impaired ulcer healing, thereby suggesting that the beneficial effects of L-cysteine on 
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ulcer healing were indeed related to its metabolism to liberate H2S. Collectively, the 
findings suggest that H2S generated by gastric mucosa in response to gastric injury 
may contribute to enhancement of ulcer healing [105].  
 
Ulcerative colitis 
In a rat model of colitis induced by intracolonic administration of trinitrobenzene 
sulfonic acid, marked elevation of H2S synthesis was observed [106]. Inhibition of 
colonic H2S synthesis markedly exacerbated colitis, resulting in significant mortality 
whereas intracolonic administration of H2S donors resulted in a significant reduction 
in expression of TNF-α and severity of colitis. Besides, inhibition of H2S synthesis in 
healthy rats resulted in inflammation and mucosal injury in the small intestine and 
colon along with downregulation of cyclooxygenase-2 (COX-2) and prostaglandin 
synthesis. Thus, these results suggest that H2S produced in the context of colitis is 
exerting a predominantly beneficial effect (inhibition of its synthesis leads to 
exacerbated colitis). Moreover, in healthy animals, H2S synthesis appears to act as a 
tonic downregulator of granulocyte infiltration into intestinal tissues [106]. The 
protective role of H2S in modulating ulcerative colitis was further supported by the 
effect of H2S-releasing derivative of mesalamine (ATB-429). Specifically, ATB-429 
treatment in trinitrobenzene sulfonic acid-induced colitis in mice facilitated rapid 
resolution of the disease, most probably by reducing expression of pro-inflammatory 
cytokines and accelerating healing of injured gastrointestinal tissues [107]. 
 
1.2.5.4 Roles of H2S in endocrine system  
Abnormal biosynthesis and metabolism of H2S have been implicated in the regulation 
of insulin secretion from pancreatic β-cells and may contribute to the pathogenesis of 
27 
 
diabetes melitus. Increased concentration of glucose resulted in increased intracellular 
ATP accumulation, blockade of K+ATP channels, depolarization of plasma membrane, 
Ca2+ influx, and insulin release. Indeed, it was reported that plasma L-cysteine level 
and expression of both CSE and CBS were significantly elevated in diabetic rats [108]. 
Likewise, an overproduction of H2S and an upregulated gene expression of CBS and 
CSE in the liver and pancreas were evident in streptozotocin diabetic rats [109]. In 
addition, overexpression of CSE gene and NaHS intervention in cultured rat 
insulinoma cell line have been demonstrated to abolish glucose-potentiated insulin 
release through stimulation of K+ATP channels [110]. L-cysteine also inhibited insulin 
release by multiple actions on the insulin secretory machinery including activation of 
K+ATP channels through H2S synthesis [111].   
 
Apart from the involvement of K+ATP channels, H2S induced apoptosis of insulin-
secreting β-cells by enhancing endoplasmic reticulum stress via p38 mitogen-
activated protein kinases (MAPKs) activation [112]. Recent data also suggest that 
endogenous H2S derived from adipose tissues may inhibit the basal and insulin-
stimulated glucose uptake via PI3K but not K+ATP channels, implying that H2S might 
function as a novel insulin resistance regulator [113]. Nevertheless, all these findings 
suggest that deranged synthesis of H2S could be a relevant pathogenic step in the 
disease progression of diabetes mellitus and that novel therapeutic strategy for 
diabetes could be achieved by inhibiting endogenous H2S production from pancreas 






1.2.5.5 Roles of H2S in reproductive system  
H2S has been shown to exert vasodilatory and pro-erectile actions on penile corpus 
cavernosum, a highly vascularized penile tissue, in the rats and monkeys [60]. H2S 
also relaxed the rabbit corpus cavernosum, with the possibility of involvement of the 
cAMP pathway [114]. These studies have unambiguously suggested the importance 
of H2S in facilitating erectile function. More importantly, human penile tissue 
expresses both CBS and CSE, and can efficiently convert L-cysteine to H2S. Both 
NaHS and L-cysteine caused a concentration-dependent relaxation in strips of human 
corpus cavernosum. Moreover, the L-cysteine-induced relaxation was inhibited by 
CBS inhibitor amino oxyacetic acid, further confirming the role of H2S in the 
regulation of erectile function [61].  
 
Besides, H2S relaxed uterine smooth muscle whereas L-cysteine and NaHS inhibited 
spontaneous contractility of isolated pregnant rat uterine strips in vitro [115, 116]. 
Recent data have also identified the endogenous production of H2S, possibly via CBS 
and CSE enzymes, in rat and human intrauterine tissues. Furthermore, NO was shown 
to increase the production of H2S in rat fetal membranes. Also, H2S generation was 
significantly elevated in human placenta, rat uterus, and rat fetal membranes under 
low oxygen conditions. Hence, H2S may play an important role in maintaining uterine 
quiescence during pregnancy as an oxygen sensor and vasodilator [117].  
 
1.2.5.6 Roles of H2S in inflammation 
Inflammation is a protective physiological reaction of vascularized tissue to local 
injury or tissue destruction. It is a complex, highly regulated sequence of events that 
can be provoked by a variety of stimuli including pathogens, noxious mechanical and 
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chemical agents, metabolic and autoimmune responses. The five clinical (‘cardinal’) 
signs of inflammation, which represent the macroscopic culmination of a multitude of 
molecular and cellular processes, include redness (rubor), heat (calor), swelling 
(tumor), pain (dolor) and loss of function (functio laesa) [118]. The goal of 
inflammation is to eliminate the cause, to remove destructed tissue and, through 
regeneration or repair, to restore metabolism and function of the organs to the state of 
dynamic balance [119]. The inflammatory response occurs in the vascularized 
connective tissue, including plasma, circulating cells, blood vessels, cellular and 
extracellular components [118]. It comprises activation of multiple pathways, 
including several molecular components such as the cytokine network, the 
coagulation cascade, the complement system, and their multidirectional interactions; 
while the cellular components are in particular the leukocytes and the vascular 
endothelium [120]. Activation of these inflammatory systems results in a massive 
influx of inflammatory cells to the site of injury, followed by release of chemokines 
and soluble mediators from locally residing cells, including vascular endothelial cells, 
dendritic cells, macrophages, and interstitial fibroblasts. Signals from these events 
alter the local adhesion molecule profile and create a chemotactic gradient that 
recruits cells from the circulation, such as polymorphonuclear neutrophils, 
monocytes/macrophages and lymphocytes. All of these inflammatory/immune 
effector cells participate in the orchestration of inflammatory response, leading to 
increased microvascular caliber, enhanced vascular permeability, leukocyte 
recruitment, and release of inflammatory mediators [118].  
 
Inflammation is usually a localized event. However, when an infectious agent is 
capable of escaping the confines of the immediate tissue via the circulatory system or 
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lymphatic system, where it may spread to other parts of the body, systemic 
inflammation or SIRS ensues. SIRS can be precipitated by both infective and non-
infective causes. Infective causes of SIRS include sepsis and septic shock, infection 
caused by bacterial pathogens, viruses, fungi, and parasites whilst non-infective 
causes of SIRS include acute pancreatitis, trauma, surgery, and burns [119]. At times, 
SIRS can compromise, without therapeutic intervention, the function of various organ 
systems resulting in MODS and eventually death of the host [119, 120].  
 
Depends on the duration and kinetics of the reaction, the process of inflammation can 
be divided into acute or chronic. Generally, acute inflammation is the immediate and 
early host response to injurious insults. It is of relatively short duration, lasting for 
minutes, several hours, or a few days. The exudation of fluid and plasma proteins 
(edema), emigration of leukocytes (predominantly neutrophils), increased leukocyte 
adhesion to the vascular endothelium via adhesion molecules, release of biochemical 
mediators such as cytokines, chemokines, prostaglandins, plasma proteases, as well as 
gaseous mediators including NO, CO, and H2S, characterize acute inflammatory 
response [118]. Examples of acute inflammation are sepsis, septic shock, multi-organ 
failure and pancreatitis. Chronic inflammation is of longer duration (weeks or months) 
in which active inflammation, tissue destruction, and attempts at healing proceed 
simultaneously. Its main features are the infiltration of mononuclear cells 
(macrophages, lymphocytes and plasma cells), tissue destruction mediated 
predominantly by the inflammatory cells, and the proliferation of blood vessels 




H2S seems to present paradoxical effects in the inflammatory process. Both pro- and 
anti-inflammatory actions of H2S have been reported in vitro and in vivo, depending 
on the experimental model and dose/concentration used. In particular, different H2S 
donors may produce conflicting results due to their dissimilar pharmacokinetic and 
pharmacodynamic properties. Different regimen (dose and time of drug 
administration) may also contribute to the diverse outcomes of H2S in different 
disease conditions. Due to the nature of different disease etiologies, H2S may exert 
distinctive functions in diverse disease states and thus contributes to the observed 
opposing effects. At micromolar concentrations (i.e. low/physiological 
concentrations), multiple studies have demonstrated the cytoprotective and anti-
inflammatory effects of H2S. In contrast, higher (milimolar) exposure of H2S, which 
could be endogenously produced in an already inflamed site, tends to be cytotoxic and 
pro-inflammatory [19]. Its biological significance in the context of inflammation 
remains complex. Hence, it is still in an early stage to definitely conclude on the pro-
inflammatory and/or anti-inflammatory roles of H2S. 
 
1.2.5.6.1 Pro-inflammatory roles of H2S  
 
Immune cells 
Several early studies have reported that polymorphonuclear leukocytes (PMNs) exert 
enhanced anti-bacterial functions in the presence of high concentrations of H2S. A 
preliminary work reported that exposure of PMNs to 1 mM sulfide had no effect on 
their MPO activity or their capacity to initiate respiratory burst, and only decreased 
phagocytosis and killing of bacteria to a minor extent. The findings imply that PMNs 
may be able to function in infected sites with high sulfide levels such as in the 
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gingival pockets of periodontal disease [121]. In a subsequent study, it was shown 
that PMNs had similar capacity for chemotaxis and release of granule contents under 
both aerobic and anaerobic conditions. Presence of sulfide only slightly decreased the 
migration of PMNs but had no effect on their degranulation functions, suggesting that 
PMNs could defend tissues against bacteria under harsh condition prevailing in the 
periodontal pockets where low oxygen and high H2S levels were evident [122]. 
Besides, it was found that sodium sulfide, an H2S donor, prevented the increase of 
cytosolic free Ca2+ concentration induced by ionomycin in PMNs, resulting in 
suppression of Ca2+-dependent cytoskeleton activities such as chemotaxis and 
degranulation. However, H2S primed PMNs for a stronger oxidative response both to 
Ca2+-dependent or Ca2+-independent stimulations. The findings may account for a 
more efficient phagocytic activity of PMNs and the subsequent oxidative killing 
under reoxygenation of the anaerobic infectious areas [123]. 
 
Furthermore, it has been reported that reactive oxygen species generated from 
activated neutrophils could oxidize H2S to form sulfite; which then acts to upregulate 
leukocyte adhesion and neutrophil functions, through activation of Mac-1 β2-integrin 
(CD11b/CD18) and PKC/Ca2+-calmodulin pathway, respectively [31, 124, 125]. 
Administration of NADPH oxidase inhibitor suppressed whilst exogenous application 
of NaHS enhanced these responses [124]. In addition, H2S provoked the short-term 
survival of granulocytes via inhibition of caspase-3 cleavage and p38 MAPK 
activation, thereby contributed to the bactericidal activity of neutrophils [126]. In 
human monocyte cell line U937, H2S dose-dependently triggered monocyte activation, 
leading to enhanced synthesis of pro-inflammatory cytokines through activation of the 
extracellular signal-regulated kinase-nuclear factor-κB (ERK-NF-κB) pathways. 
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Notably, pre-treatment with NF-κB inhibitor (Bay 11-7082) or ERK kinase (MEK-1) 
antagonist (PD 98059) markedly inhibited H2S-evoked activation of NF-κB and 
production of TNF-α, interleukin (IL)-1β, and IL-6 [127]. Collectively, these data 
reveal that H2S may augment inflammatory response through stimulation of immune 
cell functions. 
 
Hindpaw edema  
Edema is the excessive accumulation of serous fluid in the intercellular spaces of 
tissues in skin or in one or more cavities of the body. Edema occurs as a result of 
increased blood vessel wall permeability and represents part of the acute, defined, and 
non-immune inflammatory response. It is commonly modeled in the laboratory 
through the use of carrageenan, a mucopolysaccharide extract of a species of red algae 
called Chondrus crispus [128]. Importanltly, inhalation of H2S gas is known to induce 
substantive edematogenic effects in the lungs, suggesting that endogenous H2S could 
also promote tissue swelling [129]. Indeed, in a rat model of carrageenan-induced 
hindpaw edema, an increase in endogenous H2S synthesizing enzyme activity was 
observed in inflamed hindpaws, suggesting a localized overproduction of H2S during 
inflammation. Treatment with PAG, an irreversible inhibitor of CSE, significantly 
attenuated H2S synthesizing enzyme activity and MPO activity in a dose-dependent 
manner, thereby leading to alleviation of hindpaw edema as evident by reduction in 
hindpaw weight. Since hindpaw edema induced by intraplanar injection of 
carrageenan in the rat is commonly used to assess local inflammatory response, these 
data suggest that H2S is pivotally involved in the manifestation of hindpaw local 
inflammation [7]. The underlying mechanism remains unclear but the vasodilatory 
effect of H2S is likely to contribute to the pathological process of edema.  
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Furthermore, increased concentration of H2S was found in homogenates prepared 
from rat hindpaws injected with 5% formalin. Elevated levels of animal nociceptive 
flinching and hindpaw edema were also observed. Notably, these effects were 
markedly attenuated by treatement with PAG while co-injection of formalin with 
NaHS into the rat hindpaws increased animal nociceptive behaviour. Collectively, 
these findings support a pro-inflammatory and pro-nociceptive role for H2S in the 
formalin model of rat hindpaw inflammatory pain [130].  
 
In a more recent study, injection of NaHS and L-cysteine into mouse hindpaw resulted 
in edema formation characterized by a fast onset of edematogenic action, coupled 
with increased prostaglandin levels in exudates of hindpaw. Besides, the histological 
examination clearly showed an inflammatory state with a loss of tissue organization 
following NaHS or L-cysteine administration. The edematogenic response occurred 
independently of histamine or serotonin release and K+ATP channel activation. 
However, edema formation was significantly prevented by the inhibition of 
cyclooxygenases and selective blockade of phospholipase A2, suggesting the 
involvement of phospholipase A2 and prostaglandin production in the pro-
inflammatory effects of H2S in mouse hindpaw edema development [131]. 
 
Acute pancreatitis 
Acute pancreatitis is an acute inflammatory condition of the pancreas that may extend 
to local and distant extrapancreatic tissues. It is a common clinical condition broadly 
classified as mild, self-limiting form to a more severe, highly morbid, and frequently 
lethal attack. Approximately 80% of the patients suffer mild pancreatitis that is 
usually presented clinically as abdominal pain while the remaining 20% with severe 
35 
 
attack are characterised by extensive pancreatic necrosis, often with progress to SIRS, 
MODS, and eventually death [132]. The factors that determine the severity of acute 
pancreatitis are mostly unknown. Most cases are secondary to biliary disease or 
excess alcohol consumption. It is believed that intraacinar activation of pancreatic 
zymogens (particularly trypsinogen), which leads to pancreatic acinar cell damage 
and auto-digestion of the pancreas, represents the critical initiating event of acute 
pancreatitis. Subsequently, release of inflammatory mediators from necrotising acinar 
cells into the general circulation results in the manifestation of SIRS. It is this 
systemic response that is widely thought to be ultimately responsible for the majority 
of the morbidity and mortality [133]. 
 
The potentially pro-inflammatory role of endogenously produced H2S was first 
described in a mouse model of caerulein-induced acute pancreatitis [9]. In this study, 
caerulein hyperstimulation resulted in an increase in plasma H2S level. In addition, 
H2S synthesizing enzyme activity and CSE (as determined by mRNA expression) 
were present in the pancreas. Prophylactic or therapeutic treatment with PAG, an 
irreversible inhibitor of CSE, significantly mitigated the severity of caerulein-induced 
acute pancreatitis as evidenced by reduced plasma amylase activity, pancreatic MPO 
activity, pancreatic acinar cell necrosis, and pancreatic injury; and acute pancreatitis-
associated lung injury as shown by marked attenuation of lung MPO activity and 
histological evidence of diminished lung injury (alveolar thickening and leukocyte 
infiltration) [9]. In a later study, pancreatic acinar cells were identified as the cellular 
sources of H2S in acute pancreatitis. Notably, caerulein increased the concentration of 
H2S, CSE mRNA expression (but not CBS), and H2S synthesizing enzyme activity in 
these cells. The heightened H2S synthesizing activity was significantly lowered by 
36 
 
PAG, thereby suggesting that CSE may be the main enzyme involved in H2S 
formation in pancreatic acinar cells [134].  
 
In another study, the role of H2S and chemokines in acute pancreatitis was explored 
using both in vitro and in vivo approaches [135]. Inhibition of H2S synthesis with 
PAG attenuated the development of inflammatory process in caerulein-induced acute 
pancreatitis and the associated lung injury, and acts as an anti-inflammatory agent 
through downregulation of CC chemokine (monocyte chemotactic protein (MCP)-1 
and macrophage inflammatory protein (MIP)-1α) and CXC chemokine (MIP-2) 
production in pancreatic acini, pancreas, and lungs [135]. In a more recent study, H2S 
was found to induce ICAM-1 expression and neutrophil adhesion to caerulein-treated 
pancreatic acinar cells through NF-κB and Src-family kinases (SFKs) pathways [136]. 
In particular, stimulation of caerulein-treated acinar cells with NaHS resulted in a 
time-dependent activation of SFKs, concurrent with inhibitory κBα (IκBα) 
degradation and NF-κB activation. Similarly, an upregulated expression of ICAM-1 
and enhanced neutrophil adhesion to acinar cells were observed. Inhibition of SFKs 
with PP2, a potent and selective SFK inhibitor, impaired H2S-induced ICAM-1 
expression and neutrophil adhesion secondary to the inhibition of NF-κB activation. 
Moreover, blocking of NF-κB with NF-κB inhibitor inhibited NaHS-induced ICAM-1 
expression. Taken together, these data indicate that H2S engages SFKs to signal 
ICAM-1 expression in caerulein-treated pancreatic acinar cells by a mechanism 






Chronic obstructive pulmonary disease 
Apart from the role of H2S in acute inflammatory diseases, its inflammatory 
contribution in chronic inflammatory pathologies such as that in chronic obstructive 
pulmonary disease (COPD) has been explored [137]. COPD is characterized by 
progressive airflow obstruction and airway inflammation, in which co-occurrence of 
both chronic bronchitis (lung damage and inflammation in the large airways) and 
emphysema (lung damage and inflammation of the air sacs/alveoli) are evident. In 
COPD, serum H2S level was markedly elevated in stable COPD patients as compared 
to age-matched controls or those with acute exacerbation of COPD (AECOPD).  It 
was negatively correlated with severity of airway obstruction in stable COPD patients 
but positively correlated with lung functions in all patients with COPD and healthy 
controls. Patients with AECOPD and increased systolic pulmonary artery pressure 
had lower serum H2S concentrations than those with normal systolic pulmonary artery 
pressure, indicating a negative relation between H2S and systolic pulmonary artery 
pressure in AECOPD patients. In addition, AECOPD patients had greater neutrophil 
but lower lymphocyte proportion in sputum than patients with stable COPD, 
suggesting a potential role of H2S in regulating inflammatory response at different 
stages of COPD. Collectively, this study supports the involvement of H2S in the 
pathogenesis of airway obstruction and inflammation characteristic of COPD. More 
importantly, it highlights that alterations in H2S levels may be closely associated with 
disease activity and severity of COPD [137].  
 
Endotoxemia and sepsis 
Bacterial endotoxins, such as LPS, have been demonstrated to induce excessive 
activation and upregulation of vascular K+ATP channels, to induce hypotension, and to 
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substantially reduce vascular sensitivity to vasoconstrictive agents [138, 139]. 
Speculation that endogenous H2S may play a role in endotoxic and/or septic shock has 
been proposed since it functions as a potential endogenous ligand for K+ATP channels 
and induces K+ATP channel-mediated vasorelaxation in vascular tissues [62]. Indeed, 
in one study of endotoxic shock in the mouse, LPS administration produced a dose- 
and time-dependent increase in plasma H2S level and H2S synthesizing activity in the 
liver and kidney. LPS injection also caused an elevation in liver and kidney CSE gene 
expression, lung and kidney MPO activity alongside histological evidence of lung, 
liver, and kidney tissue inflammatory damage. Administration of NaHS resulted in 
marked histological signs of lung inflammation, elevated lung and liver MPO activity, 
and raised plasma TNF-α concentration while treatment with PAG exhibited 
significant anti-inflammatory effects as evidenced by reduced MPO activity and 
ameliorated tissue damage in lung and liver [10]. Besides, endotoxemia induced 
significant increase in MPO activity and in the expression and activity of CBS and 
CSE in the liver. Notably, inhibition of endogenous H2S formation by PAG 
significantly attenuated the LPS-induced increase in H2S formation and neutrophil 
infiltration in the liver, concurrent with mitigation of hepatocellular, pancreatic, and 
neuromuscular injury associated with endotoxic shock [140]. 
 
Apart from endotoxemia, H2S has been shown to be overproduced in polymicrobial 
sepsis. Using a clinically relevant animal model of sepsis, CLP-induced sepsis 
significantly increased plasma H2S level, liver H2S synthesizing activity, and liver 
CSE mRNA expression 8 h after CLP compared with sham operation. Induction of 
sepsis also resulted in heightened lung and liver MPO activity, coupled with 
histological evidence of lung and liver injury. Administration of NaHS further 
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aggravated these parameters whereas prophylactic or therapeutic administration of 
PAG abolished these deleterious effects, concurrent with lowered plasma H2S level 
and liver H2S synthesizing activity, as well as sepsis-associated mortality [11]. Using 
two complementary and different approaches: administration of NaHS as an H2S 
donor and inhibition of H2S synthesis by PAG, this study highlighted the pro-
inflammatory role of H2S in regulating sepsis-evoked systemic inflammation and 
multiple organ injury. In a later study, H2S was shown to mediate inflammation in 
CLP-induced sepsis through upregulation of cytokines and chemokines via NF-κB 
[141]. CLP-induced sepsis caused a significant increase in the mRNA and protein 
levels of TNF-α, IL-1β, IL-6, MIP-2, and MCP-1 in the plasma, lung, and liver. 
Inhibition of endogenous H2S formation by PAG significantly decreased the 
concentrations of these pro-inflammatory cytokines and chemokines, coupled with 
decreased nuclear translocation and activation of NF-κB in lung and liver. Blockade 
of H2S formation also attenuated pulmonary and hepatic injury, as indicated by 
reduced lung microvascular permeability and plasma alanine aminotransferase 
activity, respectively. On the other hand, application of exogenous NaHS further 
aggravated sepsis-associated systemic inflammation and increased NF-κB activation. 
The involvement of NF-κB in  H2S-induced lung inflammation in sepsis was further 
confirmed using specific NF-κB inhibitor Bay 11-7082, in which it reduced 
pulmonary NF-κB activity and protein expression of inflammatory cytokines and 
chemokines aforementioned [141].  
 
Using intravital microscopy, it was demonstrated in a subsequent study that CLP-
induced sepsis resulted in an obvious increase in leukocyte-endothelial interaction in 
mesentery venules [142]. Prophylactic and therapeutic administration of PAG 
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significantly alleviated whereas injection of NaHS further upregulated leukocyte 
rolling and adherence. Similar patterns were observed for the mRNA and protein 
expression levels of adhesion molecules, including ICAM-1, P-selectin, and E-
selectin in the lung and liver of septic mice. These results suggest that endogenous 
H2S may exert its effect at the leukocyte-endothelium interface in sepsis through 
modulation of tissue levels of adhesion molecules. Furthermore, in normal mice 
administrated with NaHS to induce lung inflammation, NaHS caused an evident 
increase in the pulmonary level of adhesion molecules and consequently amplified 
lung neutrophil sequestration. Notably, these changes were reversed by treatment with 
Bay 11-7082. In neutrophils obtained from H2S-treated mice, CXC chemokine 
receptor-2 expression was upregulated, leading to an obvious elevation in MIP-2-
directed migration of neutrophils. Therefore, it is clear that H2S acts as an important 
endogenous regulator of leukocyte activation and trafficking in CLP-induced sepsis 
through a mechanism involving NF-κB activation [142].  
 
Finally, H2S was found to regulate inflammatory response in polymicrobial sepsis 
through activation of the ERK signaling pathway [143]. In this study, CLP-induced 
sepsis resulted in a time-dependent increase in the synthesis of endogenous H2S. 
Maximum phosphorylation of ERK1/2 and degradation of IκBα in lung and liver were 
observed 4 h after CLP. Inhibition of H2S formation by PAG significantly reduced the 
phosphorylation of ERK1/2 in lung and liver, coupled with decreased degradation of 
IκBα and activation of NF-κB. In contrast, injection of NaHS significantly enhanced 
the activation of ERK1/2 in lung and liver, therefore leading to a further rise in tissue 
NF-κB activity. As a result, treatment with PAG significantly reduced the production 
of cytokines and chemokines in sepsis, whereas exogenous H2S greatly increased it. 
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In addition, treatment with PD98059, an inhibitor of ERK kinase (MEK-1), 
significantly prevented NaHS from aggravating systemic inflammation in sepsis [143]. 
Since previous report has demonstrated the association of H2S with NF-κB in 
regulating sepsis-evoked inflammatory response [141], this study, therefore, implied 
that H2S may regulate SIRS in sepsis by activating ERK and NF-κB pathways.  
 
Burn injury 
Burn injury represents one of the most widespread and devastating forms of trauma. A 
burn injury occurs when some or all layers of skin and other tissues are destroyed by 
hot liquid, hot contact, flame, radiation, electricity or chemicals. The majority of 
burns are due to flame related injuries and scald burns resulting from contact with hot 
liquid [144]. Secondary organ damage, particularly ALI and ARDS, are common 
complications in patients with extensive burns [145]. In severe cases of burn injury, 
even in the absence of inhalational injury and infection, the ongoing local burn wound 
inflammation is sufficient to incite SIRS and consequent remote organ injury. The 
degree of inflammatory response correlates directly with the percentage of total body 
surface area burn. The underlying mechanism is thought to be a network combination 
of burn-induced liberation of inflammatory mediators, such as cytokines, chemokines, 
complement factors, activation of neutrophil trafficking, and potentially neural pro-
inflammatory stress signaling [146]. 
 
Recently, H2S has been shown to act as a critical mediator of severe burn injury-
induced inflammation in the mouse [8]. The result in this study showed that burn 
injury in mice subjected to 25% total body surface area full thickness burn augmented 
significant increase in plasma H2S levels, liver and lung CSE mRNA expression, and 
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liver CSE synthesizing activity. Furthermore, the enhanced H2S/CSE pathway 
correlated with heightened burn-associated systemic inflammation, as evidenced 
biochemically and histologically by increased MPO activity and worsened 
histological changes in the lung and liver. Importantly, the development of systemic 
inflammation and multiple organ damage were mitigated when endogenous H2S 
synthesis was blocked by prophylactic or therapeutic treatment of PAG, along with 
attenuation of plasma H2S levels, liver and lung CSE mRNA expression, and liver 
CSE synthesizing activity. Administration of NaHS at the same time of burn injury 
resulted in a further rise in MPO activity and more severe tissue injury in the lung and 
liver. Collectively, these findings have shown for the first time the role of H2S in 
contributing to exaggerated inflammatory damage after burn injury [8].  
 
1.2.5.6.2 Anti-inflammatory roles of H2S   
Apart from the strong pro-inflammatory actions of H2S, multiple studies have also 
suggested an anti-inflammatory role for H2S. H2S can interfere with inflammatory 
process by diminishing tissue injury induced by neutrophils. Such mechanisms 
involved induction of apoptosis in neutrophils by H2S [147] and inhibition of tissue 
injury mediated by neutrophil-derived hypochlorous acid [32]. Indeed, H2S has been 
shown to attenuate brain tissue injury caused by neutrophil-derived hypochlorous acid. 
In cultured neuroblastoma cells, H2S inhibited hypochlorous acid-mediated 
cytotoxicity, intracellular protein oxidation, and lipid peroxidation. It has also been 
reported to interfere with peroxynitrite-mediated cytotoxicity and tyrosine nitration 




In addition, H2S can contribute to resolution of inflammatory reaction by stimulating 
upregulation of heme oxygenase-1 and CO, both of which are well-documented with 
anti-inflammatory and cytoprotective effects [148]. In cultured murine RAW264.7 
macrophages, H2S suppressed the LPS-induced expression of inducible NO synthase, 
NO production, and NF-κB activation. These effects were mediated by H2S-evoked 
increased expression of heme oxygenase-1 and CO production via ERK1/2 signaling 
pathway [149]. Likewise, both endo- and exogenous H2S significantly reduced LPS-
induced NO production and TNF-α secretion in both primary and cultured microglia 
as well as immortalized murine BV-12 microglia cells through inhibition of LPS-
induced activation of p38 MAPKs [150]. Recently, GYY4137, a novel slow-releasing 
H2S donor, was shown to dose-dependently inhibit LPS-stimulated release of pro-
inflammatory mediators such as IL-1β, IL-6, TNF-α, NO and prostaglandin E2 (PGE2) 
but enhanced the production of anti-inflammatory chemokine IL-10 in macrophages. 
Interestingly, in the same study, NaHS at high concentration resulted in increased 
synthesis of IL-1β, IL-6, TNF-α, NO, and PGE2 [151]. The findings not only explain 
some of the apparent discrepancies in the literature regarding the pro- and anti-
inflammatory roles of H2S, but also imply that the role of H2S in inflammation could 
be influenced by the presence of different concentrations of H2S.  
 
H2S has also been implicated in alleviation of other inflammatory hallmarks including 
swelling and pain. Specifically, H2S-releasing drug S-diclofenac was shown to inhibit 
carrageenan-evoked hindpaw edema and neutrophil infiltration and that S-diclofenac 
produced these effects more potently than its parental moiety diclofenac. Hence, the 
enhanced anti-inflammatory effect of S-diclofenac was proposed to be related to its 
ability to release H2S at the inflamed site [152]. Using intravital microscopy, both 
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NaHS and Na2S were found to inhibit aspirin-evoked leukocyte adherence in 
mesenteric venules via activation of K+ATP channels. Several different H2S donors 
were also found to inhibit leukocyte infiltration in rat air pouch model and 
carrageenan-induced paw edema. Although opposing to the pro-inflammatory role 
reported in Bhatia et al. [7],  these data suggest that endogenous H2S acts as a tonic 
regulator of leukocyte adhesion to endothelium and leukocyte infiltration in acute 
local inflammation [153].  
 
In murine sepsis, a recent study by Spiller et al. [154] reported that H2S-induced 
neutrophil migration to the infectious focus attenuated sepsis-associated lethality. 
These data were consistent with that of Zhang et al.[142] in terms of H2S-induced 
leukocyte trafficking, however, Spiller et al. observed lung damage and mortality 
when H2S synthesis was reduced. The inconsistency may be largely attributed to the 
doses of NaHS used. Zhang et al. used NaHS at 10mg/kg, which increased plasma 
concentration of H2S and caused obvious lung and liver damage [11] whereas Spiller 
et al. used three doses of NaHS (10, 30, 100 µmol/kg) that approximated the 
physiological concentrations of H2S. Since low concentrations of H2S are closely 
associated with anti-inflammatory effects, these opposing findings of H2S are not 
surprising. Finally, the H2S-promoted gastric ulcer healing effects and alleviation of 
NSAID-induced gastric injury discussed earlier were also related to the anti-
inflammatory actions of H2S [105-107]. Collectively, these findings provide evidence 






1.2.5.6.3 H2S and neurogenic inflammation 
 
The concept of neurogenic inflammation  
The participation of the nervous system in inflammatory reactions was suggested over 
a century ago. In 1910, Bruce observed that the inflammatory response elicited by the 
application of mustard oil to the conjunctival sac in experimental animal models could 
be abolished by sensory nerve ablation [155, 156]. Later work by Jancsό et al. 
furnished firm evidence for the existence of an inflammatory response induced by a 
purely neurogenic route that results from the activation of sensory afferent nerves 
[157]. It was demonstrated that capsaicin, the pungent principle of red pepper, causes 
pain and inflammation, which can eventually be completely prevented by prior 
repeated local or systemic administration of this agent, a phenomenon termed 
“capsaicin desensitization”. Capsaicin desensitization or chronic sensory denervation 
prevented the inflammatory effect of many chemical irritants including mustard oil 
and capsaicin. It was concluded that a variety of chemical irritants exert their 
nociceptive and inflammatory effects including vasodilatation and increased vascular 
permeability by the stimulation of capsaicin-sensitive sensory nerve endings in the 
periphery [157]. More importantly, these early investigations of the sensory neuron-
related inflammatory reactions led to the concept of “neurogenic inflammation”, 
which encompasses manifestations of inflammatory events triggered by the activation 
of primary sensory neurons and the subsequent release of inflammatory molecules in 
response to an injurious stimulus. Neurogenic inflammation was thus recognized as a 





Figure adapted from Matthay and Ware, Nat Med, 2004 [159]. 
 
Figure 1.4 Neural modulation of inflammation. Neural modulation of inflammation 
consists of both pro- and anti-inflammatory pathways. In response to noxious stimuli 
or tissue injury, unmyelinated sensory C-fibers or myelinated Aδ-fibers release pro-
inflammatory tachykinins such as substance P (SP) that induces vasodilation, 
increases endothelial permeability, and provokes inflammatory cell influx. In addition, 
SP binds to neurokinin-1 receptor (NK-1R) on inflammatory cells and stimulates the 
release of pro-inflammatory cytokines, initiating and perpetuating neurogenic 
inflammation. On the other hand, the anti-inflammatory arm of neural modulation 
involves the cholinergic anti-inflammatory pathway that signals through the efferent 
vagus nerve and the sympathetic nervous system that interact with immune cells or 
the adrenal neuro-endocrine axis; activation of these pathways result in decreased 





The components of neurogenic inflammation include plasma protein extravasation, 
vasodilatation, release of mast cell mediators, leukocyte trafficking and infiltration, 
recruitment and activation of inflammatory cells, and possibly other effects. 
Additional tissue-specific responses produced by neurogenic inflammatory 
mechanisms include smooth muscle relaxation/contraction in the urinary bladder, 
urethra and iris, inotropic and chronotropic effects on the heart, bronchoconstriction 
and hypersensitivity in the airways, and other effects [160]. All these effects are 
mediated by the peripheral release of neuropeptides known to coexist in the nerve 
endings of primary sensory neurons through the coordinated regulation of cellular 
signaling cascades that control the expression and secretion of pro-inflammatory 
cytokines, chemokines, adhesion molecules, and other bioactive substances required 
to orchestrate all phases of the collective neural inflammatory response [158].  
 
Transient receptor potential vanilloid type 1 
Formerly known as the vanilloid (capsaicin) receptor, the TRPV1 (transient receptor 
potential cation channel, subfamily V, member 1) receptor is a polymodal transducer 
belongs to the superfamily of TRP ion channels [161]. It is a single polypeptide of 
838 amino acids with a predicted molecular mass of 95 kD. TRPV1 is a tetrameric 
membrane protein with four identical subunits; each subunit contains large 
intracellular amino- and carboxyl-terminal cytosolic domains and six transmembrane-
spanning domains, which form a non-selective voltage-gated cation channel with high 
Ca2+ permeability (Figure 1.5) [162]. It is activated by diverse exogenous activators, 
including vanilloids (capsaicin, resiniferatoxin, olvanil), heat (≥ 43°C), and low pH (≤ 
6.0). Several endogenous ligands termed “endovanilloids” were also identified. For 
instance, anandamide, trypsin, arachidonic acid-derived lipoxygenase metabolites 
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such as prostaglandins and leukotriene B4, inflammatory mediators like nerve growth 
factor, bradykinin, H2S, and ATP [163]. TRPV1 is found predominantly in primary 
sensory (dorsal root, trigeminal, and vagal ganglion) neurons. These sensory nerves 
are of mixed type composed of small-diameter, unmyelinated sensory C-fibers that 
are most abundant, with also myelinated Aδ-fibers. They innervate all tissues and 
organs of the body, particularly those forming the respiratory, gastrointestinal, 
musculoskeletal, and cardiovascular systems [161-163]. 
 
 
Figure 1.5 Membrane topology of TRPV1 channel. TRPV1 has large intracellular 
amino- (N-) and carboxyl- (C-) terminal located in the cytosol and six transmembrane 
helices for sensing stimuli, with the cation pore forming between domains 5 and 6. 
The N-terminal contains at least three ankyrin repeats which are essential for channel 
function.  
 
Apart from its pivotal role in nociception and pain sensations, TRPV1 is critically 
important in the initiation and perpetuation of neurogenic inflammation (Figure 1.6) 
[161, 162, 164]. Many of the mediators released locally during tissue injury or during 
an inflammatory state can activate TRPV1 in the plasma membrane of sensory nerve 
fibers, leading to opening of channel pore and influx of cation, predominantly Ca2+, 
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followed by membrane depolarization with consequent release of sensory 
neuropeptides that initiate the cascade of neurogenic inflammation [164]. The 
peripheral release of neuropeptides such as SP, neurokinin-A (NK-A), neurokinin-B 
(NK-B), and calcitonin gene-related peptide (CGRP) are pro-inflammatory mediators 
capable of eliciting an inflammatory and immune response. Among these, SP serves 
as one of the principle mediators in neuro-immune interactions and plays a definitive 
role for the initiation of neurogenic inflammation in numerous pathological conditions 
[165].  
 
Figure modified from Julius and Basbaum, Nature, 2001 [166]. 
 
Figure 1.6 Involvement of TRPV1 in the mechanism of neurogenic inflammation. 
Tissue injury may release a variety of different types of inflammatory molecules that 
act to activate the TRPV1 channels in the plasma membrane of sensory nerve fibers. 
This leads to opening of channel pore and influx of cation, followed by generation of 
action potential signaling towards the CNS in the brain and membrane depolarization, 
and consequent release of sensory neuropeptides such as SP and CGRP that initiate 




SP was discovered by von Euler and Gaddum as an 11-amino acid peptide, with a 
structure comprising of: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 [167]. 
SP belongs to the tachykinin family of bioactive neuropeptides defined by their 
common carboxyl-terminal sequence Phe-X-Gly-Leu-Met-NH2, where X is an 
aromatic (Tyr or Phe) or a hydrophobic (Val or Ile) amino acid. This conserved 
sequence is essential for tachykinin’s binding and activation to its receptor [165]. In 
mammals, the tachykinin family of peptides comprises the neuropeptides SP, NK-A, 
NK-B, and the newly discovered endokinins/hemokinins. These peptides are encoded 
by three separate genes designated TAC1, TAC3, and TAC4, which replace the 
previously used terms preprotachykinin-A (PPT-A), PPT-B, and PPT-C. The TAC1 
gene gives rise to SP and NK-A whilst the TAC3 and TAC4 genes encode NK-B and 
endokinins/hemokinins, respectively (Figure 1.7) [168]. Expression of the TAC1 gene 
has been detected in both central and peripheral nervous systems, in enteric neurons 
of the gut, and in various cells of the immune system. In contrast, the TAC3 gene is 
found exclusively in the CNS [169]. The newly identified TAC4 gene is expressed 
most abundantly in pro- and pre-B lymphocyte cells [170], but is also detected in a 
variety of human and mouse peripheral tissues [171, 172].  
 
Biosynthesis of SP initially occurs as a larger protein in the ribosome of neuronal cell 
bodies of the trigeminal, jugular, and nodose ganglia. It is then packaged into storage 
vesicles and exported to the terminal endings of the central and peripheral branches of 
sensory neurons by a mechanism of axonal transport, where it is enzymatically 
converted to the undecapeptide and stored [173, 174]. Immunohistochemical and 
biochemical studies show that the accumulation of SP in the peripheral branches is 
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four times greater compared to the dorsal root [174]. SP is contained in and released 
from a distinct subpopulation of primary afferent nerves that are characterized by 
sensitivity to capsaicin due to the rich expression of TRPV1 [165]. Although neuronal 
sources represent the primary source of SP, in recent years, it has been suggested that 
SP is also produced by numerous immune cells, including neutrophils, macrophages, 




Figure 1.7 Biosynthesis of SP and related tachykinin peptides. Tachykinin 
peptides are synthesized through proteolytic cleavage of larger precursors called 
preprotachykinins (PPT) or TAC. The PPT-A (or TAC1) gene has three splice 
variants termed α, β, and γ forms. All three forms are able to produce SP, whereas 
only β- and γ-PPT-A yield neurokinin-A (NK-A). Neuropeptide-K (NP-K) and 
neuropeptide-γ (NP-γ) are two N-terminally extended forms of NK-A. The PPT-B (or 
TAC3) gene gives rise to neurokinin-B (NK-B) and the PPT-C (or TAC4) gene 
encodes for hemokinin/endokinin. For PPT-A, the location of each peptide sequence 





The biological actions of SP are mediated by at least three different seven-
transmembrane domain G protein-coupled receptors known as neurokinin-1 receptor 
(NK-1R), NK-2R, and NK-3R. Of these, the membrane-bound NK-1R has the highest 
affinity for SP, while NK-A and NK-B preferentially bind to NK-2R and NK-3R, 
respectively. The relative affinity of NK-1R for SP is 500 and 100 folds higher than 
its affinity for NK-A and NK-B [165]. Interestingly, the novel tachykinin designated 
hemokinin behaves like SP, showing remarkable selectivity for NK-1R as compared 
with NK-2R and NK-3R [176]. It should be emphasized, however, that at high 
concentrations, all tachykinins can act as full agonists on the three different 
tachykinin receptors but with lower affinities than on the preferred receptor. 
Furthermore, the distribution of NK-1R is found in all major organs of the body, and 
has been shown to be expressed in numerous immune cells, including neutrophils, 
eosinophils, lymphocytes, monocytes, macrophages, and mast cells. Binding of SP to 
NK-1R mediates rapid endocytosis and internalization of the receptor, resulting in 
desensitization of cells to SP signaling [165]. The effects of SP can be terminated by 
enzymatic degradation, mainly by the action of ectoenzyme neutral endopeptidase and 
to a lesser extent by angiotensin converting enzyme [177].  
 
SP has been established to exert a vast range of potent neuroimmunomodulatory 
effects in vitro and in vivo, influencing many immune and inflammatory disorders of 
the respiratory, gastrointestinal, and musculoskeletal systems. Its actions are evidently 
pro-inflammatory and hence plays a critical role in many inflammatory pathological 
conditions, including asthma, COPD, immune-complex-mediated lung injury, 
rheumatoid arthritis, inflammatory bowel disease, polymicrobial sepsis, endotoxemia, 
acute pancreatitis, and burns [165, 169]. In particular, SP activates inflammatory cells 
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to produce a variety of inflammatory molecules such as cytokines, chemokines, 
reactive oxygen species, and arachidonic acid derivatives that potentiate tissue 
inflammation, and vasoactive substances like histamine and serotonin that promote 
vascular leakiness and edema at the injured tissue site. Additionally, SP can 
specifically enhance lymphocyte proliferation and immunoglobulin production, 
provoke leukocyte chemotaxis and expression of adhesion molecules, and elicit 
activation of pro-inflammatory transcription factors; all of which exacerbate tissue 
injury and amplify the overall inflammatory response [165, 178]. Therefore, it is 
obvious that SP represents one of the major mediators in neuro-immune interactions, 
and that an extensive neuro-immune intersystem crosstalk exists between SP and the 
inflammatory response to injury. 
 
The involvement of H2S in neurogenic inflammation   
In recent years, H2S has been shown to implicate in neurogenic inflammation 
mediated by SP and TRPV1. In one study, H2S induced excitatory motor responses in 
the rat urinary bladder by activating capsaicin-sensitive primary afferent neurons. 
Following activation, these neurons released tachykinins activating post-junctional 
NK-1R and NK-2R [13]. Likewise, by stimulating TRPV1-expressing sensory nerve 
terminals, intratracheal instillation of NaHS increased total lung resistance and 
provoked the release of SP and CGRP from isolated guinea pig airways, thereby 
leading to the development of TRPV1-mediated neurogenic inflammation. Notably, 
these deleterious respiratory effects were greatly attenuated by capsaicin 




In the first report [179] on the direct interaction between H2S and SP in vivo, it was 
shown that exogenous administration of NaHS to normal mice caused a significant 
increase in circulating levels of SP in a dose-dependent manner. H2S, by itself, could 
also cause lung inflammation, as evidenced by significant increase in lung MPO 
activity and histological evidence of lung injury. The maximum effects of H2S on SP 
levels and on lung inflammation were observed 1 h after NaHS administration. At this 
time, an obvious elevation in pulmonary levels of TNF-α and IL-1β was also observed. 
In PPT-A knockout (PPT-A-/-) mice, H2S did not induce lung inflammation. 
Furthermore, treatment with CP96345 (NK-1R antagonist) protected mice against 
H2S-evoked lung inflammation. In contrast, treatment with antagonists of NK-2R, 
NK-3R, and CGRP receptor did not have any effect on lung inflammation caused by 
H2S. Lastly, blockade of neuropeptide release from sensory neurons by capsaicin 
desensitization or by treatment with capsazepine significantly protected mice against 
H2S-induced lung inflammation. These results demonstrated a key role of SP in 
modulating neurogenic inflammation in H2S-induced lung injury [179].  
 
In a murine model of caerulein-induced acute pancreatitis, PAG, given 
prophylactically or therapeutically, significantly reduced SP concentrations in plasma, 
pancreas, and lung [180]. Furthermore, PAG greatly suppressed PPT-A and NK-1R 
mRNA expressions in the pancreas and lung of mice subjected to caerulein-induced 
acute pancreatitis. These results suggested that the pro-inflammatory effects of H2S 
may be mediated by SP-NK-1R signaling in acute pancreatitis [180]. Similarly, in 
isolated mouse pancreatic acini, caerulein stimulation resulted in an obvious 
upregulation of SP levels and mRNA expression of PPT-A and NK-1R. 
Administration of NaHS further augmented these parameters in acinar cells whilst 
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inhibition of endogenous H2S production by PAG significantly suppressed them [134]. 
Collectively, both studies of the in vitro and in vivo models of acute pancreatitis 
highlighted the involvement of H2S as a novel mediator of neurogenic inflammation 
through interaction with SP and its primary receptor, NK-1R. 
 
In addition, H2S has been shown to upregulate SP in polymicrobial sepsis-associated 
lung injury as well [181]. In this study, PAG significantly decreased PPT-A gene 
expression and production of SP in lung, whereas administration of NaHS resulted in 
a further rise in pulmonary level of SP in CLP-induced sepsis. PPT-A gene deletion 
and treatment with L703606, an NK-1R antagonist, prevented H2S from aggravating 
lung inflammation. These same mice did not exhibit further increase in lung 
permeability after injection of NaHS. These findings showed that in sepsis, H2S 
upregulates the generation of SP that contributes to lung inflammation and injury 
mainly via activation of NK-1R [181]. Despite the compelling evidence showing that 
an increase in the endogenous synthesis of H2S can enhance release of SP, the 
interaction between H2S and TRPV1 has not been characterized in animal models of 
SIRS such as polymicrobial sepsis.  
 
1.3 Sepsis  
1.3.1 Definition of sepsis 
A consensus conference organized by the American College of Chest Physicians and 
the Society of Critical Care Medicine in 1991 has put forth the concept of SIRS. To 
meet the SIRS criteria, patients needed to satisfy at least two of the following: fever or 
hypothermia, tachycardia, tachypnea or hyperventilation, and leukocytosis or 
leukopenia. SIRS can be diagnosed without evidence of infection (i.e. without 
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positive blood cultures). When a documented or suspected infection is present, the 
occurrence of SIRS is termed sepsis. Hence, sepsis is a clinical condition that results 
from the presence of both SIRS and infection. Sepsis and its sequelae represent 
progressive stages of the same illness. Sepsis associated with organ dysfunction, 
hypoperfusion, or hypotension characterize severe sepsis. Septic shock is defined by 
severe sepsis accompanied by arterial hypotension, despite adequate fluid 
resuscitation [182]. The 2001 International Sepsis Definitions Conference revisited 
the 1991 sepsis consensus definitions and has validated the conceptual 
appropriateness of these terms. However, this conference concluded that the initial 
criteria for SIRS established in 1991 were overly sensitive and non-specific, and that 
an expanded list of signs and symptoms of sepsis would better reflect the clinical 
response to infection [1]. Hence, the diagnostic criteria for sepsis (Table 1.1) and the 
current definitions of sepsis and its sequelae (Table 1.2) are presented according to the 
2001 sepsis definitions conference.  
 
Table 1.1 Diagnostic criteria for sepsis  
Infection (documented or suspected) and some of the following. 
General variables  
 Fever or hypothermia 
 Tachycardia 
 Tachypnea 
 Altered mental state 
 Unexplained hyperglycemia  
Inflammatory variables  
 Leukocytosis or leukopenia 
 Increased C-reactive protein 
 Increased procalcitonin  
Hemodynamic variables 
 Arterial  hypotension  
 Abnormal cardiac index 
Tissue perfusion variables 
 Unexplained hyperlactatemia 
 Decreased capillary refill or skin mottling  
Organ dysfunction variables 
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 Unexplained hypoxemia  
 Acute oliguria 
 Coagulation abnormalities 
 Ileus 
 Hyperbilirubinemia 
 Thrombocytopenia  
 
 
Table 1.2 Standard definitions for sepsis and sepsis-associated conditions 
Terminology Definition 
Infection A pathologic process induced by a microorganism 
SIRS 
The systemic inflammatory response to a variety of severe clinical insults. 
The response is manifested by two or more of the following conditions: 
1. Temperature > 38°C or < 36°C 
2. Heart rate  > 90 beats/min 
3. Respiratory rate > 20 breaths/min or PaCO2 < 32 mm Hg 
4. White blood cell count >12000/mm3 or < 4000/mm3 or > 10% immature 
forms 
Sepsis The systemic inflammatory response to the presence of infection 
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion, or hypotension 
Septic shock Severe sepsis with hypotension despite adequate fluid resuscitation   
MODS 
Presence of altered organ function in an acutely ill patient such that 
homeostasis cannot be maintained without intervention.  
 
 
1.3.2 Epidemiology of sepsis 
A very large epidemiological study of up to 6 million people found that the 1995 
incidence of sepsis was approximately 3.0 cases per 1,000 population or about 
750,000 cases a year in the United States. The overall mortality is approximately 30%, 
rising to 40% in the elderly and is about 50% or greater in patients with septic shock. 
This translates into an annual healthcare burden of $22,100 per case of sepsis with a 
total cost of $16.7 billion nationally [183]. In Europe, the Sepsis Occurrence in 
Acutely Ill Patients study reported that more than 35% of ICU patients developed 
sepsis at some point during their stay in ICUs, and the mortality rate was estimated at 
27% [184]. Despite advances in the development of powerful antibiotics, 
technological support of organ function, and critical care management, the incidence 
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of sepsis continues to increase. In a more recent study based on National Hospital 
Discharge Survey database in the United States, there was an annualized increase in 
the incidence of sepsis of 8.7%, from about 164,000 cases (83 cases per 100,000 
population) in 1979 to nearly 660,000 cases (240 cases per 100,000 population) in 
2000. The total in-hospital mortality rate declined from 27.8% during the period from 
1979 through 1984 to 17.9% during the period from 1995 through 2000, yet the total 
number of deaths continued to increase [185]. Although the risk of death per 
individual case may be falling, the overall number of patients dying from sepsis-
associated mortality is growing as more patients are affected. Hence, sepsis remains a 
critical global healthcare problem for both clinicians and scientists.  
 
1.3.3 Pathophysiology of sepsis 
Sepsis is the culmination of complex interactions between the infecting 
microorganism and the host immune, inflammatory, and coagulation responses. 
Sepsis develops when the initial, appropriate host response to invading pathogens or 
their products becomes amplified, and then delocalized and dysregulated [2]. 
Inflammatory response in sepsis may be initialized by binding of pattern recognition 
receptors (PRRs) expressed on host immune cells to conserved pathogen-associated 
molecular patterns (PAMPs) present on invading microbes. Specifically, toll-like 
receptors (TLRs) have been identified as a major class of PRRs. The TLR signaling, 
through different intracellular molecules, such as MAPKs and IκB kinases which are 
conserved signaling elements for many receptors, results in a complex pattern of cell 
activation and leads to a distinct set of pro-inflammatory gene expressions [186]. For 
example, the peptidoglycan of gram-positive bacteria and the LPS of gram-negative 
bacteria bind to TLR-2 and TLR-4, respectively. Binding of bacterial motifs to TLRs 
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initiates the intracellular signal transduction pathways, which in turn, converge at the 
activation of IκB kinases, resulting in phosphorylation and degradation of IκB, the 
inhibitory subunit of the best-known transcription factor, NF-κB. Degradation of IκB 
exposes the nuclear localization sequence of NF-κB, thereby promoting its 
translocation into the nucleus. NF-κB then engages with its consensus sequence in the 
promoter or enhancer regions of NF-κB-regulated genes and induces the transcription 
of many genes for inflammatory response [187].  
 
Following the initial host-microbial interaction, there is widespread activation of the 
innate immune response. Neutrophils and macrophages play a key role, releasing the 
classic pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, but in addition an array of 
other cytokines including IL-12, IL-15, IL-17A and IL-18, leading to a markedly 
imbalance cytokine response known as a “cytokine storm”. These cytokines, 
specifically TNF-α and IL-1β, activate a second level of inflammatory cascades 
including liberation of cytokines, chemokines, lipid mediators, complement factors, 
reactive oxygen or nitrogen species, and NO, as well as upregulate adhesion 
molecules in neutrophils and endothelial cells, which in turn, initiate inflammatory 
cell migration into tissues [2]. The activated neutrophils mediate phagocytosis and 
killing of microorganisms, but also injure endothelium by releasing mediators that 
increase vascular permeability, leading to increased plasma protein extravasation and 
edema. Activated endothelial cells also release NO, a potent vasodilator that acts as a 
key mediator of septic shock [188]. As part of the innate immunity, the complement 
system is systematically activated during early stages of sepsis, producing large 
amounts of the anaphylatoxin C5a. High levels of C5a have been associated with 
defective clearance of bacteria, disturbance of the procoagulant-anticoagulant balance, 
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immunoparalysis, multi-organ failure, apoptosis of thymocytes, and production of 
inflammatory cytokines [186]. Thus, the pro-inflammatory environment further 
orchestrates the inflammatory process, resulting in severe dysregulation of various 
body systems and development of massive tissue and organ injury.  
 
In addition, dysregulation of the coagulation cascade appears to be an essential 
component in the manifestation of multiple organ failure characteristic of sepsis. LPS 
and other microbial components stimulate endothelial cells to upregulate expression 
of tissue factor, leading to systematic activation of coagulation. The activated tissue 
factor then induces a series of proteolytic cascades that promote conversion of 
prothrombin to thrombin, which cleaves fibrinogen to fibrin, thus producing 
microvascular occlusion and further amplifying injury [188]. Simultaneous 
suppression of the fibrinolytic system results in a procoagulant state that may lead to 
widespread microvascular deposits of fibrin, inadequate tissue perfusion, and organ 
dysfunction. Interestingly, inflammation and coagulation interact in a bidirectional 
manner [2]. Inflammation promotes coagulation by provoking intravascular tissue 
factor expression, eliciting the expression of leukocyte adhesion molecules and 
suppressing the fibrinolytic cascades. Thrombin, in turn, promotes inflammatory 
responses, including production of pro-inflammatory cytokines and the complement 
factor C5a [189].  
 
On the other hand, the exaggerated pro-inflammatory response that occurs in sepsis is 
balanced by an array of counter-regulatory molecules that attempts to restore 
homeostasis. Such anti-inflammatory molecules include receptor antagonists such as 
the soluble TNF receptors and the IL-1 receptor antagonists, anti-inflammatory 
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cytokines such as IL-10 and IL-13, and the physiological anticoagulant activated 
protein C [2]. The anti-inflammatory response elicited by these molecules, when 
excessive, can cause immune hyporesponsiveness and predispose patients to 
nosocomial infection and death; but, when insufficient, is associated with 
uncontrolled systemic inflammation. Hence, if an imbalance develops between the 
pro- and the anti-inflammatory response during sepsis, the equilibrium is violated and 
a range of clinical sequelae may subsequently ensue [190]. Nevertheless, the nature of 
the response is influenced by a number of other factors, comprising of the virulence of 
the infecting agent, presence of co-morbidities, age, nutritional status, size of the 
infectious challenge, and genetic factors. 
 
1.3.4 Animal models of sepsis 
Several experimental animal models have been developed in an effort to create 
reproducible systems for studying mechanisms of sepsis pathophysiology. Generally, 
sepsis models can be generated by three methods: exogenous administration of a toxin 
(such as LPS, endotoxin, or zymosan); exogenous administration of a viable pathogen 
(such as bacteria); or alteration of the animal’s endogenous protective barrier 
(inducing colonic permeability, allowing bacterial translocation). All models attempt 
to mimic pathophysiological changes typically seen in septic patients. Depending on 
the microbial pathogen, the dose, the route, and other experimental conditions the host 
may develop sepsis with a range of severity.  
 
1.3.4.1 Toxemia models 
Bolus injection of LPS or its lipid A moiety, the endotoxic principle of Gram-negative 
bacteria, has been used to induce sepsis-like symptoms in different experimental 
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animal species. It commonly induces a hypodynamic cardiovascular state immediately 
but unfortunately does not reproduce the hemodynamic changes observed in human 
sepsis. By inducing a very rapid and transient increase in systemic cytokine levels 
such as TNF-α and IL-1, LPS injection model fails to accurately mimic the cytokine 
profiles in clinical sepsis that is characterized by a prolonged elevation of systemic 
cytokines [191, 192]. LPS injection causes suppressed gluconeogenesis and 
subsequent hypopglycemia but the opposite effects occur in septic patients [191]. 
Furthermore, circulatory level of endotoxin is poorly associated with clinical findings, 
outcome, or microbiological conditions of sepsis as the isolated use of toxins might 
not reproduce the complex physiological responses observed during sepsis 
progression caused by viable pathogens [191, 193, 194]. Therefore, LPS injection is 
currently considered a model of endotoxic shock but not sepsis. Finally, comparison 
of the response to endotoxin in humans and mice has demonstrated that mice are 
relatively more resistant to endotoxin, further limiting the extrapolation of results 
between species [195].  
 
1.3.4.2 Bacterial infection models 
A more complex sepsis model is provided by the inoculation of animals with pure or 
mixed bacterial flora. Depending on the infecting bacterial load, strain specificity of 
the infecting bacteria, strain specificity of the host response, and the compartment of 
infection, these models can lead to hyperinflammation, endotoxic shock, or to 
controllable and reproducible infections. The use of complete bacteria exposing many 
bacterial components to activate different host receptors provides important insights 
into mechanisms of the host response to pathogens [194]. Notably, human sepsis may 
also be caused by a single pathogen. Unlike host-barrier disruption models that 
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produce polymicrobial sepsis, bacterial infection model can approximate introduction 
of a single pathogen in a controlled manner, thus allowing reproducible infection 
[196]. However, high infecting bacteria load often leads to rapid lysis by complement 
instead of bacterial colonization and replication within the host, thereby generating a 
potential model of intoxication with endotoxins rather than a true model of infection 
[197].   
 
1.3.4.3 Host-barrier disruption models 
Host-barrier disruption models of sepsis involve breaching the normal protective 
barriers that shield normally sterile compartments from pathogens. Typical examples 
are the CLP model and the colon ascendens stent peritonitis (CASP) model. Both are 
designed to closely mimic the clinical course of intra-abdominal sepsis [194]. 
Specifically, the systemic cytokine profile exhibited by both CLP and CASP models 
is more reminiscent of that observed in sepsis patients, demonstrating both continuous 
and sustained increase [198, 199]. Although both models result in mixed bacterial 
infection, they differ substantially in surgical manipulations (Figure 1.8). 
 
In the CASP model, a stent of defined diameter is implanted into the colon ascendens 
of mice, leading to persistent leakage of fecal material into the peritoneal cavity and 
infection with intestinal bacteria [199, 200]. The surgical manipulation involves 
laparotomy, insertion and fixation of the stent, and fluid resuscitation of animals. The 
intestinal leakage needs to be terminated by removal of the implanted stent. 
Depending on stent size and implantation time, the CASP model can be adapted to 
induce sepsis with a range of severity including sepsis, severe sepsis, septic shock, 
and sepsis-associated multiple organ failure. In fact, the CASP model represents a 
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relatively new model of sepsis and acts to complement the CLP model. It is more 
technically challenging since it requires careful surgical technique during placement 
of the stent to maintain patency and to prevent abscess formation. Due to its unknown 
issues of variability, the CASP model system has limited use in sepsis research [194].  
 
In contrast, the CLP model has become the most widely used model for experimental 
sepsis and is currently considered the gold standard for sepsis research [198, 201, 
202]. The technique involves midline laparotomy, exteriorization of the cecum, 
ligation of the cecum distal to the ileocecal valve, and puncture of the ligated cecum 
with needles. Since the cecum is an endogenous source of bacterial contamination, the 
surgical manipulation produces bowel perforation with leakage of fecal contents into 
the peritoneum, followed by translocation of mixed enteric bacteria into the blood 
compartment. At the onset of sepsis, bacteremia then triggers systemic activation of 
the inflammatory response, subsequent septic shock, multi-organ dysfunction, and 
finally death of the host. The severity of CLP can be adjusted by increasing the needle 
puncture size, the number of punctures, the percentage of cecum ligated, or the load 
of fecal material that leaks from the ligated cecum. As some of these variables are 
difficult to control between laboratories, different outcomes may exist despite use of 
the same experimental system [194]. Apart from these variables, the CLP model has 
achieved its popularity because of its ease, general reproducibility, and resemblance 
to human disease progression [203]. In addition to systemic cytokine and chemokine 
profiles [198, 199], the CLP model recapitulates the hemodynamic and metabolic 
phases of human sepsis [203]. Recent studies have also reported that apoptosis of 
several cell types and host immune responses in CLP-induced sepsis appear to mimic 




Figure modified from Buras et al., Nat Rev Drug Discov, 2005 [194]. 
 
Figure 1.8 The CLP and CASP models of sepsis. The CLP model of sepsis is 
induced by laparotomy and exposure of the junction between the large and small 
intestine. The small intestine joins the large intestine at the ileocecal valve (blue 
arrow). The cecum extends inferiorly as a blind pouch, and normally fecal content 
passes distally into the large intestine (blue arrow). Cecal ligation takes place below 
the ileocecal valve in a non-obstructing manner. The percentage of the cecum ligated 
is shown as 50% in the figure. The ligated cecum is punctured through-and-through 
allowing entrapped fecal material to leak into the normally sterile peritoneal cavity. 
The CASP model of sepsis is induced by laparotomy and exposure of the colon 
ascendens portion of the large intestine just distal to the ileocecal valve. A stent is 
placed by incision (shown as a dotted line) of the colon ascendens allowing flow of 




Chapter II Research Rationale and Objectives 
 
2.1 Question of interest 
 
H2S – A novel mediator of neurogenic inflammation in sepsis? 
Sepsis and sepsis-associated multiple organ failure remain an insurmountable medical 
challenge for both scientists and clinicians. Despite advances in the development of 
powerful antibiotics, technological support of organ function, and critical care 
management, the mortality rate of sepsis has not improved significantly over the last 
three decades [206]. Sepsis is now the second leading cause of death in non-coronary 
ICUs and the tenth most common cause of death overall in the United States [185]. 
Despite high lethality, the pathophysiology of sepsis is still not fully understood. It is 
generally accepted that sepsis is initiated and perpetuated by the overzealous systemic 
production of inflammatory molecules [2, 207]. For years, tremendous research 
efforts have been made on the identification of inflammatory mediators involved and 
elucidation of their pathophysiological mechanisms. In recent years, considerable 
evidence points towards a prominent role for H2S as one important inflammatory 
mediator implicated in sepsis.  
 
Endogenous H2S functions as a cardiovascular modulator and was associated with 
vascular consequences of endotoxic and septic shock [84]. Besides, it has been 
demonstrated to be overproduced and played a pro-inflammatory role in CLP-induced 
polymicrobial sepsis in the mouse [11]. Importantly, several recent investigations 
have proposed the potential involvement of H2S in neurogenic inflammation. 
Specifically, H2S induced contraction in the rat urinary bladder via a neurogenic 
67 
 
mechanism that involved TRPV1 stimulation with consequent release of tachykinins 
[13]. Likewise, by stimulating TRPV1-expressing sensory nerve terminals, 
intratracheal instillation of NaHS increased total lung resistance and provoked the 
release of SP from isolated guinea pig airways, thereby leading to the development of 
TRPV1-mediated neurogenic inflammation. Notably, these deleterious respiratory 
effects were greatly attenuated by capsaicin desensitization or treatment of selective 
TRPV1 antagonist capsazepine [14]. In addition, it was shown that exogenous 
administration of NaHS to normal mice provoked the release of SP in a dose-
dependent manner and that blockade of neuropeptide release from sensory neurons by 
capsaicin desensitization or by capsazepine treatment significantly protected mice 
against H2S-induced lung inflammation [179]. Taken together, these data demonstrate 
the potential roles of H2S in promoting neurogenic inflammatory response. However, 
the interaction was established based on exogenous administration of H2S and was 
only studied in single organ or isolated tissue in normal mice. None have addressed 
the in vivo association of endogenously produced H2S with TRPV1-mediated 
neurogenic inflammation in the setting of sepsis.  
 
Additionally, the contribution of TRPV1-expressing neurons to neurogenic 
inflammation has been well documented in a large variety of diseases, including 
migraine, osteoarthrtitis, cystitis and detrusor hyperreflexia, fecal urgency and 
inflammatory bowel diseases, post-herpetic neuralgia and post-mastectomy pain, 
asthma, COPD, scleroderma, pancreatitis, and many other diseases [208-212]. 
However, to our knowledge, there has been little progress in understanding the 
potential involvement of TRPV1 in sepsis, an infective disease associated with 
systemic inflammation.  
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Knowledge on characteristics of individual inflammatory mediators is undoubtedly a 
central research theme, but an in-depth understanding of the effect of these mediators 
at the molecular, cellular, and physiological level is important in identifying potential 
targets for future pharmacological manipulation. Therefore, the purpose of the present 
study is to determine the role of H2S in mediating TRPV1-mediated neurogenic 
inflammation in sepsis and to examine the underlying molecular mechanisms by 
which H2S regulates the neural inflammatory responses in sepsis in a TRPV1-
dependent manner. 
 
2.2 Approach  
The focus of this study is on three major areas: H2S, sepsis, and neurogenic 
inflammation. To ascertain the role of H2S, two different and complementary 
approaches were used: exogenous administration of NaHS as an H2S donor and 
inhibition of endogenous H2S synthesis with PAG, an irreversible inhibitor of CSE. 
With regard to animal models of sepsis, the CLP model was chosen since this model 
is more clinically relevant and is the gold standard in sepsis research. To investigate 
the interplay between H2S and TRPV1, capsazepine, a selective antagonist of TRPV1, 
was employed. In the later part of the study to examine the effect of H2S on COX-2 in 
sepsis-induced ALI, a potent and selective inhibitor of COX-2, parecoxib, was applied. 
Uses of these pharmacological tools enable study of the interaction between H2S and 








Using a murine model of CLP-induced polymicrobial sepsis, the aims of the current 
study are: 
 
1. To investigate if endogenous H2S causes TRPV1-mediated neurogenic 
inflammation in sepsis  
2. To determine if SP is the endogenous neural element involved in H2S-induced, 
TRPV1-mediated neurogenic inflammation in sepsis  
3. To evaluate the anti-inflammatory effects of TRPV1 antagonist capsazepine 
4. To study the underlying molecular mechanisms by which H2S regulates 
TRPV1-mediated neural inflammatory responses in sepsis  
5. To examine if H2S augments COX-2 and PGE2 production in sepsis-evoked 















Chapter III H2S Promotes TRPV1-Mediated Neurogenic 
Inflammation in Polymicrobial Sepsis 
 
3.1 Introduction 
Sepsis represents an uncontrolled SIRS following an active infectious process in the 
host [1]. Sepsis and its consequences remain a major medical concern worldwide, 
with an increasing incidence globally despite huge advances made in the field of 
sepsis in the last hundred years. It is a significant public health problem with 
tremendous economic and societal burden. Not only does sepsis mortality range from 
20% to 80% depending on illness severity [185], but survivors of sepsis also 
experience significant morbidity and impaired quality of life [213]. Therefore, 
continued progress in the field of sepsis is urgently needed.  
 
H2S has been proposed as a third physiological gaseous mediator along with CO and 
NO. Its endogenous formation in mammalian cells and tissues is catalyzed 
predominantly by CBS in the CNS and CSE in the cardiovascular system, ultilizing 
the amino acid L-cysteine as the main substrate [5]. Most importantly, H2S has been 
implicated in many inflammatory disorders, including hindpaw edema, acute 
pancreatitis, LPS-induced endotoxemia, burn-induced ALI, and CLP-induced sepsis 
[7-11]. Besides acting as a potent vasodilator and an atypical neuromodulator, mainly 
through the activation of K+ATP channels and NMDA receptors [5, 6], mounting 
evidence have shown that H2S is overproduced in CLP-induced sepsis and septic 




In addition, there is increasing evidence that H2S is involved in the stimulation of 
sensory neuropeptide release, such as SP, leading to the development of inflammation 
in sepsis [179, 181]. This phenomenon, termed “neurogenic inflammation”, refers to 
inflammatory responses that result from the release of molecules from primary 
sensory nerve fibers [158]. Of major importance in the development of neurogenic 
inflammation is the TRPV1 receptor, a non-selective cation channel that is best 
characterized for its location on these neurons. Besides causing the classic afferent 
function of nociception, TRPV1-expressing sensory nerve terminals exert local and 
systemic efferent activities. Specifically, activation of TRPV1 by painful heat, the 
chili extract capsaicin, protons, and diverse lipid and vanilloid derivatives, as well as 
H2S, causes the release of sensory neuropeptides that initiate and perpetuate 
neurogenic inflammation [14, 161, 208]. The contribution of H2S in neurogenic 
inflammation has been suggested in normal airways and urinary bladder [13, 14]. 
However, to our knowledge, there has been little progress in understanding the 
potential involvement of both H2S and TRPV1 in the setting of sepsis. Therefore, the 
aim of this part of the study was to investigate the interaction and involvement of H2S 
and TRPV1 in the pathogenesis of SIRS and MODS characteristic of sepsis using a 
mouse model of CLP-induced sepsis.  
 
3.2 Materials and methods 
3.2.1 Induction of sepsis 
All experiments were approved by the Animal Ethics Committee of National 
University of Singapore and were conducted in accordance with established 
International Guiding Principles for Animal Research. A previously described model 
of CLP-induced sepsis was used with minor modifications [214]. Briefly, male Swiss 
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albino mice (5-6 week of age, weighing 25–30 g) were anesthetized with a mixture of 
ketamine and medetomindine (7.5 ml/kg) under aseptic conditions. After shaving the 
abdominal fur and applying a topical disinfectant, a 1-cm midline incision was made 
through the skin and peritoneum of the abdomen. The cecum was exposed, ligated 
below the ileocecal valve without occluding the bowel passage, and then perforated at 
two locations with a 22-gauge needle distal to the point of ligation. Then, a small 
amount of cecal content was squeezed out gently to ensure persistence of the 
punctures. Finally, the bowel was repositioned, and the abdomen was closed in layers. 
Animals with sham operation underwent the same procedure except that the cecum 
was neither ligated nor punctured. All animals received 1 ml of saline (s.c.) 
immediately after the surgery. Capsazepine (15 mg/kg, s.c.; Sigma-Aldrich, St. Louis, 
MO), a TRPV1 antagonist, or vehicle (dimethyl sulfoxide [DMSO]) was 
administrated to mice 30 min before CLP or sham operation. The dosage of 
capsazepine has been described in the literature and found to be effective in vivo [179, 
215-219]. PAG (50 mg/kg, i.p.; Sigma-Aldrich), an irreversible inhibitor of CSE, was 
administered either 1 h before (“prophylactic”) or 1 h after (“therapeutic”) surgery. 
NaHS (10 mg/kg, i.p.; Sigma-Aldrich), an H2S donor, was given to mice at the time of 
CLP operation. The doses of NaHS and PAG used are well established and have been 
used extensively in many animal models to study H2S [7, 8, 11]. Animals were killed 
by a lethal dose of pentobarbitone (90 mg/kg, i.p.) 8 h after the operation. The time 
point was established as described in the literature [143]. Samples of lung, liver, and 






3.2.2 Measurement of MPO activity 
Neutrophil sequestration in lung and liver was quantified by measuring tissue MPO 
activity. Tissue samples were thawed, homogenized in 20 mM phosphate buffer (pH 
7.4), centrifuged (13,000 × g, 10 min, 4°C) and the resulting pellet was resuspended 
in 50 mM phosphate buffer (pH 6.0) containing 0.5% w/v 
hexadecyltrimethylammonium bromide (Sigma-Aldrich). The suspension was 
subjected to four cycles of freezing and thawing and further disrupted by sonication 
(40 s). The samples were then centrifuged (13,000 × g, 5 min, 4°C) and the 
supernatants were used for the MPO assay. The reaction mixture which consisted of 
the supernatant (50 µl), 1.6 mM tetramethylbenzidine, 80 mM sodium phosphate 
buffer (pH 5.4) and 0.3 mM hydrogen peroxide (reagent volume: 50 µl) was 
incubated at 37°C for 110 s. The reaction was terminated with 50 µl of 0.18 M H2SO4. 
The absorbance was measured at 450 nm and corrected for the DNA content of the 
tissue sample [220]. The results were expressed as fold increase over control.  
 
3.2.3 Measurement of plasma H2S 
Aliquots of plasma (120 µl) were mixed with distilled water (100 µl), trichloroacetic 
acid (10% w/v, 120 µl), zinc acetate (1% w/v, 60 µl), N,N-dimethyl-p-
phenylenediamine sulfate (20 µM; 40 µl) in 7.2 M HCl and FeCl3 (30 µM; 40 µl) in 
1.2 M HCl in 96-well plates. The absorbance of the resulting solution was measured 
10 min thereafter at 670 nm [62, 75, 221]. All samples were assayed in duplicate and 
H2S was calculated against a calibration curve of NaHS (3.125–100 µM). Results 





3.2.4 Assay of liver CSE activity 
CSE activity in liver homogenates was measured as described elsewhere [10]. Briefly, 
liver tissue was homogenized in 100 mM ice-cold potassium phosphate buffer (pH 
7.4). The assay mixture contains 100 mM potassium phosphate buffer (pH 7.4), L-
cysteine (20 µl, 20 mM), pyridoxal 5’-phosphate (20 µl, 2 mM), saline (30 µl), and 
4.5% w/v tissue homogenate (430 µl). The reaction was performed in tightly sealed 
microcentrifuge tubes and initiated by transferring the tubes from ice to a water bath 
at 37°C. After incubation for 30 min, 250 µl of zinc acetate (1% w/v) was added to 
trap evolved H2S followed by 250 µl of trichloroacetic acid (10% w/v) to denature the 
protein and stop the reaction. Subsequently, N, N-dimethyl-p-phenylenediamine 
sulfate (20 µM; 133 µl) in 7.2 M HCl was added, immediately followed by FeCl3 (30 
µM; 133 µl) in 1.2 M HCl. The absorbance of the resulting solution at 670 nm was 
measured by spectrophotometry (Tecan Systems, Männedorf, Switzerland) in a 96-
well microplate reader [62, 75, 221]. The H2S concentration was calculated against a 
calibration curve of NaHS. Results were then corrected for the DNA content of the 
tissue sample [220] and are expressed as nanomoles of H2S formed per microgram of 
DNA. 
 
3.2.5 Histopathological examination 
A small portion of lung and liver was excised and fixed with 10% buffered 
formaldehyde (Sigma-Aldrich), dehydrated, and embedded in paraffin for routine 
histology. Sections of 5-µm thickness were stained with hematoxylin and eosin, and 
examined by light microscopy, using a Carl Zeiss microscope (objective lens 




3.2.6 Survival studies 
The time of onset of mortality and disease progression of male Swiss albino mice (5-6 
week of age, weighing 25–30 g) after sham or CLP operation were monitored every 
24 h during the study. The survival of these mice was followed until day 12. Mice that 
survived beyond this time point were considered as permanent survivors. 
 
3.2.7 Statistics 
Statistical analysis was performed using SPSS software version 13.0 for Windows 
(SPSS Inc., Chicago, IL, USA). All data except survival studies were expressed as 
mean ± standard error of the mean (SEM). The significance of difference among 
groups was evaluated by analysis of variance (ANOVA) with a post hoc Tukey’s test 
for multiple comparisons. A value of p < 0.05 was regarded as statistically significant. 
The overall survival analysis for lethal injury was described using Kaplan-Meier plots. 
The significance of difference among groups was tested by using the log rank test, 
and expressed as survival rate. A value of p < 0.05 was regarded as statistically 
significant. 
 
3.3 Results  
3.3.1 Capsazepine attenuates systemic inflammation and multiple organ damage 
in sepsis 
The pathological manifestations of sepsis includes a marked influx of PMNs into 
distant organs of infectious foci, leading to systemic inflammation and subsequently 
multiple organ damage characteristic of severe sepsis [222]. Therefore, to determine 
whether endogenous H2S is critical in mediating TRPV1-mediated neurogenic 
inflammation and associated organ injury in sepsis, we quantified MPO activity and 
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examined histology sections of lung and liver tissue of septic mice treated with 
TRPV1 antagonist capsazepine. 
 
Evidence of CLP-induced systemic inflammation was indicated by the lung and liver 
MPO activity, which serves as a marker of tissue neutrophil sequestration, and 
histological changes of the two tissues. As expected, lung MPO activity was 
significantly increased in mice subjected to CLP surgery as compared with mice 
undergoing sham operation (Figure 3.1A). In sharp contrast, septic mice treated with 
capsazepine showed significantly lower MPO activity than did their vehicle control 
counterparts (Figure 3.1A). Similarly, there was a significant despite smaller elevation 
of liver MPO activity in mice undergoing CLP as compared with sham-operated mice 
(Figure 3.1B). However, the intensity of neutrophil infiltration in the liver of septic 
mice treated with capsazepine was markedly reduced than that in septic mice given 
vehicle injection (Figure 3.1B). These results indicate that the occurrence of 
neutrophil sequestration in remote organs and the resulting systemic inflammation in 
sepsis partly depends on TRPV1 activation.  
 
Histological examination of lung and liver tissues further suggested the involvement 
of endogenous H2S in TRPV1-mediated neurogenic inflammation and associated 
multiple organ damage in sepsis. Lung sections from septic mice exhibited 
characteristic signs of lung injury, which included alveolar congestion, perivascular 
and interstitial inflammatory cellular infiltrates, interstitial edema, and thickening of 
alveolar septa (Figure 3.2E). Treatment with capsazepine in septic mice restored 
normal lung histoarchitecture (Figure 3.2G), as observed in normal and sham-
operated mice (Figure 3.2, A and B), when compared to their vehicle control 
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counterparts (Figure 3.2F). In liver sections, hepatocyte swelling, slight hepatocyte 
necrosis, marginated and transmigrated neutrophil, and increased inflammatory 
cellular infiltrates in the extracellular space could be observed in septic mice (Figure 
3.2L) as well as those with CLP and vehicle injection (Figure 3.2M). However, these 
signs of liver injury were absent from normal and sham-operated mice (Figure 3.2, H 
and I), and septic mice treated with capsazepine (Figure 3.2N). Lung and liver 
histoarchitecture of sham-operated mice injected vehicle or capsazepine were found 
normal (Figure 3.2, C and D; Figure 3.2, J and K). 
 
3.3.2 Capsazepine has no effect on endogenous generation of H2S in sepsis  
We tested the hepatic activity of CSE and plasma level of H2S in septic mice treated 
with capsazepine to determine whether TRPV1 activation would affect the 
endogenous synthesis of H2S in sepsis. CLP-induced sepsis significantly increased 
liver CSE activity (Figure 3.3A) and plasma level of H2S (Figure 3.3B). Furthermore, 
we noticed that hepatic CSE activity and plasma H2S level in septic mice treated with 
capsazepine were comparable to their vehicle control counterparts (Figure 3.3, A and 
B). Also, there were no significant differences observed in both parameters in sham-
operated mice treated with capsazepine as compared to those given vehicle injection 
(Figure 3.3, A and B).  
 
3.3.3 Capsazepine protects against mortality in CLP-induced sepsis  
We conducted survival studies to determine whether blockade of neurogenic 
inflammation induced by H2S in sepsis would protect against CLP-induced mortality. 
As shown in Figure 3.4, the onset of lethality in untreated septic mice occurred at 24 h 
after CLP by which time these mice had a significant 60% mortality than septic mice 
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treated with capsazepine in which it was only 5% and delayed until 48 h. Furthermore, 
untreated septic mice displayed 0% survival by day 4. In contrast, in mice treated with 
capsazepine, survival was 40% from day 4 onwards, and this remained unchanged 
throughout the study period till day 12 (Figure 3.4). Sham-operated mice were found 
normal and 100% survival was observed throughout the study.  
 
3.3.4 Capsazepine reverses the pro-inflammatory effects of NaHS in sepsis 
Administration of NaHS further enhanced tissue neutrophil sequestration as 
evidenced by a significant elevation in MPO activity in lung (Figure 3.5A) and liver 
(Figure 3.5B) of mice subjected to both CLP operation and NaHS intervention. 
However, septic mice that received NaHS intervention and at the same time treated 
with capsazepine showed significantly lower lung (Figure 3.5A) and liver (Figure 
3.5B) MPO activity. Moreover, histological examination of lung tissue from untreated 
septic mice received NaHS and vehicle injection revealed more severe lung injury. In 
addition to obvious leukocyte infiltration and alveolar wall thickening, marked 
pulmonary congestion and the presence of numerous red blood cells could be easily 
detected (Figure 3.6A). Consistently, the liver sections from septic mice subjected to 
NaHS and vehicle injection had more inflammatory cellular infiltrates in the 
extravascular space (Figure 3.6C). In sharp contrast, treatment with capsazepine 
significantly attenuated the histological damages in lung (Figure 3.6B) and liver 
(Figure 3.6D).  
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3.3.5 Capsazepine protects against NaHS-augmented mortality in CLP-induced 
sepsis 
We have found that administration of NaHS in septic mice correlates with 
exacerbated systemic inflammation and multiple organ damage, and that TRPV1 
antagonism by capsazepine reverses these effects. Therefore, further effort to 
determine the protective effect of capsazepine on CLP-induced mortality in septic 
mice administrated with NaHS would substantiate the role of H2S in inducing 
TRPV1-mediated neurogenic inflammation. As shown in Figure 3.7, NaHS further 
aggravated CLP-induced mortality. The survival rate in septic mice receiving NaHS 
intervention was only 16% at 24 h, whereas the respective vehicle control groups 
displayed 40% survival rate and survived for an additional 24 h. Nevertheless, septic 
mice that received NaHS and were treated with capsazepine had a higher survival rate 
at 23%, compared to their vehicle control counterparts that displayed 0% survival 
(Figure 3.7).  
 
3.3.6 Capsazepine has no effect on blockade of endogenous generation of H2S in 
sepsis  
Administration of PAG, either 1 h before (“prophylactic”) or 1 h after (“therapeutic”) 
CLP surgery almost completely abolished the H2S synthesizing activity in the liver 
(Figure 3.8A), thereby leading to a significant reduction in plasma H2S level (Figure 
3.8B). Prophylactic and therapeutic PAG intervention not only reduced the plasma 
H2S level significantly after CLP but also recovered it to a comparable level of mice 
with sham operation. Because two pyridoxal-5’-phosphate-dependent enzymes, CSE 
and CBS, are responsible for the majority of the endogenous production of H2S in 
mammalian tissues [5, 223], PAG, an irreversible inhibitor of CSE [224], only 
80 
 
restored plasma H2S level to a similar level of sham operation and did not eliminate 
the circulatory H2S.  However, there were no significant differences in hepatic CSE 
activity and plasma H2S level in septic mice treated with capsazepine as compared to 
their vehicle control counterparts when endogenous H2S formation was inhibited by 
PAG (Figure 3.8, A and B).  
 
3.3.7 Capsazepine has no effect on PAG-mediated attenuation of pro-
inflammatory effects of H2S in sepsis  
Prophylactic or therapeutic administration of PAG mitigated the systemic 
inflammation and multiple organ damage caused by CLP-induced sepsis. Compared 
with vehicle-injected septic mice, MPO activity in the lung from septic mice pre-
treated or post-treated with PAG was significantly reduced (Figure 3.9A). Similarly, 
there was a significant reduction in liver MPO activity in septic mice received 
prophylactic or therapeutic PAG, as compared with vehicle-injected septic mice 
(Figure 3.9B). However, the intensity of neutrophil sequestration in the lung and liver 
remained unchanged in the presence of capsazepine when H2S synthesis was blocked 
by PAG (Figure 3.9, A and B).  
 
Consistently, histological examination of lung (Figure 3.10, A and C) and liver 
(Figure 3.10, E and G) tissues from septic mice subjected to prophylactic or 
therapeutic PAG revealed significant improvement in tissue histoarchitecture. Signs 
of lung and liver injury were absent and PAG restored normal lung and liver 
histoarchitecture after the induction of sepsis, as observed in normal and sham-
operated mice. Furthermore, we noticed no difference in lung (Figure 3.10, B and D) 
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and liver (Figure 3.10, F and H) histoarchitecture from septic mice treated with both 
PAG and capsazepine as compared to their vehicle control counterparts.  
 
3.3.8 Capsazepine has no effect on PAG-mediated protection of mortality in 
CLP-induced sepsis  
Because prophylactic or therapeutic intervention of PAG alone is sufficient to 
attenuate systemic inflammation and multiple organ damage, PAG was tested for the 
ability to protect or potentially reverse the progression of CLP-induced sepsis. We 
found that both prophylactic and therapeutic PAG significantly decreased mortality 
for up to 30% to 40% throughout the 12-day study period,  as compared to vehicle-
injected septic mice that exhibited 0% survival on day 4 (Figure 3.11, A and B). 
Survival rate in septic mice treated with both PAG and capsazepine was similar to 
those administrated with PAG and vehicle (Figure 3.11, A and B).  
 
3.4 Discussion 
Results in the present study reveal for the first time that the enhanced neutrophil 
sequestration and associated lung and liver injury in septic mice, as evidenced both 
biochemically (MPO activity) and histologically (hematoxylin and eosin-stained 
tissue sections), could be reversed by treatment with capsazepine, pointing to a role of 
endogenous H2S in modulating neurogenic inflammation in sepsis. If H2S-induced 
neurogenic inflammation contributed significantly to the overall inflammatory 
response in the pathogenesis of sepsis, it seemed reasonable that blocking TRPV1-
expressing sensory nerves should reduce markers of inflammation and injury. 
Moreover, these observations are of particular importance because under 
pathophysiological conditions, TRPV1 undergoes remarkable sensitization by a large 
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variety of exogenous agents and endogenous stimuli, including noxious heat, low 
extracellular pH, and many other substances [14, 161]. These other mediators, in 
which their expressions are upregulated during inflammation, may well synergize 
with H2S to exaggerate TRPV1 excitation on afferent and efferent discharge of 
sensory nerve terminals, thus aggravating the symptoms produced by sensory nerve 
stimulation.  
 
In addition, the attenuation of systemic inflammation and multiple organ damage by 
TRPV1 antagonism has a great clinical significance in the development of therapeutic 
interventions. Recent studies have proposed that sequestration of neutrophils in 
tissues could be a key stage in the initiation of multiple organ damage characteristic of 
severe sepsis [225]. Neutrophils have a pivotal role in the defence against bacterial 
infections but, in severe sepsis, overwhelming activation of neutrophils by an 
excessive and inappropriate response to an infectious stimulus and to the 
inflammatory milieu generated elicits tissue damage. Also, studies have demonstrated 
that with large numbers of neutrophils accumulate in organs undergoing failure, 
subsequent multiple organ damage will ensue as insult of one organ could trigger the 
widespread recruitment and sequestration of neutrophils in other organs [226, 227]. 
Hence, these data propose that suppression of neutrophil activity in sepsis could 
ameliorate organ dysfunction, although conventional wisdom suggests that 
maintenance of neutrophil activity is critical to combat microbial infections. 
 
The data in the current report suggest that CLP-induced sepsis significantly increased 
MPO activity and caused histological damage in the lung and liver. However, a slight 
increase in lung MPO activity 8 h after sham operation was obtained in our 
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experiment. In contrast, perhaps due to tissue-specific difference, the increase in liver 
MPO activity was comparable to that in normal mice. This is consistent with previous 
findings from the literature [11, 228]. Since the survival rate in mice undergoing sham 
operation was sustained at 100% throughout the 12-day study period, it seemed 
logical to assume that the modest elevation of lung MPO activity found in this study 
was correlated with non-specific inflammation caused by sham operation. This was 
further supported by the fact that the lungs are frequently the first organ to fail in 
patients with multiple organ damage following systemic insults [229]. Hence, the lung 
was chosen as one of the two main organs to be investigated, with the other one being 
the liver. Because of its central role in metabolism and host defence mechanisms, the 
liver is thought to be a major organ responsible for the initiation of multiple organ 
damage during sepsis and the second organ to fail in multiple organ failure [230]. It is, 
therefore, worth investigated. Unfortunately, we did not find any histological damage 
or elevation of MPO activity in kidney 8 h after CLP (data not shown). It is likely that 
kidney injury and associated systemic inflammation may occur at the mid or late stage 
of sepsis rather than at the early stage. Therefore, this study only focused on the 
alterations of liver and lung. Furthermore, it is known that CSE is the main H2S-
forming enzyme in the cardiovascular system [21], with its highest expression and 
distribution in hepatocytes [231]. A substantial amount of H2S has also been found to 
be present in circulation [62]. As such, we measured CSE activity in the liver and 
quantified H2S concentration in the plasma. 
 
In addition, we have demonstrated in this study that hepatic CSE activity and plasma 
H2S level in septic mice treated with capsazepine, and those with PAG and 
capsazepine, were comparable to their vehicle control counterparts, suggesting that 
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TRPV1 antagonism by capsazepine has no effect on endogenous generation of H2S in 
sepsis. These data suggest that H2S is located upstream of TRPV1 activation, and may 
play an important role in regulating the release of sensory neuropeptides in sepsis.  
 
In order to further ascertain the role of H2S in TRPV1-mediated neurogenic 
inflammation in sepsis, we used two different and complementary approaches: 
exogenous administration of NaHS as an H2S donor and inhibition of endogenous H2S 
synthesis by pre- and post-treatment of PAG. NaHS decomposes to Na+ and HS-; the 
latter then partially binds H+ to form undissociated H2S [5]; whereas PAG blocks 
endogenous H2S formation by acting as an irreversible inhibitor of CSE [224]. In the 
current study, exacerbation of systemic inflammation and multiple organ damage in 
sepsis by administration of NaHS is reversed by treatment with capsazepine, 
suggesting that capsazepine not only alleviates sepsis-induced systemic inflammation 
and multiple organ damage but also prevents H2S from aggravating these deleterious 
effects. These findings are consistent with earlier observations [11] and reinforce the 
essential role of H2S in promoting neurogenic inflammation in sepsis. Further 
evidence of neurogenic contribution of H2S was confirmed by non-significant 
alterations in lung and liver MPO activities, as well as histoarchitecture of the two 
tissues in septic mice treated with both PAG and capsazepine, as compared to their 
vehicle control counterparts. These data demonstrated that, in the presence of the 
inhibition of H2S formation, pharmacological blockade of TRPV1 with capsazepine 
has no effect on attenuation of systemic inflammation and multiple organ damage in 
sepsis. It is important that the beneficial effects of PAG alone appear not to be a 
consequence of blood pressure changes, given that at the doses used PAG did not 
significantly change blood pressure [85]. Besides, it is also shown that inhibition of 
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H2S formation by PAG had no significant effect on tissue MPO activity in sham-
operated mice. As such, the non-specific effects of PAG are negligible in this study 
[143]. Moreover, it should be underlined that the protection conferred by TRPV1 
antagonism is not entirely secondary to an enhanced formation of H2S. There are 
certainly some other mediators contributing to TRPV1 activation. Nevertheless, we 
proved from our data that sepsis has a significant neurogenic inflammatory 
component that is mediated by H2S in a TRPV1-dependent manner.   
 
Sepsis is a complex clinical syndrome with high lethality [2, 207]. Our findings 
indicate that capsazepine not only protects against acute pro-inflammatory response 
but also confer long-term protective effect against CLP induced-mortality. At day 4, 
100% mortality was observed in untreated septic mice, whereas 40% survival was 
observed in septic mice treated with capsazepine. Additionally, the decreased survival 
rate in septic mice injected NaHS as compared to mice undergoing CLP only was 
most likely attributed to the exacerbation of systemic inflammation and multiple 
organ damage caused by NaHS. Besides the development of heightened mortality in 
untreated septic mice, obvious difference in the onset of lethality in these mice was 
also observed. The onset of lethality in untreated septic mice occurred at 24 h after 
CLP whereas in septic mice treated with capsazepine it was delayed until 48 h. 
Nevertheless, improved survival rate was not significantly different in mice treated 
with both PAG and capsazepine when compared to those treated with PAG only, 
suggesting that the improved survival rate of septic mice was likely associated with 
inhibition of H2S formation. With endogenous synthesis of H2S blocked, H2S is 
unable to elicit the downstream neurogenic inflammatory events in sepsis, and hence 
the presence or absence of TRPV1 activation or blockade does not make a difference. 
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Nevertheless, CLP-induced sepsis is certainly a complex disease; the pathomechanism 
is only now beginning to be unravelled, and it is complicated by heterogeneous 
presentation with numerous mediators other than H2S [2, 207]. Therefore, inhibition 
of endogenous H2S formation only partly reversed the pathological progression of 
sepsis. Likewise, septic mice treated with PAG, either with or without capsazepine, 
displayed 32% to 40% survival rate. Taken together, these data show that capsazepine 
significantly protected against CLP-induced mortality, delayed the onset of lethality, 
and improved long-term survival following septic insults, raising the possibility of a 
therapeutic window for clinical therapy. 
 
In conclusion, the present study shows that H2S induces systemic inflammation and 
multiple organ damage characteristic of severe sepsis via TRPV1-mediated 
neurogenic inflammation. The H2S-driven neurogenic inflammation through TRPV1 


















Figure 3.1 Effect of capsazepine on (A) lung and (B) liver MPO activity in septic 
mice. Mice were randomly given capsazepine (Capz) (15mg/kg, s.c.) or vehicle 
(DMSO) 30 min before CLP. Sham mice served as controls. Eight hours after CLP or 
sham operation, MPO activity was measured. Results shown are the mean values ± 
SEM (n = 12 mice per group). The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 







Figure 3.2 Effect of capsazepine on CLP-induced (A-G) lung and (H-N) liver 
injury in septic mice. Lung and liver damage were assessed by determining 
morphological changes in hematoxylin and eosin stained tissue sections (n = 6-8 mice 
per group). Representative lung sections shown include: (A) normal mice, (B) sham 
mice, (C) sham + vehicle, (D) sham + capsazepine, (E) CLP, (F) CLP + vehicle, and 
(G) CLP + capsazepine. Representative liver sections shown include: (H) normal 
mice, (I) sham mice, (J) sham + vehicle, (K) sham + capsazepine, (L) CLP, (M) CLP 














Figure 3.3 Lack of effect of capsazepine on (A) liver CSE enzyme activity and (B) 
plasma H2S level in septic mice. Mice were randomly given capsazepine (Capz) 
(15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice served as controls. 
Eight hours after CLP or sham operation, liver CSE enzyme activity and plasma H2S 
level were measured. Results shown are the mean values ± SEM (n = 12 mice per 
group). The significance of difference among groups was evaluated by ANOVA with 






Figure 3.4 Effect of capsazepine on CLP-induced mortality in septic mice. Mice 
were randomly given capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min 
before CLP. Sham mice served as controls. Survival was monitored every 24 h for up 
to 12 days. Results are expressed as survival rate (n = 12-20 mice per group). The 
survival rate was estimated by the Kaplan-Meier method and compared by log rank 

















Figure 3.5 Effect of NaHS and capsazepine on (A) lung and (B) liver MPO 
activity in septic mice. Mice were randomly given NaHS (10mg/kg, i.p.) at the same 
time of CLP operation; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 
min before CLP. Sham mice served as controls. Eight hours after CLP or sham 
operation, MPO activity was measured. Results shown are the mean values ± SEM (n 
= 12 mice per group). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01; **p < 0.05; 









Figure 3.6 Effect of NaHS and capsazepine on (A-B) lung and (C-D) liver injury 
in septic mice. Lung and liver damage were assessed by determining morphological 
changes in hematoxylin and eosin stained tissue sections (n = 6-8 mice per group). 
Representative lung sections shown include: (A) CLP + NaHS + vehicle and (B) CLP 
+ NaHS + capsazepine. Representative liver sections shown include: (C) CLP + 
















Figure 3.7 Effect of NaHS and capsazepine on CLP-induced mortality in septic 
mice. Mice were randomly given NaHS (10mg/kg, i.p.) at the same time of CLP 
operation; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before 
CLP. Sham mice served as controls. Survival was monitored every 24 h for up to 12 
days. Results are expressed as survival rate; n = 12-20 mice per group. The survival 
rate was estimated by the Kaplan-Meier method and compared by log rank test. 
















Figure 3.8 Effect of PAG and capsazepine on (A) liver CSE enzyme activity and 
(B) plasma H2S level in septic mice. Mice were randomly given PAG (50mg/kg, i.p.) 
1 h before (‘prophylactic’) or 1 h after (‘therapeutic’) CLP operation; and capsazepine 
(Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice served as 
controls. Eight hours after CLP or sham operation, liver CSE enzyme activity and 
plasma H2S level were measured. Results shown are the mean values ± SEM (n = 12 
mice per group). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01; **p < 0.01; 






Figure 3.9 Effect of PAG and capsazepine on (A) lung and (B) liver MPO activity 
in septic mice. Mice were randomly given PAG (50mg/kg, i.p.) 1 h before 
(‘prophylactic’) or 1 h after (‘therapeutic’) CLP operation; and capsazepine (Capz) 
(15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice served as controls. 
Eight hours after CLP or sham operation, MPO activity was measured. Results shown 
are the mean values ± SEM (n = 12 mice per group). The significance of difference 
among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 







Figure 3.10 Effect of PAG and capsazepine on (A-D) lung and (E-H) liver injury 
in septic mice. Lung and liver damage were assessed by determining morphological 
changes in hematoxylin and eosin stained tissue sections (n = 6-8 mice per group). 
Representative lung sections shown include: (A) CLP + Prophylactic PAG + vehicle, 
(B) CLP + Prophylactic PAG + capsazepine, (C) CLP + Therapeutic PAG + vehicle, 
and (D) CLP + Therapeutic PAG + capsazepine. Representative liver sections shown 
include: (E) CLP + Prophylactic PAG + vehicle, (F) CLP + Prophylactic PAG + 
capsazepine, (G) CLP + Therapeutic PAG + vehicle, and (H) CLP + Therapeutic PAG 







Figure 3.11 Effect of PAG and capsazepine on CLP-induced mortality in septic 
mice. Mice were randomly given PAG (50mg/kg, i.p.) (A) 1 h before (‘prophylactic’) 
or (B) 1 h after (‘therapeutic’) CLP operation; and capsazepine (Capz) (15mg/kg, s.c.) 
or vehicle (DMSO) 30 min before CLP. Sham mice served as controls. Survival was 
monitored every 24 h for up to 12 days. Results are expressed as survival rate (n = 12-
20 mice per group). The survival rate was estimated by the Kaplan-Meier method and 




Chapter IV H2S Promotes TRPV1-Mediated Neurogenic 




The neuropeptide SP is an 11-amino acid peptide encoded by the PPT-A gene. It is 
widely distributed throughout the nervous system of human and animal species [165, 
178]. Belonging to the tachykinin family of neurotransmitters, SP is well recognized 
for its numerous potent neuroimmunomodulatory effects. Its biological activities are 
primarily mediated through membrane-bound NK-1R. SP has been established to 
exert a vast range of pro-inflammatory effects in vitro and in vivo, influencing many 
immune and inflammatory disorders of the respiratory, gastrointestinal, and 
musculoskeletal systems [165]. Studies have shown that it plays a pathogenic role in 
several inflammatory pathological disorders, including asthma, COPD, immune-
complex-mediated lung injury, rheumatoid arthritis, inflammatory bowel disease, 
acute pancreatitis, burn-induced ALI, endotoxemia, and sepsis [165, 169].  
 
SP is a well recognized mediator of neuro-immune intersystem crosstalk. It is 
contained in and released from a distinct subpopulation of primary afferent nerves that 
are characterized by sensitivity to capsaicin due to the rich expression of TRPV1 
[165]. Upon activation, TRPV1 channels expressed on these sensory nerve terminals 
undergo opening of channel pore, leading to influx of cation, followed by membrane 
depolarization and generation of action potential signaling, and eventually the release 
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of sensory neuropeptide such as SP that initiates the cascade of neurogenic 
inflammation [164].  
 
Subsequent to its release, SP elicits numerous systemic inflammatory effects such as 
increased microvascular permeability and plasma extravasation, immune cell influx, 
increased edema, vasodilation, and glandular secretions, thereby contributing to 
heightened systemic inflammation [165]. SP has also shown to directly activate and 
induce the chemotaxis of numerous immune-inflammatory cells, including 
neutrophils, macrophages, lymphocytes, monocytes, eosinophils, and mast cells to 
release a diverse spectrum of signaling messengers such as cytokines, chemokines, 
adhesion molecules, and other mediators in organs remote from the initial insult [165]. 
Thus, by promoting these systemic inflammatory effects SP could potentially 
contribute to manifestation of SIRS, and in a later stage, work in conjunction with 
SIRS to instigate the development of MODS in severe sepsis. Notably, multiple 
clinical and animal studies have established that the persistence of SIRS can lead to 
early MODS with an attendant high mortality, occurring in 20% to 30% of individuals. 
As such, it is obvious that overactive SIRS can compromise the function of various 
organ systems resulting in MODS, which then adds to the disease severity of 
polymicrobial sepsis [119, 120].  
 
Importantly, our findings in previous chapter have shown that H2S promotes TRPV1-
mediated neurogenic inflammation in CLP-induced sepsis in the mouse. However, 
endogenous neural factors that modulate this event have yet to be identified. Hence, in 
this chapter, we set out to investigate if SP is one important neural element that 
implicates in H2S-driven neurogenic inflammation in sepsis through a TRPV1 
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channel-dependent mechanism, and if so, to focus our understanding on the effects of 
SP, under the neurogenic influences of H2S, in eliciting SIRS and MODS following 
septic injury. 
 
4.2 Materials and methods 
4.2.1 Induction of sepsis  
For details, see section 3.2.1, page 71. 
 
4.2.2 Measurement of SP levels 
Samples of lung and plasma were collected from the animals. Plasma was prepared 
from anti-coagulated blood samples by centrifugation at 13,000 rpm for 10 min at 4°C. 
Lung samples were homogenized in 1 ml of ice-cold SP assay buffer for 20 s (Bachem, 
Peninsula Laboratories, San Carlos, CA). The homogenates were centrifuged (13,000 
× g, 20 min, 4°C) and the supernatants collected. The supernatants were adsorbed on 
C18 cartridge columns (Bachem, Peninsula Laboratories) as previously described 
[232]. The adsorbed peptide was eluted with 1.5 ml of 75% (v/v) acetonitrile. The 
samples were freeze-dried and reconstituted in the SP assay buffer (Bachem, 
Peninsula Laboratories). SP content in the samples were determined with an enzyme-
linked immunosorbent assay (ELISA) kit (Bachem, Peninsula Laboratories) according 
to the manufacturer’s instructions and expressed as nanograms per milliliter. Results 
were then corrected for the DNA content of the tissue samples fluorometrically using 




4.2.3 Cytokines, chemokines, and adhesion molecules analysis  
Single-analyte ELISA assays were performed for the measurement of cytokines, IL-
1β, IL-6, TNF-α; chemokines, MIP-1α, MIP-2; and adhesion molecules, P-selectin, E-
selectin, ICAM-1, and vascular cell adhesion molecule (VCAM)-1 in homogenized 
lung and liver tissues, according to the manufacturer’s instructions (R&D Systems, 
Minneapolis, MN). The lower limits of detection for the levels of IL-1β, IL-6, TNF-α, 
MIP-1α, MIP-2, P-selectin, E-selectin, ICAM-1, and VCAM-1 were 15.625, 15.625, 
31.25, 3.91, 15.625, 31.25, 31.25, 62.5, and 62.5 pg/ml, respectively. The ELISA 
results were reproducible with inter-assay variability of <9.5% and intra-assay 
variability of <6.5%. Results were then corrected for the DNA content of the tissue 
samples [220] and were expressed as picograms per microgram of DNA. 
 
4.2.4 Reverse transcriptase-polymerase chain reaction analysis 
Total RNA from lung and liver was extracted with TRIzol reagent (Invitrogen Life 
Technologies, Carlsbad, CA) according to the manufacturer’s protocol. One 
microgram of RNA was reverse transcribed using the iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA) at 25°C for 5 min, 42°C for 30 min, followed by 85°C for 5 
min. The cDNA was used as a template for polymerase chain reaction (PCR) 
amplification by iQ Supermix (Bio-Rad). The primer sequences for detection of PPT-
A, TNF-α, IL-1β, IL-6, MIP-1α, MIP-2, P-selectin, E-selectin, ICAM-1, VCAM-1, 
and 18S, optimal annealing temperature, optimal cycles, and product sizes are as 
shown in Table 4.1. PCR amplification was conducted in MyCycler (Bio-Rad). The 
reaction mixture was first subjected to 95°C for 3 min, followed by an optimal cycle 
of amplifications, consisting of 95°C for 30 s, optimal annealing temperature (Table 
4.1) for 30 s, and 72°C for 30 s. Final extension was at 72°C for 10 min. PCR 
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products were analyzed on 1.5% (w/v) agarose gels containing 0.5 µg/ml ethidium 
bromide. The intensity of bands was quantified using LabWorks image analysis 
software (Ultra-Violet Products Ltd., Cambridge, UK). 
 
4.2.5 Measurement of pulmonary edema 
As an index of lung edema, the amount of extravascular lung water was calculated 
according to established techniques [233-235]. Briefly, mice were killed 8 h after 
sham or CLP surgery and blood was collected by cardiac puncture. The lungs were 
excised from mice, cleared of all extrapulmonary tissue, blotted and weighed (total 
lung wet weight); they were then dried in an incubator for 48 h at 80°C and weighed 
again (total dry weight). For each animal, pulmonary edema was expressed as the 
ratio of total wet weight to total dry weight.  
 
4.2.6 Alanine aminotransferase and aspartate aminotransferase assay 
Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
activities were measured with the Infinity ALT and AST liquid stable reagent 
(Thermo Electron Corporation, Pittsburgh, PA) according to the manufacturer’s 
instructions.  
 
4.2.7 Statistics  
Statistical analysis was performed using SPSS software version 13.0 for Windows 
(SPSS Inc., Chicago, IL, USA). All data were expressed as mean ± SEM. The 
significance of difference among groups was evaluated by ANOVA with a post hoc 












r18S Sense: 5’-CCATCCAATCGGTAGTAGCG-3’  









TNF-α Sense: 5’-CCTGTAGCCCACGTCGTAGC-3’  




IL-1β Sense: 5’-AAGGAGAACCAAGCAACGAC-3’  




IL-6 Sense: 5’-TGCTGGTGACAACCACGGCC-3’ 









MIP-2 Sense: 5’-GCTGTCAATGCCTGAAGACC-3’  




P-selectin Sense: 5’-TACGAGCTGGACGGACCCG-3’  




E-selectin Sense: 5’-TCAACTTGAGTGCACATCTCAGG-3’  




ICAM-1 Sense: 5’-CAACTGGAAGCTGTTTGAGCTG-3’  













4.3.1 Capsazepine attenuates endogenous SP concentrations in both septic and 
septic mice administrated with NaHS  
The concentration of SP was significantly increased after induction of sepsis as 
compared with sham-injured mice in both lung (Figure 4.1A) and plasma (Figure 
4.1B). Densitometric analysis of PCR products on agarose gel showed that pulmonary 
PPT-A mRNA expression correlated well with protein levels, with septic mice 
showing a significant increase in expression as compared with sham mice (Figure 
4.1C). Next, we investigated the link between SP and TRPV1-mediated neurogenic 
inflammation in sepsis at both the protein and gene levels. Capsazepine significantly 
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suppressed the protein levels of lung (Figure 4.1A) and plasma (Figure 4.1B) SP. 
Consistently, pulmonary PPT-A gene expression was markedly reduced upon 
treatment with capsazepine (Figure 4.1C). We also examined whether blockade of 
TRPV1 channels with capsazepine would have an effect on the level of SP in the 
presence of H2S following septic injury. As shown in Figure 4.1, administration of 
NaHS resulted in a further rise in the pulmonary (Figure 4.1A) and plasma (Figure 
4.1B) SP levels in sepsis. Likewise, pulmonary mRNA level of PPT-A was 
significantly elevated in septic mice administrated with NaHS (Figure 4.1C). 
Importantly, in the presence of capsazepine, a significant attenuation of endogenous 
SP concentration was observed in both lung (Figure 4.1A) and plasma (Figure 4.1B), 
consistent with a parallel decrease in pulmonary gene expression for SP (Figure 4.1C), 
in septic mice received NaHS intervention.  
 
4.3.2 The attenuated SP concentration correlates with reduced production of 
pro-inflammatory molecules in both septic and septic mice administrated with 
NaHS 
To relate if alleviated SP levels by TRPV1 antagonism would simultaneously impair 
liberation of inflammatory mediators after septic injury, we examined the production 
of several pro-inflammatory cytokines, chemokines, and adhesion molecules in lung 
and liver tissues at both the protein and gene levels. The protein levels of pro-
inflammatory cytokines, TNF-α, IL-1β, IL-6; chemokines, MIP-1α, MIP-2 (Figure 4.2, 
A-E); and adhesion molecules, P-selectin, E-selectin, ICAM-1, and VCAM-1 (Figure 
4.4, A-D) in both lung and liver homogenates showed a marked rise in septic mice as 
compared with sham mice. All of these were significantly lowered by capsazepine 
(Figure 4.2 and 4.4). Administration of NaHS in septic mice further enhanced the 
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production of these mediators but capsazepine alleviated them (Figure 4.2 and 4.4). 
At the gene level, a similar trend was observed that correlated well with protein levels 
showing significant increase in cytokines and chemokines (Figure 4.3, A-E), and 
adhesion molecules (Figure 4.5, A-D) listed above in sepsis, consistent with an 
evident reduction upon capsazepine treatment (Figure 4.3 and 4.5). Likewise, a 
greater elevation of mRNA expression levels for these mediators was observed in 
lung and liver of septic mice injected with NaHS (Figure 4.3 and 4.5). Notably, all of 
their levels were significantly decreased by capsazepine (Figure 4.3 and 4.5).  
 
4.3.3 Capsazepine protects against MODS in both septic and septic mice 
administrated with NaHS 
MODS is recognized to be the ultimate cause of death in patients with sepsis [2]. In 
an attempt to determine if TRPV1 antagonism by capsazepine is beneficial in 
preventing MODS in sepsis, we examined pulmonary edema levels to assess the 
severity of lung injury [232], and measured plasma ALT and AST activities as indices 
of hepatic dysfunction [236]. Evidence of lung and liver damage after septic injury 
was confirmed by the heightened levels of pulmonary edema as indicated by wet-to-
dry weight ratio (Figure 4.6C), and increased activities of plasma ALT (Figure 4.6A) 
and AST (Figure 4.6B), respectively. However, septic mice treated with capsazepine 
showed significantly lower lung wet-to-dry weight ratio (Figure 4.6C), and plasma 
ALT (Figure 4.6A) and AST (Figure 4.6B) activities. Administration of NaHS in 
septic mice further exacerbated these organ injury parameters but capsazepine 




4.3.4 Capsazepine has no effect on PAG-mediated attenuation of SP levels in 
sepsis 
Our data showed that prophylactic or therapeutic administration of PAG mitigated 
both pulmonary (Figure 4.7A) and plasma (Figure 4.7B) SP levels caused by CLP-
induced sepsis. This is consistent with a parallel decrease in pulmonary gene 
expression for SP (Figure 4.7C) in septic mice received PAG intervention. However, 
there were no significant differences in both the protein and gene levels of SP in 
septic mice treated with both PAG and capsazepine as compared to their vehicle 
control counterparts (Figure 4.7, A-C).  
 
4.3.5 Inhibition of H2S formation impaired pro-inflammatory molecules 
production after septic injury, but capsazepine has no effect on them 
We found that both pre- and post-treatment of PAG decreased protein levels of pro-
inflammatory cytokines, TNF-α, IL-1β, IL-6; chemokines, MIP-1α, MIP-2 (Figure 4.8, 
A-E); and adhesion molecules, P-selectin, E-selectin, ICAM-1, and VCAM-1 (Figure 
4.10, A-D) in both lung and liver homogenates, as compared with vehicle-injected 
septic mice that exhibited significant increments in the protein levels of these 
inflammatory mediators. A similar profile of the mRNA expression for these 
molecules was also observed. Notably, their gene expression levels correlated well 
with the protein levels, showing significant alleviation in production of cytokines and 
chemokines (Figure 4.9, A-E), and adhesion molecules mentioned above (Figure 4.11, 
A-D) in septic mice administrated with PAG. However, there were no significant 
differences in the levels of these inflammatory mediators, at both the protein and gene 
levels, in septic mice treated with both PAG and capsazepine when compared to those 
that received PAG only (Figure 4.8 to 4.11).  
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4.3.6 Beneficial effects of capsazepine and PAG are not additive in protection 
against MODS in sepsis  
Further evidence of neurogenic contribution of H2S in sepsis was demonstrated by 
non-significant changes of pulmonary edema levels, plasma ALT and AST activities 
in septic mice treated with both PAG and capsazepine, as compared with their vehicle 
control counterparts (Figure 4.12). These data demonstrated that absence of H2S alone 
is sufficient to ameliorate lung and liver dysfunction as indicated by decreased levels 
of lung wet-to-dry weight ratio (Figure 4.12C) and reduced activities of plasma ALT 
(Figure 4.12A) and AST (Figure 4.12B), respectively.  
 
4.4 Discussion  
Sepsis remains the primary cause of death from infection despite advances in modern 
medicine. Millions of people die of sepsis every year worldwide. Thus, identifying 
endogenous neural elements that modulate H2S-driven neurogenic inflammation in 
sepsis in a TRPV1 relevance context is of paramount importance. In previous chapter, 
we demonstrated that H2S promotes TRPV1-mediated neurogenic inflammation in a 
murine model of polymicrobial sepsis. In the present chapter, we showed that the 
excessive production of endogenous neuro-mediator, SP, significantly increases the 
severity of sepsis through a TRPV1 channel-dependent mechanism, and that this 
phenomenon occurred under the influences of the pro-inflammatory effects of H2S.  
 
Studies over the past several years have provided convincing evidence that the 
neuropeptide SP acts as a key endogenous mediator in regulating the pathological 
inflammatory conditions in sepsis [179, 181, 232]. It has become apparent that LPS-
evoked endotoxemia and CLP-induced sepsis, as well as human sepsis and septic 
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shock are associated with increased biosynthesis of SP [179, 181, 237, 238]. High 
systemic SP level, which correlated with increased sepsis-induced lethality, was 
evident in patients with postoperative sepsis [238]. The increased release of SP from 
capsaicin-sensitive afferents was also documented in endotoxin-induced mouse model 
of airway inflammation [239]. Furthermore, it has been reported that PPT-A gene 
product, which encodes SP, is a critical inflammatory mediator of lung injury in 
sepsis [232]. Taken together, these findings position SP to influence the neural 
regulation of inflammatory response in sepsis. 
 
Of even greater significance, H2S has been shown to implicate in neurogenic 
inflammation mediated by SP and TRPV1. By stimulating TRPV1-expressing sensory 
nerve terminals, exogenous application of NaHS provoked the release of SP from 
isolated guinea pig airways [14]. Likewise, heightened circulatory level of SP was 
observed in normal mice administrated with NaHS [179]. Notably, in both studies, 
elevation of SP levels was greatly attenuated by capsaicin desensitization or by the 
treatment of capsazepine. Furthermore, H2S has been found to induce contraction in 
the rat urinary bladder via a neurogenic mechanism that involved TRPV1 stimulation 
with a consequent release of tachykinin [12, 13]. More importantly, studies have 
indicated that endogenous H2S regulates sepsis-associated lung injury and caerulein-
induced acute pancreatitis through upregulation of SP levels in the lungs and pancreas, 
respectively [180, 181]. Here, we show that H2S regulates TRPV1-mediated 
neurogenic inflammation in sepsis through upregulation of pulmonary and plasma SP. 
Our findings are consistent with earlier observations and reinforce the essential role of 
SP, and its interaction with H2S in sepsis. It must be noted, however, that with the 
usage of capsazepine, a synthetic competitive antagonist of TRPV1; our results 
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provide the first pharmacological evidence that H2S provokes tachykinin-mediated 
neurogenic inflammatory responses involving SP in CLP-induced sepsis in a TRPV1-
dependent manner.   
 
In previous chapter, it was demonstrated that hepatic CSE activity and plasma H2S 
level in septic mice treated with capsazepine and those treated with both PAG and 
capsazepine were comparable to their vehicle control counterparts. As such, blockade 
of TRPV1 channels by capsazepine has no effect on endogenous generation of H2S in 
sepsis. In this chapter, we report that capsazepine significantly attenuated endogenous 
SP levels in both septic and septic mice administrated with NaHS. Furthermore, 
capsazepine has no effect on PAG-mediated attenuation of SP levels in sepsis. Taken 
together, the interplay between H2S and TRPV1 implies that endogenous H2S 
signaled via TRPV1 which resulted in the subsequent release of sensory neuropeptide 
SP, thereby allowing SP to elicit its potent pro-inflammatory effects in sepsis. It is 
worth mentioning that TRPV1 is broadly expressed in all “port of entry” tissues such 
as the skin, gut, airway, and conjunctiva [165, 240], hence we restricted measurement 
of SP to the lungs. Nevertheless, a systemic role of SP via the circulatory system was 
investigated to substantiate its generalized role in mediating neurogenic inflammation 
in sepsis.  
 
SIRS and MODS are major hallmarks of sepsis. Excessive synthesis of inflammatory 
mediators in organs remote from the initial insult synergistically interacts to mediate 
tissue damage, followed by cardiovascular collapse and multiple organ failure, and 
consequently death of the host [2]. The current study revealed that pharmacological 
blockade of TRPV1 markedly reduced pulmonary and hepatic levels of IL-1β, IL-6, 
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TNF-α, MIP-1α, MIP-2, P-selectin, E-selectin, VCAM-1, and ICAM-1 in both septic 
and septic mice administrated with NaHS. Likewise, a significant protection against 
lung injury and liver dysfunction was conferred by capsazepine. Most importantly, 
both observations corresponded with concurrent attenuation of SP levels, suggesting 
that H2S stimulation of TRPV1 and the subsequent release of SP can induce 
upregulation of pro-inflammatory mediators that implicated in SIRS and work in 
conjunction with them to compromise organ functions in sepsis.  
 
The precise mechanism of MODS in sepsis is incompletely understood, however, it is 
generally established that it has a multi-pronged injury pathway consisting of tissue 
hypoperfusion and hypoxia, derangement of apoptosis, coagulation and endothelial 
cell dysfunction, and direct inflammation-induced injury [2]. Among these proposed 
mechanisms, inflammation-induced organ injury is of particular relevance in our work. 
Given that MODS in sepsis is closely linked to excessive inflammation [241], it 
appears likely that capsazepine mitigated MODS in sepsis through attenuation of the 
generation of inflammatory mediators, such as SP, cytokines, chemokines, and 
adhesion molecules aforementioned. The observed protection was further associated 
with improved survival benefits since capsazepine has been shown in preceding 
chapter to reduce sepsis-induced mortality even in the presence of NaHS. Furthermore, 
it is widely accepted that pronounced damage and dysfunction of lung and liver 
presented severe features of sepsis, directly contributing to the initiation of MODS, 
worsened outcome, and ultimately mortality in the manifestation of sepsis.  
 
In contrast, beneficial effects of TRPV1 antagonism in ameliorating SIRS and MODS 
in sepsis were diminished when endogenous synthesis of H2S was blocked, as seen in 
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septic mice received PAG intervention as compared to the same mice treated with 
capsazepine. It appears that inhibition of H2S generation alone is sufficient to account 
for these observations, and that the presence or absence of TRPV1 antagonism makes 
no difference. Nonetheless, with regard to the inhibitory effects of CSE synthesizing 
activity, it should be underlined that the effects of PAG alone seem not to be a 
consequence of blood pressure changes, given that at the doses used PAG did not 
significantly change blood pressure [85]. Besides, the effect of capsazepine is not 
entirely secondary to an enhanced formation of H2S. Since sepsis is a multifactorial 
disease, other inflammatory mediators may stimulate TRPV1 and trigger the release 
of SP. Nevertheless, we ascertained from our data that sepsis has a significant sensory 
neurogenic component that involved SP and mediated by H2S in a TRPV1 relevance 
context. 
 
Collectively, our results established that the H2S stimulation of TRPV1 and the 
downstream release of SP as a key element in the transition of infection and SIRS to 
MODS in the disease progression of sepsis, and identified TRPV1 antagonist as a 
possible therapeutic target for the treatment of sepsis and/or other inflammatory 
pathologies. Overall, our study provides convincing evidence that H2S regulates 
TRPV1-mediated neurogenic inflammation in polymicrobial sepsis through 















Figure 4.1 Effect of NaHS and capsazepine on (A) lung and (B) plasma SP levels, 
and (C) lung PPT-A mRNA expression in septic mice. Mice were randomly given 
NaHS (10mg/kg, i.p.) at the same time of CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, levels of SP and PPT-A mRNA were measured. 
Results shown are the mean values ± SEM (n = 8-12 mice per group). The 
significance of difference among groups was evaluated by ANOVA with a post hoc 
Tukey’s test for multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP 






































Figure 4.2 Effect of NaHS and capsazepine on protein levels of cytokines and 
chemokines in the lung and liver of septic mice. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP; and capsazepine (Capz) (15mg/kg, s.c.) or 
vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight hours 
after CLP or sham operation, protein levels of (A) TNF-α, (B) IL-1β, (C) IL-6, (D) 
MIP-1α, and (E) MIP-2 were measured. Results shown are the mean values ± SEM (n 
= 8-12 mice per group). The significance of difference among groups was evaluated 
by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus 
sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.05 versus CLP + vehicle; †p < 0.01 















Figure 4.3 Effect of NaHS and capsazepine on mRNA expression of cytokines 
and chemokines in the lung and liver of septic mice. Mice were randomly given 
NaHS (10mg/kg, i.p.) at the same time of CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, mRNA levels of (A) TNF-α, (B) IL-1β, (C) IL-6, 
(D) MIP-1α, and (E) MIP-2 were measured. Results shown are the mean values ± 
SEM (n = 8-12 mice per group). The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 
0.01 versus sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.05 versus CLP + vehicle; 
















Figure 4.4 Effect of NaHS and capsazepine on protein levels of adhesion 
molecules in the lung and liver of septic mice. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP; and capsazepine (Capz) (15mg/kg, s.c.) or 
vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight hours 
after CLP or sham operation, protein levels of (A) P-selectin, (B) E-selectin, (C) 
ICAM-1, and (D) VCAM-1 were measured. Results shown are the mean values ± 
SEM (n = 8-12 mice per group). The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 
0.01 versus sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.05 versus CLP + vehicle; 















Figure 4.5 Effect of NaHS and capsazepine on mRNA expression of adhesion 
molecules in the lung and liver of septic mice. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP; and capsazepine (Capz) (15mg/kg s.c.) or 
vehicle (DMSO) 30 min before CLP.  Sham mice were used as controls. Eight hours 
after CLP or sham operation, mRNA levels of (A) P-selectin, (B) E-selectin, (C) 
ICAM-1, and (D) VCAM-1 were measured. Results shown are the mean values ± 
SEM (n = 8-12 mice per group). The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 














Figure 4.6 Effect of NaHS and capsazepine on  plasma (A) ALT and (B) AST 
activities, and (C) pulmonary edema (measured as lung wet-to-dry weight ratio) 
in septic mice. Mice were randomly given NaHS (10mg/kg, i.p.) at the same time of 
CLP; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. 
Sham mice were used as controls. Eight hours after CLP or sham operation, plasma 
levels of ALT and AST, and lung wet-to-dry weight ratio were measured. Results 
shown are the mean values ± SEM (n = 10-15 mice per group). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 
multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP + vehicle; ‡p < 





































Figure 4.7 Effect of PAG and capsazepine on (A) lung and (B) plasma SP levels, 
and (C) lung PPT-A mRNA expression in septic mice. Mice were randomly given 
PAG (50mg/kg, i.p.) 1 h before (“prophylactic”) or 1 h after (“therapeutic”) CLP; and 
capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham 
mice were used as controls. Eight hours after CLP or sham operation, levels of SP and 
PPT-A mRNA were measured. Results shown are the mean values ± SEM (n = 8-12 
mice per group). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus 
sham; **p < 0.01 versus CLP + vehicle.   
























Figure 4.8 Effect of PAG and capsazepine on protein levels of cytokines and 
chemokines in the lung and liver of septic mice. Mice were randomly given PAG 
(50mg/kg, i.p.) 1 h before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) 
or 1 h after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and 
capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham 
mice were used as controls. Eight hours after CLP or sham operation, protein levels of 
(A) TNF-α, (B) IL-1β, (C) IL-6, (D) MIP-1α and (E) MIP-2 were measured. Results 
shown are the mean values ± SEM (n = 8-12 mice per group). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 
multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP + vehicle; †p < 













Figure 4.9 Effect of PAG and capsazepine on mRNA expression of cytokines and 
chemokines in the lung and liver of septic mice. Mice were randomly given PAG 
(50mg/kg, i.p.) 1 hr before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) 
or 1 hr after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and 
capsazepine (Capz) (15mg/kg s.c.) or vehicle (DMSO) 30 min before CLP. Sham 
mice were used as controls. Eight hours after CLP or sham operation, mRNA levels of 
(A) TNF-α, (B) IL-1β, (C) IL-6, (D) MIP-1α and (E) MIP-2 were measured. Results 
shown are the mean values ± SEM (n = 8-12 mice per group). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 
multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP + vehicle; †p < 













Figure 4.10 Effect of PAG and capsazepine on protein levels of adhesion 
molecules in the lung and liver of septic mice. Mice were randomly given PAG 
(50mg/kg, i.p.) 1 h before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) 
or 1 h after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and 
capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham 
mice were used as controls. Eight hours after CLP or sham operation, protein levels of 
(A) P-selectin, (B) E-selectin, (C) ICAM-1, and (D) VCAM-1 were measured. Results 
shown are the mean values ± SEM (n = 8-12 mice per group). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 














Figure 4.11 Effect of PAG and capsazepine on mRNA expression of adhesion 
molecules in the lung and liver of septic mice. Mice were randomly given PAG 
(50mg/kg, i.p.) 1 hr before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) 
or 1 hr after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and 
capsazepine (Capz) (15mg/kg s.c.) or vehicle (DMSO) 30 min before CLP. Sham 
mice were used as controls. Eight hours after CLP or sham operation, mRNA levels of 
(A) P-selectin, (B) E-selectin, (C) ICAM-1, and (D) VCAM-1 were measured. Results 
shown are the mean values ± SEM (n = 8-12 mice per group). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 












Figure 4.12 Effect of PAG and capsazepine on plasma (A) ALT and (B) AST 
activities, and (C) pulmonary edema (measured as lung wet-to-dry weight ratio) 
in septic mice. Mice were randomly given PAG (50mg/kg, i.p.) 1 h before 
(“prophylactic”) or 1 h after (“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, plasma levels of ALT and AST, and lung wet-to-
dry weight ratio were measured. Results shown are the mean values ± SEM (n = 10-
15 mice per group). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus 






















Chapter V H2S Promotes TRPV1-Mediated Neurogenic 
Inflammation in Polymicrobial Sepsis by Activating ERK1/2 and  
NF-κB Signaling Pathways 
 
5.1 Introduction 
To date, six distinct groups of MAPKs have been characterized in mammals: ERK1/2, 
c-Jun N-terminal kinases (JNK1/2/3), p38 kinases (p38 α, β, γ, δ), ERK7/8, ERK3/4, 
and ERK5. They are generally expressed in all cell types, are activated by a plethora 
of distinct stimuli, and are phosphorylated on threonine and tyrosine. In spite of their 
ubiquitous presence and seemingly enormous cross-talk with each other, their actions 
are very specific [242]. As part of a three-kinase module, MAPKs are phosphorylated 
and activated by MAPK kinases. MAPK kinase kinases phosphorylate and activate 
MAPK kinases [243]. The MAPKs most intensely studied are the ERK1/2, p38 
kinases, and JNKs [242]. In particular, ERK1/2 and p38 kinases have been shown to 
mediate systemic inflammatory response in CLP-induced sepsis and septic shock [143, 
244-246].  
 
The transcription factor NF-κB is frequently associated with immune and 
inflammatory response in sepsis [247]. It is regulated through its localization in the 
cell. In the cytoplasm, NF-κB is bound to inhibitory IκB proteins such as IκBα, IκBβ, 
and IκBε. During a stimulus, phosphorylation of IκB by IκB kinase leads to IκB 
degradation. The nuclear translocation signal of NF-κB is then exposed, thereby 
allowing translocation of NF-κB into the nucleus, followed by its binding to 
consensus decameric sequence located in the promoter region of genes involved in the 
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inflammatory response, encoding various immunoreceptors, cell adhesion molecules, 
cytokines, and chemokines [248]. Notably, activation of NF-κB has been implicated 
as an important event that results in increased gene expression and biosynthesis of 
pro-inflammatory mediators in sepsis [247]. Inhibition of NF-κB activation improved 
lethality in mouse endotoxemia and in patients suffering from sepsis [249]. In 
addition, activation of ERK has been shown to be important for the temporal control 
of NF-κB transcriptional activity and expression of NF-κB-regulated genes, as well as 
upstream activator of NF-κB [250, 251]. Indeed, several studies highlighted the 
significance of NF-κB and ERK in sepsis. Specifically, inhibition of ERK signaling 
protected against LPS-induced endotoxemia through suppression of NF-κB activation 
[250-253]. Furthermore, H2S was found to regulate inflammatory response in sepsis 
through activation of the ERK1/2 pathway [143]. Several in vitro studies also reported 
that H2S could induce the phosphorylation and activation of ERK1/2 in immune cells. 
For example, administration of NaHS resulted in increased activity of ERK1/2 in 
mouse macrophages [149]. In human monocyte cell line U937, H2S dose-dependently 
triggered monocyte activation, leading to enhanced synthesis of pro-inflammatory 
cytokines through activation of the ERK-NF-κB signaling pathways [127]. However, 
none has investigated the detailed signaling mechanism of endogenous H2S in 
mediating neurogenic inflammation in polymicrobial sepsis in a TRPV1 relevance 
context. Therefore, the present chapter aimed to elucidate whether H2S would regulate 
TRPV1-mediated neurogenic inflammatory response in CLP-induced sepsis by 




5.2 Materials and methods 
5.2.1 Induction of sepsis 
For details, see section 3.2.1, page 71. 
 
5.2.2 Nuclear extraction and measurement of NF-κB activation 
Nuclear extracts from lung (50 mg) and liver (100 mg) were prepared by using a 
nuclear extraction kit as described by the manufacturer (Active Motif, Carlsbad, CA). 
Protein concentrations in nuclear extracts were determined using Bradford assay (Bio-
Rad). To monitor NF-κB activation in lung and liver tissues, we used a TransAM NF-
κB p65 transcription factor assay kit (Active Motif). The kit consists of a 96-well 
plate, into which oligonucleotide containing the NF-κB consensus site (5’-
GGGACTTTCC-3’) is bound. The active form of NF-κB in the nuclear extract 
specifically binds to this consensus site and is recognized by a primary antibody 
specific for the activated form of p65 of NF-κB. An horseradish peroxidase (HRP)-
conjugated secondary antibody provides the basis for the colorimetric quantification. 
The absorbance of the resulting solution was measured 2 min later (450 nm with a 
reference wavelength of 655 nm), using a 96-well microplate reader (Tecan Systems, 
Mannedorf, Switzerland). The wild-type consensus oligonucleotide was provided as a 
competitor for NF-κB binding to monitor the specificity of the assay. Results were 
expressed as fold increase over the control group. 
 
5.2.3 Western immunoblot  
Lung (50 mg) and liver (100 mg) tissues were homogenized at 4°C in 
radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with 1% 
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protease (Product No. P8340) and 1% phosphatase (Product No. P2850 and P5726) 
inhibitor cocktails (Sigma-Aldrich). The tissue homogenates were centrifuged at 
14,000 × g for 10 min at 4°C. Protein concentration in the soluble fraction was 
determined by the Bradford method. Protein samples (50-100 μg) were separated by 
SDS-PAGE on Novex Bis-Tris polyacrylamide gels (Invitrogen Life Technologies) 
and transferred onto polyvinylidene difluoride membranes (Invitrogen Life 
Technologies) by electroblotting in Novex transfer buffer (Invitrogen Life 
Technologies) containing 20% (v/v) methanol. Membranes were then washed, 
blocked, and probed overnight at 4°C with rabbit anti-IκBα, phospho-IκBα, ERK1/2, 
and phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA; 1:1000 dilution for 
all), followed by secondary detection for 2 h with an HRP-conjugated goat anti-rabbit 
IgG (Santa Cruz Biotechnology, CA; 1:1000 dilution). Membranes were washed and 
then incubated in SuperSignal West Pico chemiluminescent substrate (Pierce 
Biotechnology, Rockford, IL) before exposure to X-ray films (CL-XPosure, Pierce 
Biotechnology). Gels were calibrated by protein kaleidoscope standards (Bio-Rad). 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) (Santa Cruz Biotechnology; 
1:2000 dilution) was applied as an internal control to normalize protein loading. The 
intensity of bands was quantified using LabWorks image analysis software (Ultra-
Violet Products Ltd.). 
 
5.2.4 Statistics 






5.3 Results  
5.3.1 Effect of capsazepine on ERK1/2 activation in H2S-induced neurogenic 
inflammation in sepsis 
To investigate the signaling mechanisms by which H2S regulates TRPV1-mediated 
neurogenic inflammation in sepsis, we evaluated the ERK1/2 and NF-κB signaling 
pathways, with the usage of capsazepine, using two different and complementary 
approaches: exogenous administration of NaHS as an H2S donor and inhibition of 
endogenous H2S formation by PAG. We observed activation of pulmonary and 
hepatic ERK1/2 in mice subjected to CLP-induced sepsis as compared with sham-
injured mice (Figure 5.1A). Upon treatment with capsazepine, phosphorylation of 
ERK1/2 in lung and liver tissues were abolished (Figure 5.1A). Administration of 
exogenous NaHS further enhanced tissue ERK1/2 activation in sepsis, whereby 
capsazepine-treated, NaHS-injected septic mice revealed significantly reduced lung 
and liver phospho-ERK1/2 expression levels (Figure 5.1A). Additionally, 
prophylactic or therapeutic administration of PAG markedly suppressed tissue 
phosphorylation of ERK1/2 in sepsis (Figure 5.1B). Interestingly, the status of 
ERK1/2 activation in lung and liver of septic mice administrated with both PAG and 
capsazepine remained unchanged when compared to those that received PAG only 
(Figure 5.1B).  
 
5.3.2 Effect of capsazepine on IκBα phosphorylation and degradation levels in 
H2S-induced neurogenic inflammation in sepsis 
Subsequently, we analyzed whether ERK1/2 signaling leads to activation of IκBα in 
H2S-induced neurogenic inflammation in sepsis. Treatment with capsazepine in septic 
mice drastically reduced pulmonary and hepatic expression of phospho-IκBα 
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compared to the elevated levels detected in untreated septic mice (Figure 5.2A). 
Consistently, phospho-IκBα levels in the lung and liver of septic mice injected with 
NaHS were greatly enhanced; while these levels were significantly suppressed upon 
treatment with capsazepine (Figure 5.2A). In contrast, PAG intervention drastically 
reduced lung and liver phospho-IκBα levels in sepsis but capsazepine has no effect on 
them, as evidenced by non-significant changes of the phospho-IκBα expression levels 
in septic mice received PAG and the same mice treated with capsazepine (Figure 
5.2B).  
 
More importantly, assessment of IκBα degradation displayed a similar profile that 
correlated well with the levels of phospho-IκBα, with untreated septic mice showing a 
significant reduction in lung and liver IκBα levels in comparison with the heightened 
levels exhibited in capsazepine-treated septic mice (Figure 5.3A). Likewise, the 
expression levels of IκBα in lung and liver tissues from septic mice injected with 
NaHS were again lowered; while these levels were elevated with capsazepine (Figure 
5.3A). Additionally, treatment with PAG markedly enhanced tissue IκBα expression 
levels in comparison to their vehicle control counterparts, suggesting an obvious 
inhibition of IκBα degradation (Figure 5.3B). However, treatment of capsazepine 
failed to further modulate these levels (Figure 5.3B).  
 
5.3.3 Effect of capsazepine on NF-κB activation in H2S-induced neurogenic 
inflammation in sepsis 
Next, we examined whether phosphorylation and degradation of IκBα result in NF-κB 
nuclear translocation. Our results showed that capsazepine significantly decreased the 
DNA binding activity of nuclear NF-κB in the lung and liver of septic mice (Figure 
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5.4A). Exogenous administration of NaHS further amplified the activation of NF-κB 
while treatment with capsazepine significantly disrupted the activity of NF-κB (Figure 
5.4A). Finally, the DNA binding activity of nuclear NF-κB was greatly reduced in the 
absence of endogenous H2S (Figure 5.4B).  As anticipated, we noticed no difference 
in lung and liver NF-κB activation in septic mice treated with both PAG and 
capsazepine as compared to their vehicle control counterparts (Figure 5.4B).  
 
5.4 Discussion  
The ubiquitous and highly conserved family of MAPKs represents major signaling 
pathways regulating cellular responses to external stimuli, such as microbial infection 
and stress [254, 255]. The three major MAPKs signaling pathways include p38 
kinases, ERK1/2, and JNKs [242]. Several studies have suggested the relevance of 
ERK1/2 signaling to H2S. It has been previously reported that overexpression of CSE 
cDNA in human embryonic kidney 293 cells and human aorta smooth muscle cells 
induced phosphorylation and activation of ERK1/2 [256, 257]. Additionally, ERK1/2 
has been demonstrated to be involved in H2S-induced proliferative stimulus in 
intestinal epithelial cells [258]. In a context more relevant to inflammation, H2S is 
known to modulate NO production in RAW 264.7 macrophages and rat vascular 
smooth muscle cells through enhancement of ERK1/2 signaling cascade [259, 260]. 
H2S has also been implicated in production of pro-inflammatory cytokines and 
chemokines in human monocytes and in a murine model of sepsis via activation of the 
ERK1/2 pathway [127, 143]. Less clear is, however, whether H2S would regulate 
TRPV1-mediated and SP-involved neural inflammatory response following CLP-
induced sepsis through activation of the ERK1/2 pathway. Additionally, as ERK has 
been shown to be critical for the temporal control of NF-κB transcriptional activity 
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and expression of NF-κB-regulated genes, as well as upstream activator of NF-κB 
[250, 251], it is of considerable interest to know whether activation of ERK is 
accompanied by subsequent phosphorylation and degradation of IκB, which in turn, 
leads to NF-κB activation.  
 
In the current chapter, we showed that pharmacological antagonism of TRPV1 
inhibited phosphorylation of ERK1/2 and IκBα, along with concurrent inhibition of 
IκBα degradation, in both septic and septic mice administrated with NaHS. Most 
importantly, the DNA binding activity of nuclear NF-κB was decreased by 
capsazepine under the same pathological conditions, accompanied by concurrent 
attenuation of tissue levels of inflammatory cytokines, chemokines, and adhesion 
molecules as described in preceding chapter. Conversely, in the absence of H2S, 
capsazepine has no effect on PAG-mediated suppression of ERK1/2 and IκBα 
phosphorylation. Additionally, obvious inhibition of IκBα degradation and NF-κB 
activation caused by PAG intervention in sepsis remained unchanged in the presence 
of capsazepine. Consistent to these data, although a significant attenuation of tissue 
inflammatory mediators production by PAG intervention was observed, their levels 
were not changed with simultaneous treatment of capsazepine (described in Chapter 
IV). These findings not only indicated that H2S, SP, and TRPV1 interact to instigate 
neural inflammatory processes in sepsis through activation of ERK1/2 and NF-κB 
pathways, but also added to the growing evidence about the involvement of ERK1/2 
in regulating the activity of NF-κB [250, 251], as well as the potential association 
between H2S and ERK-NF-κB signaling cascades [127, 143]. Nevertheless, H2S has 
been linked to a number of other pathways in addition to ERK signaling. In this 
regard, direct exposure of NaHS to human aorta smooth muscle cells led to activation 
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of p38 kinases [261]. Also, studies have suggested that H2S may regulate intracellular 
calcium concentration in neuronal cells through PKA and phospholipase C (PLC)/ 
protein kinase C (PKC) pathways [262, 263]. Furthermore, H2S is involved in acute 
pancreatitis through PI3K/protein kinase B pathway [264]. Therefore, alternative 
mechanisms may exist which act in synergism with ERK signaling cascade to 
modulate the activity of NF-κB and the consequent inflammatory gene expression in 
sepsis. Additionally, since polyclonal antibody against p65 subunit was employed to 
investigate the activity of NF-κB, our results demonstrated that NF-κB dimers 
containing p65 may play a crucial role in H2S-driven neurogenic inflammatory and 
injury responses seen in this study.  
 
In agreement with findings obtained from previous chapters, the results show that H2S 
regulates TRPV1-mediated neurogenic inflammation in polymicrobial sepsis through 
enhancement of SP production and activation of the ERK-NF-κB pathway. 
Importantly, the H2S-TRPV1-SP-ERK1/2-IκBα-NF-κB signal transduction pathway 
contributes to SIRS and MODS in sepsis. Collectively, these findings contribute to a 
better understanding of the precise molecular mechanisms underlying the pro-
inflammatory effects of H2S in sepsis pathophysiology in a TRPV1 relevance context 
and provide further insight into the development of new therapeutic intervention for 








































Figure 5.1 Effect of (A) NaHS or (B) PAG and capsazepine on ERK1/2 activation 
in the lung and liver of septic mice. Mice were randomly given NaHS (10mg/kg, i.p.) 
at the same time of CLP or PAG (50mg/kg, i.p.) 1 h before (“prophylactic”) or 1 h 
after (“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 
30 min before CLP. Sham mice were used as controls. Eight hours after CLP or sham 
operation, phospho-ERK1/2 and total ERK1/2 expression levels were measured. A 
representative western blot image is shown, with densitometry data expressed as 
average ratios of phospho-ERK1/2 to total ERK1/2. Results shown are the mean 
values ± SEM (n = 6 mice per group). The significance of difference among groups 
was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p 























Figure 5.2 Effect of (A) NaHS or (B) PAG and capsazepine on phospho-IκBα 
expression levels in the lung and liver of septic mice. Mice were randomly given 
NaHS (10mg/kg, i.p.) at the same time of CLP or PAG (50mg/kg, i.p.) 1 h before 
(“prophylactic”) or 1 h after (“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, phospho-IκBα expression levels were measured. 
A representative western blot image is shown, with densitometry data expressed as 
average ratios of phospho-IκBα to HPRT levels. Results shown are the mean values ± 
SEM (n = 6 mice per group). The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 
0.01 versus sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.05 versus CLP + vehicle; 































Figure 5.3 Effect of (A) NaHS or (B) PAG and capsazepine on IκBα expression 
levels in the lung and liver of septic mice. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP or PAG (50mg/kg, i.p.) 1 h before 
(“prophylactic”) or 1 h after (“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, IκBα expression levels were measured. A 
representative western blot image is shown, with densitometry data expressed as 
average ratios of IκBα to HPRT levels. Results shown are the mean values ± SEM (n 
= 6 mice per group). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus 
sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.05 versus CLP + vehicle; †p < 0.01 









Figure 5.4 Effect of (A) NaHS or (B) PAG and capsazepine on NF-κB activation 
in nuclear extracts of lung and liver tissues in septic mice. Mice were randomly 
given NaHS (10mg/kg, i.p.) at the same time of CLP or PAG (50mg/kg, i.p.) 1 before 
(“prophylactic”) or 1 h after (“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, 
s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice were used as controls. Eight 
hours after CLP or sham operation, the DNA binding activity of NF-κB was measured. 
Results shown are the mean values ± SEM (n = 8-12 mice per group). The 
significance of difference among groups was evaluated by ANOVA with a post hoc 
Tukey’s test for multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP 
+ vehicle; †p < 0.01 versus CLP + NaHS + vehicle. 
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Chapter VI H2S Augments COX-2 and Prostaglandin E2 Metabolite 
Production in Sepsis-Evoked Acute Lung Injury by a TRPV1 
Channel-Dependent Mechanism  
 
6.1 Introduction 
Despite significant advances in critical care, mortality of sepsis remains unacceptably 
high [265]. The ultimate cause of death in severe sepsis is multiple organ failure. The 
lungs are often the first organ to succumb post systemic insult due to the early 
development of ALI or its severe form, the ARDS [266]. The underlying mechanism 
is thought to involve excessive liberation of inflammatory mediators that incite and 
perpetuate pulmonary inflammatory cascade leading to remote ALI/ARDS [265, 267]. 
Therefore, identification of these inflammatory molecules in the septic lungs may 
suggest new treatment modalities for sepsis-associated respiratory failure.  
 
As discussed in previous chapters, H2S promotes TRPV1-mediated neurogenic 
inflammation in polymicrobial sepsis. The neuropeptide SP represents an important 
endogenous neural element involved and the ERK1/2 and NF-κB pathways appear to 
regulate this event. However, the downstream inflammatory molecules implicated 
have not yet been studied. Therefore, in this part of study, we investigate the role of 
COX-2, an NF-κB-regulated gene, in modulating the severity of ALI following septic 
insults induced by CLP.  
 
Intriguingly, several reports have suggested a significant role for COX-2, an 
important inflammatory enzyme and its most abundant and potent enzymatic product, 
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PGE2, [268] in ALI/ARDS and sepsis [269-273]. Some studies suggest that COX-2 
and PGE2 might be associated with SP-related inflammatory response [274-277]. 
Unlike COX-1 that is constitutively expressed, COX-2 is an inducible enzyme 
stimulated by inflammatory and mitogenic stimuli [268], and has been shown to 
mediate inflammation by increasing vasodilation, vascular permeability, and edema in 
numerous respiratory diseases [278-280]. In sepsis, it was demonstrated that septic 
insult activates macrophages to produce PGE2 through the induction of COX-2 [281]. 
Administration of NS-398, a specific COX-2 inhibitor, was found to inhibit PGE2 
production of endotoxin-treated macrophages to improve survival and restore 
leukocyte counts in burn septic mice [273]. Similarly, in a rat endotoxin shock model, 
NS-398 significantly inhibited the heightened COX-2 gene expression and PGE2 
production in the aorta and peripheral blood leukocytes [282]. Additionally, H2S was 
shown to induce COX-2 gene and protein expression in human small intestine 
epithelial FHs 74 cells and isolated rat cardiac myocytes, respectively [283, 284]. 
Despite these findings describing the inflammatory roles of COX-2 and PGE2, the 
interactions between H2S, COX-2, and PGE2 in inciting sepsis-evoked ALI remain 
unknown. Therefore, the present study aimed to investigate whether H2S can 
upregulate COX-2 and work in conjunction with it to instigate ALI in sepsis through a 
TRPV1 channel-dependent mechanism, and if so, to elucidate whether selective 
COX-2 inhibition would attenuate H2S-augmented lung inflammation and injury, as 
well as lethality in sepsis.  
 
6.2 Materials and methods 
6.2.1 Induction of sepsis 
For details, see section 3.2.1, page 71. 
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Parecoxib (30mg/kg, i.v.; Dynastat; Pfizer, New York, NY), a water-soluble, potent, 
and selective COX-2 inhibitor [294-296], or 0.9% sterile saline was administrated to 
mice 20 min after CLP. The dosage, route and time of administration for Parecoxib 
has been described in the literature and found to be effective in vivo [274]. 
 
6.2.2 Measurement of COX-2 activity  
Lung COX-2 activity was measured according to the manufacturer’s instructions 
(Cayman Chemical Co., Ann Arbor, MI). COX-2 activity was expressed as a 
percentage of total COX activity. 
 
6.2.3 Measurement of PGE2 metabolite levels  
Lung PGE2 metabolite (13, 14-dihydro-15-keto PGE2) levels were determined by 
ELISA kits (Cayman Chemical Co.) according to the manufacturer’s instructions. The 
results were corrected for the DNA content of the tissue sample [220] and expressed 
as fold increase over control. 
 
6.2.4 Western immunoblot  
For details, see section 5.2.3, page 138. The primary antibodies used for detection for 
proteins of interest include: rabbit polyclonal anti-COX-2 (1:1000 dilution; Cayman 
Chemical Co.) and anti-HPRT (1:1000 dilution; Santa Cruz Biotechnology Inc., Santa 
Cruz, CA).  
 
6.2.5 Measurement of MPO activity 




6.2.6 Histopathogical examination  
For details, see section 3.2.5, page 74. 
 
6.2.7 Cytokines, chemokines, and adhesion molecules analysis  
For details, see section 4.2.3, page 101. 
 
6.2.8 Measurement of pulmonary edema 
For details, see section 4.2.5, page 102. 
 
6.2.9 Survival studies  
For details, see section 3.2.6, page 75. 
 
6.2.10 Statistics 
For details, see section 3.2.7, page 75. 
 
6.3 Results 
6.3.1 H2S regulates COX-2 levels in septic lungs in a TRPV1 channel-dependent 
manner 
Induction of sepsis by CLP resulted in a significant increase in lung COX-2 
expression as compared with sham-injured mice (Figure 6.1A). Administration of 
NaHS further enhanced pulmonary COX-2 expression in septic mice when compared 
to their vehicle control counterparts (Figure 6.1A). In an attempt to investigate the 
interplay between H2S and COX-2 with TRPV1-mediated neurogenic inflammation in 
sepsis, we tested the effect of a selective TRPV1 antagonist, capsazepine, on lung 
COX-2 levels. Our results revealed marked attenuation in pulmonary COX-2 
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expression with capsazepine in both septic and septic mice administrated with NaHS 
(Figure 6.1A). A similar profile was observed in lung COX-2 activity levels with 
septic mice showing significant increase while septic mice injected with NaHS 
exhibiting greater elevation in levels as compared with their respective controls 
(Figure 6.1B). Notably, when these mice were treated with capsazepine, lung COX-2 
activity levels were significantly alleviated (Figure 6.1B). Furthermore, inhibition of 
endogenous H2S formation by prophylactic or therapeutic administration of PAG 
markedly suppressed lung COX-2 expression (Figure 6.2A) and activity (Figure 6.2B) 
in untreated septic mice. Treatment of capsazepine to the same mice, however, did not 
significantly change the levels of PAG-mediated attenuation of COX-2 expression 
(Figure 6.2A) and activity (Figure 6.2B) in sepsis. Taken together, these results 
indicate that H2S upregulates COX-2 in septic lungs by a TRPV1 channel-dependent 
mechanism.  
 
6.3.2 The H2S-augmented, TRPV1-dependent COX-2 response correlates with 
concurrent PGE2 metabolite production following septic injury 
The observed increases in lung COX-2 levels lead us to examine lung PGE2 levels 
post septic injury. PGE2 is known to be rapidly metabolized in vivo to its 13, 14-
dihydro-15-keto metabolite, therefore, intact PGE2 in tissues obtained from whole 
animals are scarce [285-287]. For this reason, measurement of PGE2 metabolite is 
necessary to provide a reliable estimate of actual PGE2 production [288-290]. In this 
study, lung PGE2 metabolite levels were significantly increased in septic mice as 
compared with sham mice (Figure 6.3A). The production of PGE2 metabolite was 
further enhanced when exogenous NaHS was administrated (Figure 6.3A). 
Importantly, treatment with capsazepine abrogated lung PGE2 metabolite levels in 
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these mice (Figure 6.3A). Blockade of endogenous H2S synthesis further substantiated 
the inflammatory role of H2S in sepsis, with PAG-treated septic mice showing marked 
alleviation in PGE2 metabolite levels, and that this reduction in PGE2 metabolite 
production remained unchanged in the presence of capsazepine (Figure 6.3B). 
Therefore, it is clear that septic injury induces a concomitant increase in lung COX-2 
and PGE2 metabolite levels which are both prominently upregulated under the pro-
inflammatory influences of H2S in a TRPV1-dependent manner. 
 
6.3.3 COX-2 inhibition prevents H2S from aggravating ALI in sepsis 
The clinical pathology of ALI is characterized by pulmonary edema, neutrophil 
infiltration with hemorrhage, and increased production of inflammatory mediators 
[267]. Therefore, to assess the severity of COX-2-mediated ALI in sepsis, we 
examined the effect of a potent and selective COX-2 inhibitor, parecoxib, on lung 
MPO activity which is an important index of neutrophil sequestration, and lung wet-
to-dry weight ratio to determine the levels of pulmonary edema, as well as 
histopathological examination of lung tissues to investigate the severity of lung injury. 
Results from MPO activity revealed significant lung neutrophil sequestration in septic 
mice as compared with sham controls, and this increment was further augmented in 
septic mice administrated with NaHS (Figure 6.4A). Notably, these effects were 
markedly attenuated with treatment of parecoxib (Figure 6.4A). Histologically, septic 
mice displayed characteristic signs of ALI, which included alveolar congestion, 
inflammatory cell infiltration, hemorrhage, septal thickening, and interstitial edema 
(Figure 6.4, B2 and B3). Restoration of normal lung histoarchitecture was observed in 
septic mice treated with parecoxib (Figure 6.4, B4), as revealed in sham-operated 
mice (Figure 6.4, B1). Likewise, lung architecture in septic mice received NaHS 
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intervention was damaged more than CLP alone with marked pulmonary congestion 
and intense inflammatory cellular infiltrates in the septa in addition to erythrocytes 
originating from ruptured capillary vessels in the lung tissues (Figure 6.4, B5). 
However, such aggravation of lung alterations was improved by administration of 
parecoxib (Figure 6.4, B6). Consistent with MPO and histology results, septic mice 
showed elevated lung wet-to-dry weight ratio, whereas treatment with parecoxib to 
these mice significantly alleviated pulmonary edema (Figure 6.4C). Additionally, 
septic mice injected with NaHS demonstrated further rise in lung wet-to-dry weight 
ratio compared with their vehicle control counterparts, and which was again lowered 
with parecoxib intervention (Figure 6.4C). Together, these findings show that COX-2 
inhibition is critical in mitigating the development of sepsis-evoked ALI which was 
exacerbated under the pro-inflammatory effects of H2S.  
 
6.3.4 Blockade of H2S-mediated activation of COX-2 impaired pro-inflammatory 
cytokines, chemokines and adhesion molecules production in sepsis-induced ALI 
Septic mice showed a marked rise in levels of lung pro-inflammatory cytokines, TNF-
α, IL-1β, IL-6; chemokines, MIP-1α, MIP-2 (Figure 6.5, A-E); and adhesion 
molecules, P-selectin, E-selectin, VCAM-1, and ICAM-1 (Figure 6.6, A-D) as 
compared with sham mice. All of these were significantly reduced by blockade of 
COX-2 with parecoxib (Figure 6.5 and 6.6). Administration of NaHS in septic mice 
further enhanced the production of the aforementioned cytokines, chemokines, and 
adhesion molecules (Figure 6.5 and 6.6). Notably, all of their levels were greatly 
lowered upon treatment with parecoxib (Figure 6.5 and 6.6). These findings, along 
with lung MPO activity, pulmonary edema, and histological evidence of ALI (Figure 
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6.4), reinforce that the inhibition of H2S-mediated activation of COX-2 is crucial in 
preventing many key events leading to ALI post septic injury.  
 
6.3.5 Inhibition of COX-2 attenuates H2S-augmented PGE2 metabolite 
production in septic lungs 
Further evidence of lung protection by COX-2 inhibition was determined by 
measuring the levels of PGE2 metabolite in the presence of parecoxib. As expected, 
lung PGE2 metabolite levels were significantly increased following septic injury; 
however, treatment with parecoxib significantly decreased PGE2 metabolite levels in 
septic lungs (Figure 6.7). Consistently, blockade of COX-2 with parecoxib drastically 
reduced PGE2 metabolite production in septic lungs even in the presence of NaHS, as 
compared to the heightened levels detected in NaHS-injected septic mice (Figure 6.7). 
Together, these findings, in agreement with the evident alleviation in ALI and 
inflammatory mediators production (Figure 6.4-6.6), further verify the importance of 
H2S-augmented COX-2/PGE2 pathway in sepsis.  
 
6.3.6 Inhibition of COX-2 protects against H2S-augmented, CLP-induced 
lethality, but has no effect on PAG-mediated protection of mortality in sepsis  
Since the present study has proposed a key role of H2S-augmented COX-2 response in 
sepsis-evoked ALI, it is imperative to investigate whether COX-2 inhibition would 
influence the late phase events of sepsis, such as death. Our results revealed that mice 
subjected to CLP-induced sepsis displayed 0% survival by day 4, as compared with 
sham mice that were found normal with 100% survival throughout the 12-day study 
period (Figure 6.8). Administration of NaHS further worsened sepsis-associated 
mortality, with septic mice receiving NaHS intervention showing a drastic drop in 
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survival rate that accounted for 0% at day 3 in comparison to their vehicle control 
counterparts that showed delayed survival for an additional 24 h (Figure 6.8B). 
Importantly, treatment with parecoxib greatly improved survival in both septic and 
septic mice administrated with NaHS, as evidenced by survival rates of 35% and 25%, 
respectively, in both instances (Figure 6.8A and 6.8B). Additionally, we found that 
both prophylactic and therapeutic PAG decreased mortality significantly for up to 
35% to 45% throughout the 12-day study period, as compared with saline-injected 
septic mice that exhibited 0% survival on day 4 (Figure 6.8C and 6.8D). However, 
survival rate in septic mice treated with both PAG and parecoxib was similar to those 
that were administrated with PAG and saline (Figure 6.8C and 6.8D). 
 
6.4 Discussion  
Sepsis and its associated multi-organ failure remain a challenging global healthcare 
problem for both scientists and clinicians even in the modern era of critical care 
management. Severe sepsis, when accompanied by respiratory failure such as ALI or 
ARDS, continues to plague ICUs with high mortality that has remained over 40% 
[265, 266]. Thus, identification of endogenous inflammatory molecules that mediate 
inflammation and injury of this often lethal complication of common human maladies 
represents an important goal with immediate diagnostic and therapeutic significance. 
In previous chapters, we showed that H2S promotes TRPV1-mediated neurogenic 
inflammation in polymicrobial sepsis. Here, we report for the first time that H2S 
upregulates COX-2 and PGE2 metabolite in sepsis through TRPV1 channel activation, 
and that COX-2 inhibition with parecoxib, a potent and selective COX-2 inhibitor, 




PGE2 is largely thought to be synthesized from arachidonic acid via the actions of 
COX-2. It is known that more than 90% of circulating PGE2 is rapidly catabolized to 
inactive forms on the first pass in the lungs [286, 287, 291]. Therefore, studies have 
used the measurement of PGE2 metabolite as a common alternative to indicate the 
levels of PGE2 [288, 289, 292, 293]. Results clearly demonstrated that induction of 
sepsis by CLP resulted in a concomitant and significant overproduction of COX-2 and 
PGE2 metabolite in the lung. Administration of NaHS further enhanced the 
biosynthesis of COX-2 and PGE2 metabolite whereas PAG significantly decreased 
these levels. Although hepatic CSE activity and plasma H2S level have been reported 
to be heightened in CLP-induced sepsis in earlier chapters, the usage of two different 
yet complementary approaches in this work: exogenous administration of NaHS that 
serves as an H2S donor and inhibition of endogenous H2S synthesis by PAG which 
acts as an irreversible inhibitor of CSE, directly ascertained the involvement of H2S in 
augmenting the production of COX-2 and PGE2 metabolite in sepsis. More 
significantly, our results are consistent with earlier findings from the published 
literature in which H2S preconditioning of isolated rat cardiomyocytes upregulated the 
expression of COX-2 and increased the production of PGE2 [284]. An increase in 
gene expression for COX-2 in H2S-treated human intestinal epithelial cells was also 
observed [283].  
 
The usage of capsazepine, a selective TRPV1 antagonist, determined that H2S 
upregulates COX-2 and PGE2 metabolite in sepsis by a TRPV1 channel-dependent 
mechanism. In particular, the heightened levels of COX-2 and PGE2 metabolite seen 
in septic and septic mice administrated with NaHS were effectively attenuated by 
capsazepine. In contrast, beneficial effects of TRPV1 antagonism were diminished 
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when endogenous synthesis of H2S was blocked, as evidenced by non-significant 
alterations of lung COX-2 and PGE2 metabolite levels in septic mice received PAG 
intervention as compared to the same mice treated with capsazepine. It appears that 
inhibition of endogenous H2S formation alone is sufficient to account for these 
observations, and that capsazepine has no additive effects on them. With endogenous 
synthesis of H2S blocked, H2S is unable to elicit the downstream expression of COX-
2 in sepsis. Hence, the presence or absence of TRPV1 channel activation or blockade 
does not make a difference. In this regard, we ascertained from our data that sepsis 
has a significant sensory neurogenic component that is mediated by H2S in a TRPV1-
dependent manner, and that H2S stimulation of TRPV1 occurs upstream of COX-2 
and PGE2 metabolite in sepsis. 
 
More importantly, we were interested to know whether the H2S-augmented, TRPV1-
dependent COX-2 response can induce the production of PGE2 metabolite and work 
in conjunction with it to incite remote ALI post septic injury. To test this hypothesis, 
parecoxib, a water-soluble prodrug of valdecoxib and the first COX-2 specific 
inhibitor used for parenteral administration [294, 295], was employed. Notably, 
parecoxib exerts no deleterious effects on homeostatic functions mediated by COX-1 
activation at therapeutic doses in the stomach and blood [296]. Our results reveal that 
COX-2 inhibition with parecoxib significantly attenuated pulmonary neutrophil 
infiltration, edema formation, production of inflammatory cytokines, chemokines and 
adhesion molecules, as well as restored lung histoarchitecture in sepsis, thereby 
significantly prevented the development of sepsis-evoked ALI. Moreover, the fact that 
exogenous administration of NaHS to septic mice showed exacerbated ALI compared 
to mice subjected to CLP alone, and that these pathophysiologic consequences of ALI 
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were significantly abrogated upon treatment of parecoxib confirm the notion that 
sepsis-evoked ALI was specifically attributable to the interplay between H2S and 
COX-2. Intrigued by the strong inhibitory effects of parecoxib on H2S-induced 
inflammation and injury in the lung of septic mice, our results suggest that selective 
blockade of COX-2 could constitute an important therapeutic target for the treatment 
of sepsis-evoked ALI.  
 
A number of studies have suggested a significant role for COX-2 in the development 
of ALI [269, 270]. Specifically, COX-2 levels increased concomitantly with the 
severity of ALI while inhibition of COX-2 attenuated ALI in an acid aspiration-
induced model of ALI and carrageenan-induced pleurisy model in rats [269, 297]. In 
addition, PGE2 has been shown to be heightened in both animal models of endotoxin 
shock and clinical cases of sepsis [282, 298]. It has been shown to exert significant 
immune system dysfunction in sepsis, such as vasodilation, increased vascular 
permeability, and generation of local and systemic inflammatory response [299]. 
Furthermore, it has been reported that inhibition of COX restored immune alterations 
and improved survival caused by sepsis [273]. In agreement with these findings, our 
results reveal marked attenuation of lung PGE2 metabolite levels in both septic and 
septic mice administrated with NaHS upon treatment with parecoxib, as compared to 
the elevated levels observed in the same mice without parecoxib. These observations 
not only support the findings that the induction of COX-2 can translate into increased 





Of even greater significance, results from our work provide convincing evidence 
demonstrating that the H2S induction of COX-2/PGE2 pathway is a critical component 
of the lethal response associated with CLP-induced sepsis in mice. As described in 
earlier chapters, exogenous application of NaHS to septic mice further worsened 
while blockade of endogenous H2S synthesis by PAG protected against organ injury 
and death in sepsis. Here, we report that inhibition of COX-2 significantly protected 
against sepsis-associated mortality, as reflected by prolonged survival seen in both 
septic and NaHS-injected septic mice that received parecoxib intervention. Consistent 
to these findings, absence of COX-2 rendered COX-2-deficient mice resistant to 
endotoxin-induced inflammation and lethality [271]. Besides, our data reveal that both 
prophylactic and therapeutic PAG decreased mortality significantly for up to 35% to 
45% throughout the 12-day study period. However, survival rate was not significantly 
different in mice treated with both PAG and parecoxib when compared to those 
treated with PAG only, suggesting that the improved survival rate in sepsis was likely 
associated with blockade of H2S synthesis. Once formation of endogenously produced 
H2S is inhibited, H2S is unable to elicit the downstream activation of TRPV1 and the 
subsequent upregulation of COX-2/PGE2 in sepsis. Hence, beneficial effects of 
parecoxib and PAG are not additive in protection against CLP-associated mortality in 
sepsis.  
 
Cross-talk between H2S and SP raises another possible way that H2S may upregulate 
COX-2 and PGE2 metabolite in sepsis indirectly through the effect of SP. Indeed, 
several studies highlighted the significance of SP and COX-2 in various inflammatory 
states [274-277]. Particularly, SP has been demonstrated to stimulate COX-2 and 
PGE2 metabolite upregulation through ERK-NF-κB pathway in murine burn-induced 
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remote ALI [274]. SP was also demonstrated to augment PGE2 production in Lyme 
disease-associated inflammatory conditions in murine microglia [300] and to induce 
COX-2 expression and NF-κB activation in human PMNs [276]. Furthermore, SP 
incites COX-2 and PGE2 expression in human colonic epithelial cells and human 
umbilical vein endothelial cells through the activation of Janus kinase-signal 
transducer and activator of transcription [275] and MAPKs pathways [277], 
respectively. Of particular relevance, our work in preceding chapters suggested that 
H2S provokes tachykinin-mediated neurogenic inflammatory response involving SP in 
CLP-induced sepsis in a TRPV1-dependent manner via ERK-NF-κB pathway. Taking 
our previous findings together with our present demonstration, there exists the 
possibility that H2S may contribute to sepsis-evoked ALI via the signal transduction 
pathway of H2S-TRPV1-SP-ERK1/2-NF-κB-COX-2- PGE2 metabolite.  
 
In conclusion, we report for the first time that H2S augments the upregulation of 
COX-2 and PGE2 metabolite, which orchestrates the neurogenic inflammatory 
response via activation of TRPV1 channel, and consequently contributes to lung 
inflammation and injury in a mouse model of sepsis-induced ALI. Additionally, 
inhibition of COX-2/PGE2 pathway in the septic lungs significantly ameliorates 
inflammation, injury and sepsis-associated mortality; thereby provides a potential 



















Figure 6.1 Effect of NaHS and capsazepine on (A) protein expression and (B) 
activity of COX-2 in septic lungs. Mice were randomly given NaHS (10mg/kg, i.p.) 
at the same time of CLP; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 
30 min before CLP. Sham mice served as controls. Eight hours after CLP or sham 
operation, lung COX-2 expression and activity levels were measured. A 
representative western blot image is shown, with densitometry data expressed as 
average ratios of COX-2 to HPRT. Results shown are the mean values ± SEM (n = 4-
6 mice per group for COX-2 expression and n = 8-10 mice per group for COX-2 
activity). The significance of difference among groups was evaluated by ANOVA 
with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus sham; **p < 
0.01 versus CLP + vehicle; †p < 0.05 versus CLP + vehicle; ‡p < 0.01 versus CLP + 






















Figure 6.2 Effect of PAG and capsazepine on (A) protein expression and (B) 
activity of COX-2 in septic lungs. Mice were randomly given PAG (50mg/kg, i.p.) 1 
h before (“prophylactic”) or 1 h after (“therapeutic”) CLP; and capsazepine (Capz) 
(15mg/kg, s.c.) or vehicle (DMSO) 30 min before CLP. Sham mice served as controls. 
Eight hours after CLP or sham operation, lung COX-2 expression and activity levels 
were measured. A representative western blot image is shown, with densitometry data 
expressed as average ratios of COX-2 to HPRT. Results shown are the mean values ± 
SEM (n = 4-6 mice per group for COX-2 expression and n = 8-10 mice per group for 
COX-2 activity). The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. *p < 0.01 versus 


















Figure 6.3 Effect of (A) NaHS or (B) PAG and capsazepine on PGE2 metabolite 
production in septic lungs. Mice were randomly given NaHS (10mg/kg, i.p.) at the 
same time of CLP or PAG (50mg/kg, i.p.) 1 h before (“prophylactic”) or 1 h after 
(“therapeutic”) CLP; and capsazepine (Capz) (15mg/kg, s.c.) or vehicle (DMSO) 30 
min before CLP. Sham mice served as controls. Eight hours after CLP or sham 
operation, lung PGE2 metabolite levels were measured. Results shown are the mean 
values ± SEM (n = 8-10 mice per group). The significance of difference among 
groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP + vehicle; ‡p < 0.01 






















Figure 6.4 Effect of NaHS and parecoxib on (A) lung MPO activity, (B) 
histopathological evaluation (hematoxylin and eosin staining) of lung 
polymorphonuclear leukocyte infiltration and injury, and (C) pulmonary edema 
in sepsis. Mice were randomly given NaHS (10mg/kg, i.p.) at the same time of CLP; 
and parecoxib (30mg/kg, i.v.) or saline 20 min after CLP. Sham mice served as 
controls. Eight hours after CLP or sham operation, lung MPO activity, 
histopathological evaluation and edema were assessed. Results shown are the mean 
values ± SEM (n = 8-10 mice per group for MPO activity and histopathological 
evaluation, and n = 10-15 mice per group for pulmonary edema). The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for 
multiple comparisons. Representative lung sections shown include: (B1) sham, (B2) 
CLP, (B3) CLP + Saline, (B4) CLP + Parecoxib, (B5) CLP + NaHS + Saline, (B6) 
CLP + NaHS + Parecoxib. *p < 0.01 versus sham; **p < 0.01 versus CLP + saline; †p 





















Figure 6.5 Effect of NaHS and parecoxib on production of pro-inflammatory 
cytokines and chemokines in septic lungs. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP; and parecoxib (30mg/kg, i.v.) or saline 20 
min after CLP. Sham mice served as controls. Eight hours after CLP or sham 
operation, lung levels of (A) TNF-α, (B) IL-1β, (C) IL-6, (D) MIP-1α, and (E) MIP-2 
were measured. Results shown are the mean values ± SEM (n = 8-10 mice per group). 
The significance of difference among groups was evaluated by ANOVA with a post 
hoc Tukey’s test for multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus 




















Figure 6.6 Effect of NaHS and parecoxib on production of adhesion molecules in 
septic lungs. Mice were randomly given NaHS (10mg/kg, i.p.) at the same time of 
CLP; and parecoxib (30mg/kg, i.v.) or saline 20 min after CLP. Sham mice served as 
controls. Eight hours after CLP or sham operation, lung levels of (A) P-selectin, (B) 
E-selectin, (C) VCAM-1, and (D) ICAM-1 were measured. Results shown are the 
mean values ± SEM (n = 8-10 mice per group). The significance of difference among 
groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP + saline; ‡p < 0.01 










Figure 6.7 Effect of NaHS and parecoxib on production of PGE2 metabolite in 
septic lungs. Mice were randomly given NaHS (10mg/kg, i.p.) at the same time of 
CLP; and parecoxib (30mg/kg, i.v.) or saline 20 min after CLP. Sham mice served as 
controls. Eight hours after CLP or sham operation, lung PGE2 metabolite levels were 
measured. Results shown are the mean values ± SEM (n = 8-10 mice per group). The 
significance of difference among groups was evaluated by ANOVA with a post hoc 
Tukey’s test for multiple comparisons. *p < 0.01 versus sham; **p < 0.01 versus CLP 



























Figure 6.8 Effect of parecoxib on CLP-induced mortality in (A) septic mice, (B) 
septic mice injected with NaHS, (C) septic mice received prophylactic PAG, and 
(D) septic mice received therapeutic PAG. Mice were randomly given NaHS 
(10mg/kg, i.p.) at the same time of CLP or PAG (50mg/kg, i.p.) 1 h before 
(“prophylactic”) or 1 h after (“therapeutic”) CLP; and parecoxib (30mg/kg, i.v.) or 
saline 20 min after CLP. Sham mice served as controls. Survival was monitored every 
24 h for up to 12 days. Results are expressed as survival rate (n = 15-20 mice per 
group). The survival rate was estimated by the Kaplan-Meier method and compared 
by log rank test. Significant differences are shown in the figure.  
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Chapter VII General Discussion and Conclusion  
 
7.1 Significance of findings 
Over the last hundred years, great strides have been made in the field of sepsis in 
terms of pathophysiology, epidemiology, diagnosis, monitoring, and therapeutics. 
However, even with the best of critical care, sepsis is still life threatening and the 
mortality rate remains unacceptably high. Every year, severe sepsis strikes about 750, 
000 Americans, resulting in an enormous economic and social expense in addition to 
healthcare burden [183]. It is apparent that much work remains to be done to advance 
our understanding of this important and increasingly frequent medical problem, 
particularly the pathophysiology of the endogenous mediators that underlie the 
systemic inflammatory response to infection. Here, we offer our findings of the key 
role of H2S, a novel endogenous gasotransmitter, in mediating neurogenic 
inflammation in an in vivo mouse model of polymicrobial sepsis.   
 
In the first part of the study, we examined whether endogenous H2S would contribute 
significantly to systemic inflammation and multiple organ failure in sepsis by 
interacting with the sensory nervous system in a TRPV1 relevance context. 
Endogenously produced H2S and the synthesizing activity of CSE were measured to 
establish the involvement of endogenous H2S in regulating TRPV1-mediated 
neurogenic inflammation in sepsis. Apart from this, two complementary and different 
approaches: exogenous administration of NaHS as an H2S donor and inhibition of 
endogenous H2S synthesis with PAG, an irreversible inhibitor of CSE, were employed 
to further ascertain the role of H2S. The intensity of systemic inflammation was 
determined by tissue MPO activity while the severity of organ failure was evaluated 
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by histopathological examination of tissue sections and survival analysis. It was found 
that capsazepine significantly attenuated systemic inflammation and multiple organ 
damage caused by CLP-induced sepsis, as characterized by lowered lung and liver 
MPO activity and histological evidence of diminished pulmonary and hepatic injury. 
Moreover, capsazepine delayed the onset of lethality and protected against sepsis-
associated mortality. Administration of NaHS exacerbated but capsazepine reversed 
these deleterious effects. In the presence of PAG, capsazepine caused no significant 
changes to the PAG-mediated attenuation of systemic inflammation, multiple organ 
damage, and mortality in sepsis. More importantly, capsazepine has no effect on 
endogenous generation of H2S, suggesting that H2S is located upstream of TRPV1 
activation, and may play a critical role in regulating the release of sensory 
neuropeptides in sepsis. Therefore, this part of study showed for the first time that 
H2S induces systemic inflammation and multiple organ damage characteristic of 
severe sepsis via TRPV1-mediated neurogenic inflammation.  
 
Subsequent studies have identified the endogenous neural mediator that implicates in 
H2S-driven neurogenic inflammation in sepsis. In this second part of the study, 
capsazepine treatment resulted in a significant attenuation of circulating and 
pulmonary levels of SP in septic mice. Capsazepine also inhibited NaHS-augmented 
SP production but had no effect on PAG-mediated abrogation of SP levels in both 
plasma and lung. Reinforcing the importance of H2S stimulation of TRPV1 channels 
and the subsequent release of SP in the manifestation of sepsis, it was demonstrated 
that the attenuated SP levels correlates with reduced systemic inflammation and 
multi-organ dysfunction. It was shown that capsazepine significantly decreased H2S-
induced inflammatory cytokines, chemokines, and adhesion molecules production, 
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and protected against lung and liver dysfunction, as evidenced by alleviated 
pulmonary edema and plasma ALT and AST activities. In the absence of H2S, 
capsazepine caused no significant changes to the PAG-mediated attenuation of sepsis-
associated systemic inflammatory response and multiple organ dysfunction. These 
results, again, ascertained that sepsis has a significant sensory neurogenic component 
that involved SP and mediated by H2S in a TRPV1-dependent manner.  
 
In the next part of the study, we investigated the molecular mechanisms by which H2S 
regulates TRPV1-mediated neurogenic inflammation in sepsis. Employing the same 
experimental approach, capsazepine greatly inhibited phosphorylation of ERK1/2 and 
IκBα, concurrent with suppression of NF-κB activation even in the presence of NaHS. 
In contrast, capsazepine had no effect on PAG-mediated abrogation of these levels in 
sepsis. Assessment of IκBα degradation displayed a similar profile that correlated 
well with the levels of phospho-IκBα, with untreated septic and NaHS-injected septic 
mice showing a significant reduction in lung and liver IκBα levels in comparison with 
the heightened levels exhibited in the same mice that received capsazepine 
intervention. As anticipated, PAG markedly enhanced tissue IκBα expression levels, 
suggesting an obvious inhibition of IκBα degradation; however, capsazepine failed to 
further modulate these levels in sepsis. Taken together, these findings suggest that 
H2S regulates TRPV1-mediated neurogenic inflammation in polymicrobial sepsis 
through enhancement of SP production and activation of the ERK-NF-κB pathway.  
 
Although the third part of the study showed that H2S induced the activation of NF-κB, 
the downstream inflammatory mediators that lead to sepsis-evoked ALI have not been 
explored. Hence, it was imperative to investigate whether H2S can upregulate COX-2 
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and work in conjunction with it to instigate ALI in sepsis through a TRPV1 channel-
dependent mechanism. Since COX-2 level was high in the lung but undetectable in 
the liver during sepsis, we focused our work on the interplay between H2S and COX-2 
in sepsis-evoked ALI rather than liver injury. Our results indicate that H2S augmented 
COX-2 and PGE2 metabolite production in septic lungs by a TRPV1 channel-
dependent mechanism. Furthermore, COX-2 inhibition with parecoxib attenuated 
H2S-augmented lung PGE2 metabolite production, neutrophil infiltration, edema, pro-
inflammatory cytokines, chemokines, and adhesion molecules levels, restored lung 
histoarchitecture, and improved CLP-induced lethality. The strong anti-inflammatory 
and anti-septic actions of selective COX-2 inhibitor may provide a potential 
therapeutic approach for the prevention and management of sepsis-associated ALI. 
 
Although pro-inflammatory role of H2S was reported in this thesis, several anti-
inflammatory actions of H2S have been described in the literature (as discussed in 
Chapter I). These controversies may be attributed to several experimental differences, 
including animal models (local or systemic inflammation), regimen (dose, time, and 
route of administration) of H2S donors and/or inhibitors used, health status, age, and 
gender of the animals, as well as commercial sources of drugs used. It would appear 
that much like other gasotransmitter (e.g. NO), H2S may play different roles in 
various disease states and its effects remain complex, difficult to predict, and may 
vary depending on the specific environment/circumstances/location where it is 
generated. It is likely that it may act as a double-edged sword that restrains 
inflammatory response at physiological (low) concentration, but may contribute to 
inflammatory process in an already inflamed area when overproduced 
(pathological/high concentration).  
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In conclusion, we provide for the first time, compelling evidence of the multiple roles 
of H2S in stimulating neurogenic inflammatory responses that contribute to the 
pathophysiology of sepsis in terms of systemic inflammation and multiple organ 
damage. Our data also indicate that blockade of TRPV1 channels provides potent 
anti-inflammatory effects and protection against multi-organ injury and mortality, 
thereby highlighting the potential utility of TRPV1 antagonist as a promising 
therapeutic target for inflammatory pathologies. Furthermore, an in-depth study of 
H2S and its multiple roles in upregulating inflammatory pathways, signaling 
molecules, and other prominent mediators of inflammation such as COX-2 and PGE2 
may provide approaches for new forms of therapeutic interventions for the treatment 
and management of sepsis and its associated complications in critically ill patients. A 
summary of the findings in the present study is illustrated in Figure 7.1.   
 
7.2 Limitations of the study 
The work on the role of H2S in neurogenic inflammation in this thesis is not without 
limitations. Firstly, although inhibitors of CSE designated PAG (and β-cyano-L-
alanine) are the best pharmacological enzyme inhibitors of H2S production currently 
available, they target pyridoxal phosphate binding site of each enzyme and might also 
interfere with other pyridoxal phosphate-dependent enzymes. In addition, they are of 
low potency, low selectivity, and limited cell-membrane permeability. As with any 
pharmacological agents, we cannot exclude the possibility that PAG could exert non-
specific effects in sepsis. Because of these limitations, we carried out H2S donor 
experiment to increase the veracity of our results. It is clear that newer and more 
promising enzyme specific inhibitors are urgently needed to better understand the 
impact of H2S inhibition in biological systems. Very recently, mice genetically 
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deficient of CSE have come to the fore [301]. Availability of such CSE knockout 
mice provides researchers with new options to establish the contribution of this 
enzyme to endogenous H2S levels in vascular tissues. Secondly, although the present 
study offers the possibility that H2S may activate TRPV1, the precise molecular site 
of action (specific amino acid residue/protein domain) and the molecular mechanisms 
underlying it (protein kinase activation, calcium/calmodulin pathways), as well as its 
regulation (phosphorylation and dephosphorylation states) remain unknown. Apart 
from this, it could be possible that the release of SP caused by H2S is via an indirect 
activation of TRPV1 through other endogenous mediators evoked by H2S. 
Furthermore, the specific cell types that respond to H2S stimulation of TRPV1 
activation, as well as the types of cells that bind to SP and mediate ERK-NF-κB 
signaling, remain to be identified. Molecular mechanisms that lead to reduced 
ERK1/2 phosphorylation and NF-κB activation with PAG are issues deserving further 
investigation. Finally, investigations in large animals and human patients would be 
important to further substantiate the clinical relevance of the findings reported based 
on small animals and cell culture systems. 
 
7.3 Conclusions and future perspectives 
In summary, important contributions of this study include:  
 
 The pro-neuroinflammatory role of H2S in CLP-induced sepsis and its associated 
multiple organ damage through TRPV1 channel activation 
 The identification of the classical neuropeptide SP as a key endogenous neuro-
mediator implicated in H2S-driven neurogenic inflammation in sepsis 
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 The ability of H2S to work in conjunction with other important inflammatory 
mediators, such as COX-2, to provoke ALI following septic insults 
 The molecular mechanism by which H2S acts to regulate TRPV1-mediated 
neurogenic inflammation in polymicrobial sepsis 
 
For many years, scientists have been trying to develop medicines to arrest the 
aggressive immune inflammatory response that characterizes sepsis. Results of the 
current study may highlight potential novel therapeutic approaches useful for the 
development of new treatments targeted at resolving the early inflammatory responses 
in critically ill septic patients. By doing so, preventing the orchestration of systemic 
inflammation will prove to have more practical benefit to the patients than efforts to 
treat multiple organ injury once it has ensued.  
 
Roles of H2S in modulating neurogenic inflammation in sepsis have been identified 
but not yet completely defined. Further research is needed in the following directions: 
 
 To study the role of endogenous H2S in vascular tissues using promising genetic 
approaches such as CSE knockout mice and overexpression of CSE in animals 
 To develop wholly specific pharmacological tools that could selectively inactivate 
or inhibit CSE and CBS 
 To identify the precise molecular site of action of H2S on TRPV1 channels, the 
molecular mechanisms underlying it and its regulation 
 To investigate other candidate signaling molecules in inflammatory pathways that 
can lead to neurogenic inflammation in sepsis such as G protein-coupled receptor 
associated proteins (e.g. Gαq and Gαs); upstream kinases that mediate the 
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activation of ERK1/2 and NF-κB including protein kinases, phospholipases, small 
GTPases, and calcium; other members of the MAPKs family such as p38 MAPKs 
and JNKs, as well as other potential pathways underlying the pro-
neuroinflammatory effects of H2S following septic insults  
 To identify the specific cell types that respond to H2S stimulation of TRPV1 
activation, and the types of immune cells that bind to SP (or other neuropeptide 
released by TRPV1-expressing nerve fibers such as CGRP) in order to understand 
how the sensory nervous system influences the immune response to septic injury 
 
It is hoped that active research in these directions would help address several 
unanswered questions of H2S in the context of neuroinflammation in order to probe 
deeper the complex biological roles of H2S in health and disease. 
 
 






Figure 7.1 Flowchart summarizing the pro-neuroinflammatory role of H2S in 
polymicrobial sepsis. Sepsis results in an overproduction of endogenous H2S, which 
in turn, stimulates the activation of TRPV1 channels. H2S stimulation of TRPV1 
provokes the release of SP, initiating the cascade of neurogenic inflammation in 
sepsis. It also stimulates the activation of ERK1/2, leading to the phosphorylation and 
degradation of IκBα, as well as the translocation and activation of NF-κB, thereby 
leading to increased transcription of pro-inflammatory genes in sepsis. H2S also 
augments COX-2 and PGE2 metabolite production by a TRPV1 channel-dependent 
mechanism following septic insults. Together, these events contribute to amplified 
production of inflammatory cytokines and chemokines, heightened microvascular 
permeability and tissue edema, enhanced expression of adhesion molecules and 
recruitment of inflammatory cells, and elevated distant tissue neutrophil infiltration. 
The accumulation of all these inflammatory events aggravates the systemic 
inflammatory response syndrome in sepsis. Exaggerated activation of systemic 
inflammation can compromise the function of various organ systems, resulting in 
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